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Abstract 
Outer membrane vesicles (OMVs) are nano-sized structures that are formed when portions of the 
bacterial membrane bud and pinch off from the cell in a process called vesiculation. This process 
entraps a diverse range of bacterial products within the vesicles (including virulence factors) which are 
later released into the environment. The main project aims were to gain a fundamental understanding of 
vesiculation in a range of bacterial species and to enable targeted expression of recombinant proteins 
and other molecules for delivery and inclusion in OMVs. OMVs were isolated and characterised from 
various strains of Escherichia coli and Pseudomonas aeruginosa. It was found that OMVs from 
different bacterial strains are similar in appearance but have very different compositions and cargo. The 
proteins FimA and Flagellin were found to be heavily enriched within E. coli K-12 OMVs in a mutually 
exclusive way. They are known virulence factors that have been shown to be reciprocally regulated in 
E. coli cells but not in OMVs. FimA has previously been found to have an anti-inflammatory effect on 
human immune cells whereas Flagellin has a pro-inflammatory effect, which may be the reason that the 
two proteins are not packaged within OMVs together. This was further explored by purification of 
OMVs from a series of E. coli gene knockouts and clinical isolates to compare the protein profiles of 
the OMVs. Lastly, an E. coli strain containing GFP fused to FimA was trialled as a method of targeted 
delivery within OMVs. This method was successful as the GFP-FimA protein fusion was detected in the 
OMVs purified from this strain. Recombinant protein fusions such as this could allow use of E. coli 
OMVs for therapeutic applications such as drug delivery and vaccines. Furthermore, the packaging of 
FimA and Flagellin into E. coli OMVs may play a significant role in its pathogenicity and ability to 
modulate the host response to infection. These findings could highlight potential new drug targets 
against OMV-producing pathogens such as E. coli as well as providing further insight into using OMVs 
for drug delivery and vaccines. 
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Outer membrane vesicles (OMVs) are nano-sized structures that are formed when portions of the 
bacterial membrane bud and pinch off from the cell in a process called vesiculation. This process 
entraps a diverse range of bacterial products within the vesicles (including virulence factors) which are 
later released into the environment. The main project aims were to gain a fundamental understanding of 
vesiculation in a range of bacterial species and to enable targeted expression of recombinant proteins 
and other molecules for delivery and inclusion in OMVs. OMVs were isolated and characterised from 
various strains of Escherichia coli and Pseudomonas aeruginosa. It was found that OMVs from 
different bacterial strains are similar in appearance but have very different compositions and cargo.  
 
The proteins FimA and Flagellin were found to be heavily enriched within E. coli K-12 OMVs in a 
mutually exclusive way. They are known virulence factors that have been shown to be reciprocally 
regulated in E. coli cells but not in OMVs. FimA has previously been found to have an anti-
inflammatory effect on human immune cells whereas Flagellin has a pro-inflammatory effect, which 
may be the reason that the two proteins are not packaged within OMVs together. This was further 
explored by purification of OMVs from a series of E. coli gene knockouts and clinical isolates to 
compare the protein profiles of the OMVs. Lastly, an E. coli strain containing GFP fused to FimA was 
trialled as a method of targeted delivery within OMVs. This method was successful as the GFP-FimA 
protein fusion was detected in the OMVs purified from this strain. Recombinant protein fusions such as 
this could allow use of E. coli OMVs for therapeutic applications such as drug delivery and vaccines. 
These findings were also relevant to the study of P. aeruginosa OMVs which were also found to be 
enriched in Flagellin.  
 
E. coli and P. aeruginosa are Gram-negative bacterial strains which produce OMVs derived from the 
outer membrane of the bacterial cell envelope. As a comparison, membrane vesicles (MVs) were also 
purified from Streptomyces S4, which is a Gram-positive bacterium. Gram-positive bacteria do not have 
an outer membrane so MVs are derived from the cytoplasmic membrane instead. It had previously been 
found that Streptomyces S4 produces the antifungal agents candicidin and antimycin but it was not 
known how they were secreted. This study showed for the first time that Streptomyces S4 packages 
candicidin within membrane vesicles for release into the environment. Understanding of the natural 
packaging of cargo into the MVs of each bacterial strain is essential to maximise the selectivity and 
yield of cargo for therapeutic purposes. Furthermore, the packaging of FimA and Flagellin into E. coli 
OMVs may play a significant role in its pathogenicity and ability to modulate the host response to 
infection. These findings could highlight potential new drug targets against MV-producing pathogens 
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Chapter 1: Introduction 
1.1 Introduction to Outer Membrane Vesicles 
Outer membrane vesicles (OMVs) are produced and secreted by Gram-negative bacteria. They are 
nano-sized, spherical vesicles, which are formed from the bacterial Outer Membrane (OM). OMVs can 
contain a wide range of cargo, which travel within the OMVs to reach their target in a concentrated and 
protected form. OMV cargo often includes virulence factors such as toxins or proteases which are 
beneficial to the bacteria that secrete them. Membrane vesicle release is conserved and mechanistically 
similar across a range of both prokaryotic and eukaryotic microorganisms (Prangishvili et al. 2000, 
Deatherage et al. 2012).  
1.1.1 The discovery of OMVs 
The formation of OMVs was first observed by electron microscopy in the 1960s (Chatterjee, Das. 
1967). This was demonstrated using actively growing Vibrio cholerae cells that were in the logarithmic 
stage of growth. The electron microscopy images showed the bulging of certain parts of the bacterial 
cell wall. These portions of the membrane then pinched off to form vesicles that were released 
extracellularly (Figure 1.1). The release of these vesicles had no effect on the cell wall, which remained 
intact (Chatterjee, Das. 1966 and 1967). The authors proposed that this was a novel secretory system 
which allowed the secretion of non-diffusible materials from the bacterial periplasm (Chatterjee, Das. 
1966 and 1967).  
 
Figure 1.1 Electron microscopy images of the 
formation of membrane vesicles from Vibrio cholerae 
cells 
V. cholerae cells were grown in peptone water to 
logarithmic growth phase. The cells were stained with 
lead and electron microscopy was used to visualise the 
bulging and budding from the cell membrane. The 
authors labelled the sequence of the budding process as 
A, B and C. The arrows represent granules associated 
with the cell wall. Magnification x 100,000. Image and 





These membrane sacs were later known as OMVs and were found to be produced by many Gram-
negative bacteria during growth phase (McBroom et al. 2005). The production and secretion of OMVs 
was also established as a new bacterial secretory mechanism (Kuehn et al. 2005). Lastly, OMVs were 
found to contain a range of cargo which are advantageous to the parent cell (discussed in Section 1.3).  
 
1.2 Composition of the cell envelope in Gram-negative bacteria 
1.2.1 Summary of the main differences in the composition of the cell envelope in Gram-
positive and Gram-negative bacteria 
The role of the bacterial cell envelope is to protect bacteria from extreme environments and prevent 
lysis of the cell. The majority of bacterial cell envelopes fall into two categories: Gram-positive or 
Gram-negative. The Gram-positive bacterial cell envelope contains a plasma membrane and a thick 
layer of peptidoglycan cell wall. The Gram-negative bacterial cell envelope is composed of an inner 
(plasma) membrane, a thin peptidoglycan cell wall and an outer membrane (OM). The periplasm is the 
space between the inner and outer membrane in Gram-negative bacteria, which contains the 




















Lastly, it should be noted that there are some examples of bacteria that do not fit into either category. 
For example, the cell wall of Mycobacterium tuberculosis contains characteristics of both Gram-
negative and Gram-positive bacteria (Fu et al. 2002). 
  
Figure 1.2 Comparison of the cell envelope in Gram-positive and Gram-negative cells 
The Gram-negative bacterial cell envelope is composed of the inner (plasma) membrane, a thin 
peptidoglycan cell wall and an outer membrane (a). The Gram-positive bacterial cell envelope is 
composed of the plasma membrane and a thick peptidoglycan cell wall (b). Image sourced from 





1.2.2 Composition of the cell envelope in Gram-negative bacteria 
The Gram-negative cell envelope is composed of the inner (cytoplasmic) membrane, the periplasm and 





















1.2.2.1 The Outer Membrane (OM) 
OMVs are formed from the OM of Gram-negative bacteria. The OM serves as a barrier to protect the 
cell from the environment. The OM is composed of the inner and outer leaflet. The inner leaflet 
contains phospholipids and lipoproteins and the outer leaflet is composed of lipopolysaccharide (LPS).  
 
Lipopolysaccharide (LPS)  
LPS is unique to Gram-negative bacteria and is exposed on the bacterial cell surface. The LPS 
molecules are tightly bound and packed together making an effective barrier against the entry of 
hydrophobic molecules. The LPS component of Gram-negative bacteria is pro-inflammatory and can 
cause the endotoxic shock observed in septicaemia (Raetz, Whitfield. 2002). LPS has three different 
components: lipid A, a core polysaccharide and an O antigen polysaccharide which projects outwards 
from the cell wall (Figure 1.3). 
 
Figure 1.3 The composition of the cell envelope in Gram-negative bacteria  
There are three layers to Gram-negative cell envelope: 1. The outer membrane: an asymmetrical 
bilayer composed of an inner leaflet formed of phospholipids and an outer leaflet composed of 
lipopolysaccharide which projects outwards. 2. The peptidoglycan cell wall: a polymer that provides 
structure to the bacterial cell envelope, located within the periplasm. 3. The inner membrane: 
composed of phospholipids, also known as the cytoplasmic membrane (a). The lipopolysaccharide 
is formed of: 1. Lipid-A 2. Core polysaccharide which split into the inner and outer cores 3. O 
antigen polysaccharide which projects outwards from the cell wall (b). Image sourced from Brown et 










Lipid A is located next to the phospholipid layer of the OM and anchors the LPS to the bacterial 
membrane. It is composed of a β (1→6)-linked glucosamine disaccharide backbone (Steimle et al. 
2016). It is usually hexa-acylated meaning that there are six acyl chains associated with the backbone 
(Steimle et al. 2016). However, the number of acyl groups can vary as well as the length of the chains. 
Lipid A is responsible for much of the toxicity of Gram-negative bacteria. When Gram-negative 
bacteria are lysed by the hosts’ immune system, LPS (and Lipid A) can be released into the hosts 
circulation. It is a highly potent activator of immune cells and during bacterial infection can cause the 
body to go into septic shock which can be fatal.  
 
Core polysaccharide 
The core polysaccharide links Lipid A to the O antigen which projects outwards from the cell. The outer 
core is composed of more common sugars including hexoses such as glucose and galactose (Erridge et 
al. 2002). The inner core contains many phosphorylated glycan residues which increase the negative 
charge of the outer membrane and help to stabilise the cell. It contains a ‘high proportion of unusual 
sugars such as 3-deoxy-D-manno-octulosonic acid (Kdo) and L-glycero-D-manno heptose (Hep)’ 
(Erridge et al. 2002).  
 
O-antigen 
The O-antigen is composed of repeating oligosaccharides and is highly variable in the number of 
repeating units and sugars. Due to its variability, bacteria are classed by serotype based on the O antigen 
found on each strain (Erridge et al. 2002). On some bacterial species, the O-antigen is truncated or 
absent altogether. As the O antigen is expressed on the outside of the cell, it is one of the main antigens 
targeted by the host immune system (Erridge et al. 2002). 
Outer membrane proteins 
The majority of proteins from the OM can be classed as lipoproteins or β-barrel proteins (Silhavy et al. 
2010). Almost all of the integral, transmembrane proteins found in the OM are in a β-barrel 
conformation (Silhavy et al. 2010). This includes the Outer Membrane Proteins (OMPs) such as the 
porins which form channels in the membrane and allow the passage of small ions and molecules across 
the OM. Example of porins are OmpC and OmpF in E. coli (Figure 1.4). The porins present in the OM 
also prevent the entry of hydrophilic molecules above 700 Daltons to limit diffusion into the cell 
(Silhavy et al. 2010). For these reasons, the OM gives Gram-negative bacteria resistance to 




























The stability of the cell envelope is due to the protein links between the IM, peptidoglycan and OM. The 
OM is attached to the peptidoglycan layer by an outer membrane lipoprotein called Lpp. If there are 
places in the membrane where the Lpp link is absent, this is often the location for OMV biogenesis 
(discussed further in Section 1.4). OmpA is a protein in E. coli, which binds and links the OM to the 
peptidoglycan layer (Figure 1.4). OmpA is known to be present in E. coli OMVs, which is discussed 
further in Section 3.1.2. 
Outer membrane-associated enzymes 
OMVs contain proteins from the OM from which they are formed. The OM of Gram-negative bacteria 
(such as E. coli) contain a family of outer membrane proteases called Omptins (Vandeputte-Rutten et al. 
2001). Omptins appear to be virulence factors in pathogenic Gram-negative bacteria as they cleave a 
range of substrates at the host-pathogen interface such as antimicrobial peptides and plasminogen 
(Brannon et al. 2015). An example of this is the finding that the ompT gene is present in E. coli clinical 
isolates from patients with complicated urinary tract infections (Webb et al. 1996). OmpT cleaves and 
inactivates the antimicrobial peptide protamine which is produced by epithelial cells in the urinary tract 
(Stumpe et al. 1998). This degradation in the OM prevents protamine from reaching the inner 
(cytoplasmic) membrane which is its site of action (Stumpe et al. 1998). 
 
Figure 1.4 Structure of the Gram-negative bacterial cell envelope highlighting the location of OmpC, 
OmpF, OmpA and Lpp 
The cell envelope is composed of the inner (cytoplasmic) membrane, the outer membrane and the 
periplasmic space which contains the peptidoglycan layer (PG). The stability of the cell envelope is due to 
the protein links between the IM, peptidoglycan and OM. The lipoprotein Lpp forms crosslinks between 
the OM and the layer of peptidoglycan (purple ovals). OmpA is situated in the OM and also forms 
links to the peptidoglycan (yellow). Lastly, the Tol-Pal complex spans the whole cell envelope from 
the IM to the OM for stability (includes proteins TolQ, TolR, TolA, TolB and Pal). Image sourced 




1.2.2.2 Peptidoglycan and the Periplasm 
The periplasm is a viscous, aqueous compartment between the inner and outer membrane. It is densely 
packed with enzymes and proteins, particularly those associated with the secretory pathway. It is also a 
membrane bound compartment where potentially harmful toxins or degradative enzymes can be 
sequestered. Within the periplasmic space, there is a thin layer of peptidoglycan which is composed of 
the monosaccharides N-acetyl glucosamine (NAG) and N-acetyl muramic acid (NAM). The sugar 
component of the peptidoglycan contains strands of alternating residues of NAG and NAM, which are 
connected by the cross-linking of peptide chains present on the NAM residues (Figure 1.5). The result is 
an extremely strong 3D structure that gives the cell structure and prevents bacterial lysis (Silhavy et al. 
2010) 
 
This layer is rigid and provides structure to the cell to prevent cell lysis (Silhavy et al. 2010). The 
peptidoglycan layer is connected to the outer and inner membrane by various proteins for strength and 
stability of the bacterial cell structure.  
 
1.2.2.3 The Inner Membrane (IM) 
The IM is a phospholipid bilayer that encloses the cytoplasm. The membrane proteins in the IM 
function in lipid biosynthesis, protein secretion and energy production. In Gram-negative bacteria, 
OMVs are formed from the outer membrane rather than the inner membrane.  
1.3 OMV composition and cargo 
1.3.1 OMVs are formed from the Outer Membrane of the Gram-negative cell envelope 
OMVs range from 50 nm to 300 nm in diameter (Brandon et al. 2014) and are spherical in shape 
(Chatterjee, Chaudhuri. 2011). The formation of OMVs from the OM appears to be a controlled process 
Figure 1.5 Schematic representation of 
the structure of peptidoglycan 
Peptidoglycan is formed of the 
monosaccharides N-acetyl glucosamine 
(blue squares labelled NAG) and N-acetyl 
muramic acid (purple squares labelled 
NAM). The sugar component of the 
peptidoglycan contains strands of 
alternating residues of NAG and NAM 
which are connected by the cross-linking 
of peptide chains present on the NAM 
residues (green links). Image sourced 




that does not affect the cellular structure or integrity. Evidence suggests that OMVs are formed at sites 
where the lipoprotein (Lpp) link between the peptidoglycan layer and OM are missing or broken. The 
formation of OMVs involves the budding and pinching off of a segment of the OM which entraps some 
components of the periplasm (Ellis et al. 2010). Therefore, OMVs contain phospholipids, periplasmic 
proteins, OMPs and LPS which projects outwards (Figure 1.6). It is also evident that OMVs include 
material from the periplasm, which appears to involve a specific sorting mechanism that is not yet fully 
understood.  
 
1.3.2 Chemical components of OMVs 
Within OMVs, the ratios of each lipid type, fatty acid content and the ratio of phospholipid to protein 
(Brandon et al. 2014) resemble that of the bacterial outer membrane but not the inner membrane. As 
discussed in the Section 1.2, the sugar KDO is a marker of LPS from the OM of Gram-negative 
bacteria. KDO has also been detected on OMVs (Kato et al. 2002), which is further evidence that 
OMVs are formed from the OM. Analysis of OMV proteomes also found many OM proteins within 
OMVs such as OmpA and OmpF. OMVs also were found to selectively contain periplasmic proteins 
(Bauman et al. 2006). For example, proteins associated with peptidoglycan were found to be excluded 
from E. coli OMVs. Virulence factors (such as toxins) were found in high concentrations within the 
OMVs as if they were selectively targeted there (Horstman, Kuehn. 2002). 
 
Figure 1.6 Model to show OMV production  
In this model, OMVs bud from the Gram-negative bacterial envelope. OMVs contain proteins and lipids 
from the OM and material from the periplasm. It is thought that budding occurs at sites where the 
lipoprotein (Lpp) link between the peptidoglycan layer and OM are missing or broken. Image sourced 




Material from the inner membrane (IM) and cytoplasm are generally thought to be excluded from 
OMVs (McBroom et al. 2006) although there have been exceptions. Marker proteins of the inner 
membrane such as succinate dehydrogenase and NADH oxidase are generally absent from purified 
OMVs (Brandon et al. 2014). This is strong evidence that OMV biogenesis is a controlled and 
deliberate process.  
1.3.3 Summary of possible OMV cargo  
There are two main advantages of packing and transporting molecules within OMVs. Firstly, certain 
proteins appear to be enriched in OMVs so that they become concentrated for release into the 
environment. Secondly, the packaged material can be transported while being protected from factors 
that may cause degradation in the environment (for example proteases). Possible cargo within OMVs 
include proteins, DNA and RNA. OMVs purified from pathogenic bacteria can contain toxins, 
multidrug efflux pumps and immunomodulatory compounds (Figure 1.7).  
 
1.3.4 Why do bacteria secrete OMVs? 
1.3.4.1 Aids Pathogenicity 
Toxins 
Many Gram-negative bacteria use OMVs to secrete virulence factors. OMVs are known to contain 
toxins that can cause disease in the host. Toxins known to be OMV-associated include the Shiga toxin 
from Shigella dysenteriae serotype 1 (Knockoutling et al. 1999), which is cytotoxic and causes host cell 
apoptosis (Dutta et al. 2004). Another example is Cytolysin (ClyA) found in OMVs from 
Enterohemorrhagic E. coli (EHEC) strains. ClyA monomers spontaneously form pore complexes at 
membranes, which cause cell membrane rupture and lysis (Roderer et al. 2016). ClyA in the periplasm 
exists in an oxidised form where disulphide bonds between cysteines keep ClyA in an inactive state 
(Wai et al. 2003). In the lumen of the OMVs, however, ClyA was found in a reduced form and was able 
Figure 1.7 Cargo of a typical 
OMV 
Findings from the proteomic, 
biochemical and biological studies 
of OMVs are summarised in this 
schematic diagram. Cargo types 
were split into the following 
categories: Bacterial survival, 
Nutrient sensing, Modulation of host 
immune response, ABC 
transporters, Killing competing 
bacteria and Targeting to the host 
cell. Image sourced from Brandon et 




to form an active pore structure. Evidence suggests that ClyA within the OMV is more potent and 
cytotoxic to mammalian cells than ClyA purified from the periplasm (Wai et al. 2003).  
 
Adhesins 
OMVs contain proteins called adhesins in the outer membrane, which allow them to interact and adhere 
to host cells. Adhesins also allow OMVs to be internalised by host cells efficiently so that virulence 
factors can be released. An example of this is the Ail adhesin/invasin located in the OM of OMVs of 
some E. coli strains. OMVs from a laboratory E. coli strain that contained Ail were internalised by 
eukaryotic cells at a rate that was 10-fold higher than those that did not express Ail (Kesty et al. 2004).   
 
Proteases 
Proteases can also be associated with OMVs and when released they can act on either host cells or other 
competing bacteria. An example of this is the presence of murein hydrolases in P. aeruginosa OMVs. 
When released, these proteases cause degradation of the peptidoglycan layer in bacterial cell walls (Li et 
al. 1998). This is advantageous as this can cause lysis of competitor bacteria so that more resources are 
available in the environment for the OMV-producing bacterium as there is less competition. Another 
advantage may also be that lysis of other bacteria in the environment causes the release of organic 
compounds into the environment which can be used by the OMV-producing bacteria for growth. 
 
1.3.4.2 Aids bacterial cell survival 
Immunomodulatory functions 
Many OMVs contain compounds that modulate the hosts’ immune response. In Helicobacter pylori, the 
LPS of the OMVs are bound to Lewis antigens which induce a strong response from the host immune 
system (Hynes et al. 2005). This is beneficial for the OMV-producing cell as the host cells immune 
system functions to remove the OMVs rather than targeting the bacterial cell. Alternatively, OMV cargo 
can function to inhibit the hosts’ immune response. For example, UspA1 and UspA2 associated with 
OMVs from Moraxella catarrhalis bind to a member of the complement cascade called C3 (Tan et al. 
2007). This inhibits the complement cascade to protect the OMV-producing bacterial cell in its 
immediate environment (this is discussed further in Section 1.10). 
 
Antibiotic resistance 
OMVs have also been found to contain multidrug efflux pumps which are used to move toxic 
compounds and antibiotics out of the OMVs (Gellatly, Hancock. 2013). Some OMVs contain proteases 
to catalyse degradation of antibiotics to remove them from the environment. For example, OMVs from 
Pseudomonas aeruginosa have been found to contain β-lactamase in the lumen of the vesicles 








Antibacterial factors that have been packaged in OMVs include autolysins and murein hydrolases (Li et 
al. 1996). In 1998, OMVs from Gram-negative bacteria were found to lyse both Gram-positive bacteria 
and other Gram-negative bacteria (Li et al. 1998). As well as reducing the competition in the 
environment, lysis of non-self bacterial cells releases nutrients into the environment which can be 
utilised by the OMV-secreting bacterium. For example, Pseudomonas aeruginosa eliminates 
neighbouring bacteria by secreting periplasmic peptidoglycan hydrolases through OMVs when nutrients 
are scarce (Kadurugamuwa, Beveridge. 1997).  
 
Bacteriophage decoy 
Bacteriophages are viruses that infect bacteria to reproduce, which ultimately results in bacterial cell 
lysis. In order to prevent this, evidence suggests that bacteria such a Vibrio cholerae secrete OMVs as a 
decoy for bacteriophages. It appears that bacteriophages bind to receptors on the surfaces of OMVs and 
sequesters them so that they cannot bind to the OMV-producing bacterial cell (Reyes et al. 2018). 
 
Genetic diversity  
Evidence suggests that a range of Gram-negative bacteria package DNA into their OMVs (Kolling et al. 
1999). So far, chromosomal DNA, plasmid DNA and bacteriophage DNA have been detected within 
OMVs (Chatterjee, Chaudhuri. 2012). For example, the DNA within the lumen of P. aeruginosa OMVs 
remains present even after treatment with an extracellular DNase (Kadurugamuwa, Beveridge. 1995). 
This is evidence that the DNA is protected from degradation within the lumen of the OMV. It was 
hypothesised that DNA within OMVs could be transferred to another bacterial cell as a method of gene 
transformation (Yaron et al. 2000). To test this, OMVs were purified from an E. coli strain that 
expressed green fluorescent protein (GFP) on a plasmid with ampicillin resistance. These OMVs were 
able to transform this plasmid into a different E. coli strain that did not contain this plasmid or gene. 
The E. coli cells became ampicillin resistant and fluoresced green due to the GFP (Yaron et al. 2000). 
This evidence suggests that OMVs may play a role in gene transfer between bacteria.   
1.3.4.3 Aids cell to cell communication 
Biofilm formation 
A biofilm is a community of microbial cells attached to a surface enclosed in a self-produced 
extracellular matrix. Biofilms create a protective and nutrient-rich environment that allow microbes to 
thrive. The extracellular matrix is composed of polysaccharides, proteins and extracellular nucleic acids 
such as DNA. The polysaccharide component of the extracellular matrix provides structure and 
protection and its adhesive properties allow bacteria to adhere to the surfaces and other cells. The 
biofilm protects the cells from antibiotics, cells of the hosts’ immune system and extreme environments 
such as desiccation (Limoli et al. 2015). OMVs are used to release exopolysaccharides to form the 







Both Gram-negative and Gram-positive bacteria communicate using quorum sensing (Ramsey et al. 
2009). QS involves the release of signalling molecules, which are used for both intraspecies and 
interspecies communication. Bacteria can detect when there is an accumulation of these molecules in 
the environment, which allows the cells to sense the number of bacteria (cell density). The molecules 
involved in QS can be secreted and delivered to neighbouring bacteria using OMVs (Bielig et al. 2001). 
QS allows bacteria in a population to coordinate gene expression according to cell density (Miller, 
Bassler. 2001). Bacteria use QS to work together to respond appropriately to a change in the 
environment. For example, QS is used to adapt to a change in nutrient availability and to form biofilms. 
Bacteria often use QS to co-ordinate their virulence (for example all secreting a toxin simultaneously) 
and to avoid the host immune response by forming biofilms. 
 
Bacteria use different types of QS signalling molecules called autoinducers. The most common are the 
acyl-homoserine lactones (AHLs) (Cataldi et al. 2007). Some QS molecules are secreted into the 
environment without OMVs. However, some QS molecules are highly hydrophobic and unable to cross 
the LPS layer on Gram-negative cell envelopes or they are too large. In these cases, QS signalling 
molecules can be packaged into OMVs. An example of this is the quorum sensing molecule produced 
by P. aeruginosa called Pseudomonas Quinolone Signal (PQS). PQS is packaged into OMVs for 
transport from cell-to-cell as it is hydrophobic. PQS has been found to cause curvature in the OM of 
other P. aeruginosa cells and it has also been found to initiate and increase OMV production in other 
cells (Mashburn-Warren et al. 2008). This is discussed further in Section 1.4.1. 
1.4 OMV biogenesis 
1.4.1 Models of OMV biogenesis 
Electron microscopy images suggest that OMVs are formed by bulging of the OM which pinches off 
and captures proteins from the periplasm. However, analysis of OMV composition suggests that the 
process is more regulated and complicated than this. For example, the composition of the OMV is 
similar but can differ from the bacterial OM it is derived from. Similarly, OMV-associated proteins can 
vary greatly from the periplasm as certain proteins appear to be enriched and others excluded from the 
OMVs (Schwechheimer, Kuehn. 2015). There are many models proposing different theories for the 
process of OMV biogenesis, which are discussed below. OMV biogenesis will be discussed in three 
parts: 1. Bulging 2. Cargo enrichment and exclusion 3. Scission.  
 
 
1.4.1.1 Outer Membrane Bulging 
The first step of OMV biogenesis is the bulging of the OM, which can be explained by the four models 











































Model 3: Lipid microdomains 
• Some areas of the OM can become enriched with certain types 
of LPS, LPS-associated proteins and/or phospholipids. These 
areas are known as Lipid microdomains 
• Lipid microdomains tend to bulge outwards due to the LPS 
charge or increased membrane fluidity. This leads to an 








Figure 1.8 Four models of how the outer membrane bulges to produce OMVs  
The four models of OM bulging are: 1. Missing lipoprotein link (a) 2. Accumulation of envelope components 
or misfolded proteins (b) 3. Lipid microdomains (c) 4. Insertion of Pseudomonas quinolone signal (PQS) 
into the outer leaflet (d). Image sourced from Schwechheimer, Kuehn (2015).  
Model 4: Insertion of Pseudomonas quinolone signal 
(PQS) into the outer leaflet 
• P. aeruginosa packages the quorum sensing molecule 
Pseudomonas Quinolone Signal (PQS) into OMVs for 
transport from cell-to-cell as it is hydrophobic  
• PQS is bound to LPS in the bacterial outer membrane 
• PQS has been found to cause curvature in the P. aeruginosa 
OM and it has also been found to initiate and increase OMV 
production (Mashburn-Warren et al. 2008) 
 
d 
Model 2: Accumulation of envelope components or misfolded 
proteins 
• OM bulging occurs where there is an accumulation of misfolded 
proteins or cell envelope components such as peptidoglycan 
fragments or LPS. These areas are known as Outer Membrane 
Nanoterritories and also appear to have reduced Lpp crosslinks 
between the OM and peptidoglycan 
• This is thought to induce bulging of the OM and this leads to 
increased OMV production in these areas to remove these 
misfolded proteins from the cell in OMVs 
• There is thought to be an imbalance in the production of 
peptidoglycan in certain regions of the periplasm. This leads to an 
excess of muramic acid which generates turgor pressure and causes 




Model 1: Missing lipoprotein (Lpp link) 
• For an OMV to form, the outer membrane must detach from the 
peptidoglycan layer 
• Peptidoglycan (PG) endopeptidases are thought to form the Lpp 
link between the peptidoglycan and the outer membrane in the 
cell envelope 
• At the position where the Lpp links are reduced or missing, 





1.4.1.2 Cargo enrichment and exclusion  
The abundance of a particular protein in the OM and periplasm does not necessarily reflect the 
concentration of that protein within the OMV. A selective and regulated process of enriching and 
excluding certain proteins from the OMVs is thought to occur. It appears that cargo, which is destined 
to be incorporated into the OMVs, is targeted to the sites of OMV budding. Similarly, cargo that is not 
destined for the OMVs are located away from the sites of OM bulging (Figure 1.9). Currently, there is 


















It has been proposed that OMVs are released from the cell when the bud grows to a size where the 
membrane curvature forces it to separate and causes scission. The source of energy for membrane 
scission remains unclear. One possibility could be the transfer of energy from the cytoplasm but the 
mechanism is still unknown and further research is needed (Kulp et al. 2010). 
 
1.4.2 How are the contents of OMVs released at the target site? 
1.4.2.1 Entry of OMVs into other Prokaryotic cells 
Gram-negative bacteria 
The fusion of OMVs with other Gram-negative cell membranes is the most likely route of entry as their 
membranes are so similar. Once the OMVs have fused to the bacterial cell, the OMV luminal contents 
are released into the periplasm (Kulp et al. 2018). OMVs may contain peptidoglycan hydrolase enzymes 
Figure 1.9 Model for OMV cargo selection  
Cargo to be included within the OMVs appear to interact with OM-associated proteins which are prone to 
budding. Cargo to be excluded from OMVs are thought to interact with other cell envelope components 
which are not found at the sites of budding and OMV formation 
Image sourced from Schwechheimer, Kuehn (2015).  
 
• Certain cargo from the periplasm appear to be 
selectively included or excluded from OMVs via a 
sorting mechanism 
 
• Cargo to be included within the OMVs appear to 
interact with OM-associated proteins which are 
located in sites prone to budding 
 
• Cargo to be excluded from OMVs are thought to 
interact with other cell envelope components which 





which can degrade the peptidoglycan cell wall in the periplasm and cause bacterial cell lysis 
(Kadurugamuwa, Beveridge. 1996). 
 
Gram-positive bacteria 
Gram-positive bacteria have very different membrane compositions to OMVs produced from Gram-
negative bacteria. Evidence suggests that OMVs adhere to the cell wall of Gram-positive bacterial 
membrane then lyse. The cargo is then released and enters the cell by diffusion through the membrane 
(Kulp et al. 2018). Some OMVs contain peptidoglycan hydrolase enzymes, which digest the Gram-
positive peptidoglycan cell wall and cause lysis (Kadurugamuwa, Beveridge. 1996).  
1.4.2.2 Entry of OMVs into Eukaryotic cells 
There are four main methods that allow OMV entry into eukaryotic host cells which are summarised 
















The routes of entry into host cells can be split into the following categories: 
1. Clathrin dependent: Clathrin is a protein that plays a major role in clathrin-mediated 
endocytosis. Clathrin is the major scaffold protein that can assemble into a cagelike structure on 
cell membranes. When ligands bind to receptors on the cell surface, the clathrin structure forms 
around the desired cargo to become the inside surface of the vesicles formed during 
endocytosis. Clathrin coated pits are formed on the membrane of the host cell. OMVs contain 
ligands on their surface, which bind to the host cell receptors. The OMVs are internalised by 
the cell through clathrin-mediated endocytosis and enter the endosomal trafficking pathway of 
the host cells where the OMV cargo is released. 
2. Caveolin mediated: Lipid rafts are microdomains of the plasma membrane with increased 
concentrations of cholesterol and sphingolipids (Mulcahy et al. 2014). These domains are 
Figure 1.10 Entry of OMVs 
into eukaryotic cells 
Diagrams of four routes of 
entry are shown above: 1. 
Clathrin dependent 2.Caveolin 
mediated 3. Lipid raft 4. 
Membrane fusion. Inhibitors 
of OMV entry are also listed 
above next to the relevant 
method. Image sourced from 





sometimes enriched with the membrane protein caveolin. Caveolins form caveolae which are 
cave-shaped invaginations of the host cells plasma membrane. The internalisation of the OMVs 
using caveolin-mediated endocytosis is thought to avoid fusion with lysosomes. This means 
that the cargo of the OMVs is delivered faster with less chance of degradation compared to 
clathrin-dependent endocytosis (Lim et al. 2014). OMVs contain ligands which bind to host 
cell receptors to trigger endocytosis. 
3. Lipid raft mediated: Lipid raft domains are more compact than other areas of the plasma 
membrane and can cause an inwards curvature of the membrane (invaginations). Viruses are 
known to use lipid rafts to enter host cells and it is possible that OMVs use lipid rafts as points 
of entry too (Kulp et al. 2010). This route of OMV uptake is not reliant on clathrin or caveolin 
coated membrane invaginations. 
4. Membrane fusion: OMVs have been found to enter eukaryotic host cells despite the 
differences in membrane architecture. Model membranes representing OMVs and host 
membranes have confirmed that fusion between the two membrane types can occur (Jager et al. 
2014). However, the exact mechanism remains unclear.  
5. Macropinocytosis: Macropinocytosis is a type of endocytosis that involves the internalisation 
of extracellular material from the environment. It is characterised by polymerisation of actin to 
form actin filaments at the cell membrane. The cell membrane ruffles and closes in a way that 
engulfs extracellular material from the surroundings (Weiner et al. 2016). It is possible that 
OMVs enter host cells via micropinocytosis, however, it is not believed to be an event induced 
by the OMVs themselves (O'Donoghue, Krachler. 2016). 
 
1.5  Is OMV secretion a novel secretion system? 
Gram-negative bacteria have six major secretory mechanisms, which are summarised later on in Section 
1.5.2. In order for a molecule to be secreted from bacteria, there are two membranes to cross (the inner 
and outer membranes).  
1.5.1 Summary of the Secretory pathway (Sec) and the Twin-arginine translocation 
pathway (Tat) 
There are two different pathways to transport proteins across the inner membrane in Gram-negative 
bacteria: the Secretory pathway (Sec) and the Twin-arginine translocation pathway (Tat). In the Sec 
pathway, proteins are transported in an unfolded state. They are folded at the trans-side of the 





Sec pathway: transport of unfolded proteins  
Secreted proteins will either be released into the periplasm in an unfolded form or may be embedded in 
the inner membrane (Figures 1.11-1.13). Proteins destined for the Sec pathway have a hydrophobic 
signal sequence which is approximately twenty amino acids long. This signal sequence found at the N 
terminus of the protein is recognised by either SecB or a signal recognition particle (discussed below). 
 
Sec pathway: Proteins destined for the periplasm or extracellular secretion 
Proteins destined for the periplasm or secretion outside of the cell contain a removable signal sequence 
specific for this Sec pathway. SecB recognises the signal sequence and binds to it to keep the protein 
unfolded. SecB delivers the protein to SecA which guides the protein to a channel called SecYEG. The 







Sec pathway: Proteins destined for the inner membrane 
Proteins that are destined for the inner membrane contain a different signal sequence recognised by 
SRP. SRP binds to the protein during translation at the ribosome. The docking protein FtsY then guides 
the protein-ribosome complex to the SecYEG channel. However, in this case, the protein passes out of 







Tat pathway: transport of folded proteins 
The Tat pathway is used for the secretion of folded proteins which are folded and/or post-translationally 
modified in the cytoplasm. In this pathway, TatB and TatC bind to a specific signal peptide on the N 
terminal of the protein. TatA is then recruited to the membrane to form a channel across the inner 




Figure 1.12 Secretory pathway 
for proteins destined to be 
embedded in the inner 
membrane 
Image sourced from Green et al. 
2016. 
Figure 1.13 Twin-arginine 
translocation pathway for 
folded proteins  
Image sourced from Green et al. 
2016. 
Figure 1.11 Secretory pathway 
for proteins destined for the 
periplasm 





1.5.2 Overview of bacterial secretion systems 
Bacterial secretion systems are complexes of proteins which are found on the bacterial cell membrane 
and are used for the extracellular secretion of proteins or other substances. They are used by pathogenic 
bacteria to secrete virulence factors which can cause damage to the host or other competing 
microorganisms in the environment. There are six major bacterial secretory systems in Gram-negative 
bacteria which are outlined in Table 1.1. 
 









Uses Sec     
or Tat? 






1 No Protein contains a signal sequence specific for the 
ABC transporter. The protein is excreted outside 








2 Yes Proteins are initially transported to the periplasm 
through the Sec or Tat systems. Once in the 
periplasm, the molecule passes through the outer 






1-2 No Similar to a syringe, proteins are injected into 
eukaryotic cell cytoplasm from the bacterial 







1 Yes Uses an envelope spanning complex of proteins 
that forms a channel from the cytoplasm of the 
bacterial cell to the cytoplasm of a recipient cell.  






2 Yes Proteins are transported through the inner 
membrane using the Sec pathway. These proteins 
can form β-barrel structures in their C-terminus 
which allows insertion into the OM (this is known 
as the autotransporter). The rest of the peptide can 
reach outside the cell which is known as the 
passenger domain. The autotransporters are often 
cleaved which releases the passenger domain 
while leaving the β-barrel domain in the OM 






1 No Current models of this secretion system suggest 
that there is dynamic structure which closely 
resembles a bacteriophage. This is anchored to the 
cell by a complex which spans the cell envelope. 
Proteins can be transported to from the cytoplasm 




















1.5.3 Evidence that OMVs are a novel secretory system in Gram-negative bacteria 
The formation and secretion of OMVs containing cargo was described as a seventh bacterial secretion 
system (McBroom, Kuehn. 2007). It can be labelled as a secretion system as cargo is packaged into 
OMVs in a deliberate and selective way for later release into the environment. It is also very different 
from the existing secretion systems outlined in Table 1.1 and Figure 1.14 above. The unique 
characteristics of OMVs as a secretion system were outlined in a review in 2010 (Kulp et al. 2010) and 
were as follows: 
1. OMVs can be used to secrete bacterial lipids and other insoluble compounds that cannot be 
secreted via the other six secretory systems. 
2. Cargo is protected within the lumen of the OMVs. This means that they are protected from 
extracellular proteases in the environment until they have reached their target destination. 
3. Proteins (for example virulence factors) can be delivered to the target in high concentrations 
within the OMVs. OMVs allow these molecules to reach the target cells in a concentrated form 
where they are fully folded and biologically active. 
4. OMVs can contain adhesins on their surface to target them to specific target cells bearing the 
correct receptors. 
5. Lastly, multiple virulence factors can be packaged together for maximum damage to the target 
cell (Demuth et al. 2003). 
  
Figure 1.14 Schematic diagram of the bacterial secretory systems 
Secretory systems Type I to VI are represented here along with the Sec and Tat systems. Image 




1.6 Using Escherichia coli (E. coli) as a model system to study OMVs 
1.6.1 Introduction to E. coli  
E. coli is a commensal organism in humans and is part of the intestinal flora. It can also be found in 
every day food such as raw meat, raw egg, vegetable salads and unpasteurised milk. Some strains of E. 
coli can acquire virulence factors and become pathogenic. These strains can cause a range of diseases 
such as urinary tract infections, kidney infections, cystitis, cholangitis, food poisoning and bacteraemia. 
Treatment for infections caused by E. coli are becoming more difficult as they have developed 
resistance mechanisms to most first-line antibiotics (Sabaté et al 2008). Antibiotic resistance in E. coli 
is a major concern as it is the most common Gram-negative bacterial pathogen in humans (Rasheed et 
al. 2014). Virulence factors of pathogenic E. coli include adhesins, flagella, fimbriae and hemolysin. 
They are also easily able to acquire and accumulate antibiotic resistance genes through horizontal gene 
transfer making many strains multidrug resistant (Poirel et al. 2018). 
 
1.6.2 E. coli pathogenicity 
Urinary tract infections (UTIs) 
Approximately 50 to 60% of women will have UTIs in their lifetimes, the majority of which are caused 
by E. coli (Al-Badr, Al-Shaikh. 2013). Some of these will develop recurrent UTIs where the same 
pathogen re-infects multiple times. UTIs can infect the bladder, urethra or kidneys and can currently be 































Urinary tract infections begin when uropathogens, such as E. coli, contaminate the periurethral area. 
These bacteria can then colonise the urethra (step 1). After entering the urethra, E. coli can then migrate 
upwards towards the bladder (step 2). The bacteria can adhere to uroepthelial cells by expressing Type 1 
fimbriae and adhesins (step 3). The immune response of the host causes neutrophils to arrive to the site 
of invasion (step 4). However, bacteria can evade the immune system due to morphological changes or 
invasion of host cells. These successful bacteria multiply (step 5) then form biofilms (step 6) for 
protection. Bacteria within the biofilm can secrete toxins and proteases to damage host epithelial cells 
(step 7). Bacteria can now migrate towards the kidneys (step 8) and begin colonisation of renal tubular 
epithelial cells by expressing Type 1 fimbriae (step 9). The tissues of the kidney are also damaged by 
release of toxins such a haemolysin (step 10). Cytokines are also induced, which causes an 
inflammatory immune response. This is known as pyelonephritis (a kidney infection). If the bacteria 
cross the kidney tubular epithelial barrier, the uropathogens can enter the blood and cause bacteraemia 
which can be fatal (step 11).     
  
Figure 1.15 The stages of 
urinary tract infections (UTIs) 
The eleven stages of UTIs are 
described in detail below. In the 
case of infection due to a 
catheter, the immune response 
causes the accumulation of 
fibrinogen on the catheter. 
Uropathogens that express 
fibrinogen-binding proteins can 
form biofilms on the catheter 
(see step 3). Image sourced 




1.6.3 Type 1 fimbriae biosynthesis and introduction to FimA 
Type 1 fimbriae are extracellular appendages that are synthesised by E. coli cells (Figure 1.16 a). 
Fimbriae allow bacteria to adhere to host cells and allow colonisation of host tissues. Type 1 fimbriae in 
E. coli bind to mannose receptors on the surface of urinary epithelial cells (Nishiyama et al. 2005) to 
initiate the colonisation of a certain area. They are 2-7 nm in diameter but can be up to 2 µm in length 
(Costello et al. 2012). Fimbriae are anchored in the outer membrane of Gram-negative bacteria by FimD 
(see Figure 1.16 b). The main structural component of Type 1 fimbriae is FimA. FimA monomer 
proteins polymerise to form the rod portion of the Type 1 fimbriae, which contains approximately 300-
5000 FimA monomer subunits (Nishiyama et al. 2005). The tip fibrillum is synthesised first and 
consists of FimH, FimG and FimF. FimA monomers are then added and polymerise to form the main 
structure of the Type 1 fimbriae. 
 
To assemble the Type 1 fimbriae, the chaperone protein FimC forms complexes with new proteins 
entering the periplasm. Fimbriae-associated proteins FimA, FimF, FimG and FimH are transported 
across the inner membrane (via the Sec pathway) into the periplasm. Type 1 fimbriae components are 
assembled by FimC (the periplasmic chaperone) and an usher protein called FimD. FimD is located in 
the outer membrane and is also known as the assembly platform as it is the location where Type 1 


















The fimbrial subunits have an immunoglobulin-like fold but are missing the seventh C-terminal β strand 
(known as the ‘pilin fold’). This means that the Ig-like folds are incomplete and that the subunit folding 
is dependent on a periplasmic chaperone for the correct folding. The chaperone protein FimC forms 
complexes with each of the fimbrial subunits in the periplasm. FimC donates the missing β-strand to 
Figure 1.16 Schematic diagram of 
the formation of Type 1 fimbriae 
Type 1 fimbriae are extracellular 
appendages produced by E. coli for 
adhesion which can be visualised using 
electron microscopy (a). Diagram 
shows assembly of Type 1 fimbriae by 
the chaperone-usher pathway (b). 
Image a was sourced from Costello et 
al. 2012. Image b was sourced from 










complete the protein so it is ready for incorporation into the Type 1fimbriae. The FimC-protein 
complexes are recognised by FimD in the outer membrane. The folded subunits are released from FimC 
are guided by FimD through the outer membrane and on to the growing Type 1 fimbriae.  
 
In the assembled fimbriae, there is an N-terminal extension of approximately 15 residues preceding the 
‘pilin fold’. This acts as a donor strand to the subunit before it. Each fimbrial subunit gives its donor 
strand to the subunit before it and accepts a donor strand from the next subunit in the chain. It is thought 
that a conformation change occurs during subunit assembly, which makes Type 1 fimbriae so stable. 
The quaternary structure of the Type 1 fimbriae produced extracellularly is helical. These fimbrial 
proteins are important as FimA monomer was found to be heavily enriched in some E. coli OMVs.  
1.6.4 Flagella biosynthesis and introduction to Flagellin 
Flagella are extracellular appendages used by bacteria for motility which are used for host invasion. 
Flagella are approximately 10-30 nm in diameter and 5-20 µm in length (Atlas of Oral Microbiology, 
2015). Bacterial flagellum are complex structures and typically over 50 genes are involved in flagellar 

















Figure 1.17 Schematic diagram of flagellar assembly 
A typical flagellum consists of the following components: 1. The basal body 2. A motor 3. A switch 4. A 
hook 5. A filament 6. Export apparatus (a). The long helical filament portion rotates as a propeller which 







FlgA flagella basal body P-ring formation protein FlgA
FlgB flagellar basal-body rod protein FlgB
FlgC flagellar basal-body rod protein FlgC
FlgD flagellar basal-body rod modification protein FlgD
FlgE flagellar hook protein Flg
FlgF flagellar basal-body rod protein FlgF
FlgG flagellar basal-body rod protein FlgG
FlgH flagellar L-ring protein precursor FlgH
FlgI flagellar P-ring protein precursor FlgI
FlgK flagellar hook-associated protein 1 FlgK
FlgL flagellar hook-associated protein 3 FlgL
FlgN flagella synthesis protein FlgN
FlhA flagellar biosynthesis protein FlhA
FlhB flagellar biosynthetic protein FlhB
FliC flagellin
FliD flagellar hook-associated protein 2
FliE flagellar hook-basal body complex protein FliE
FliF flagellar M-ring protein FliF
FliG flagellar motor switch protein FliG
FliH flagellar assembly protein FliH
FliI flagellum-specific ATP synthase
FliJ flagellar FliJ protein
FliK flagellar hook-length control protein FliK
FliM flagellar motor switch protein FliM
FliN flagellar motor switch protein FliN/FliY
FliO flagellar protein FliO/FliZ
FliP flagellar biosynthetic protein FliP
FliQ flagellar biosynthetic protein FliQ
FliR flagellar biosynthetic protein FliR
FliS flagellar protein FliS
FliT flagellar protein FliT
MotA chemotaxis protein MotA






The main structural component of flagella is the protein Flagellin (FliC). Flagellin monomers are 
transported from the cytoplasm into a central channel through the basal body and hook structures to the 
filament. Flagellin monomer subunits polymerise to form the main structural subunit of the flagella and 
this occurs under the FliD filament cap. The final structure can contain 20,000-30,000 Flagellin subunits 
that form a helical structure.  
Flagellin monomers have strong oligomerisation potential and polymerise into filaments in vitro. It is 
thought that the N and C terminals of FliC are responsible for Flagellin polymerisation. In the 
monomeric form of Flagellin, the N and C terminals are exposed and have no tertiary structure. 
However, these regions become folded and incorporated into the polymer. In the cytosol, spontaneous 
polymerisation is prevented by a cytosolic chaperone protein that is specific for binding to FliC called 
FliS. FliS binds to the C terminal of Flagellin and inhibits premature polymerisation (Auvray et al. 
2008). Bacterial flagella are of interest as the Flagellin (FliC) monomer was found to be heavily 
enriched in some E. coli OMVs.  
 
1.6.5 E. coli K-12 strains vs. B strains 
E. coli K-12 strains and E. coli B strains are very commonly used as a model organism in the scientific 
community. E. coli is widely used in biotechnology due to its rapid doubling time, ease of genetic 
manipulation and our extensive knowledge of the genome, metabolomics and biochemistry. The origin 
of the E. coli K-12 strain can be traced to a stool sample in 1922 at Stanford University (Bachmann et 
al. 1972). Although the origins of the E. coli B strain are unclear, they are commonly used for bacterial 
transformations and expression of recombinant proteins. B strains are deficient in extracellular 
appendages such as flagella and fimbriae, which reduces their pathogenicity compared to K-12 strains 
(Marisch et al. 2013). E. coli B strains (such as BL21) are also deficient in certain proteases such as Lon 
and OmpT. They also have enhanced membrane permeability to allow uptake of plasmid DNA. 
 
One of the ultimate project aims was to manipulate E. coli strains into producing OMVs with specific 
cargo for therapeutic use. For this study, OMVs were purified from the E. coli B strains: BL21 and 
BL21 (DE3). The DE3 designation means that the strain carries the gene for T7 RNA polymerase under 
control of the lacUV5 promoter. This allows inducible protein expression of any gene controlled by the 
T7 promoter when induced with IPTG. It is called DE3 as the T7 RNA polymerase gene is carried on a 
DE3 lysogen. OMVs were also purified from a range of K-12 strains and six clinical isolates for 





1.7 Using Pseudomonas aeruginosa OMVs as Gram-negative comparison 
1.7.1 Introduction to Pseudomonas aeruginosa (P. aeruginosa) 
P. aeruginosa are ubiquitous Gram-negative bacteria, which are commonly found in the environment in 
soil and water. They are classed as opportunistic pathogens as they rarely cause disease in healthy 
individuals, but are a major cause of infection in patients that are immunocompromised. P. aeruginosa 
is one of the most common causes of hospital-acquired infections and ventilator-associated pneumonia 
(Barbier et al. 2013). P. aeruginosa infection can be fatal in immunocompromised patients such as 
those with cystic fibrosis (CF). CF leads to the formation of a thick layer of mucus within the lungs of 
the patients. This prevents mucociliary clearance by the cilia, which line the lungs and function to clear 
any pathogens or inhaled particles from blocking the airways. This provides an ideal area for P. 
aeruginosa to colonise and form biofilms with other opportunistic pathogens such as Bukholderia 
cenocepacia (Eberl et al. 2004). Treating P. aeruginosa infections is becoming increasingly difficult as 
P. aeruginosa strains are versatile and able to adapt well to environmental changes. P. aeruginosa 
strains have now developed resistance to many of the current antibiotics available (Okamoto et al. 
2001). The strains not only have intrinsic resistance to antibiotics, but are also easily able to acquire 
genes encoding resistance mechanisms making this strain a global threat to human health.  
 
1.7.2 Roles of OMVs in the pathogenicity of P. aeruginosa  
P. aeruginosa strains can form biofilms with other bacteria, such as Burkholderia cenocepacia, in the 
lungs of CF patients. Bacteria can communicate during the formation of biofilms by quorum sensing 
(Eberl et al. 2004). P. aeruginosa strains produce OMVs, which have been found to contain virulence 
factors, such as toxins and β-lactamases. The OMVs can diffuse across the mucus layer found within the 
lungs and are internalised by lung epithelial cells that cause the release of the cargo (Koeppen et al. 
2016). Interestingly, the virulence factor Cif (CFTR inhibitory factor) has been found in OMVs which 
was found to reduce the host immune response (Koeppen et al. 2016). Cif causes lysosomal degradation 
of CFTR (CF transmembrane conductance regulator), which is essential for mucociliary clearance 
within the lungs. Also, Cif has been found to decrease MHC class 1 antigen presentation on lung 
epithelial cells (Koeppen et al. 2016). P. aeruginosa OMVs were studied as a Gram-negative bacterial 
comparison for E. coli OMVs with an aim to compare and contrast OMV cargo in another clinically 






1.8 Membrane Vesicles from Gram-positive bacteria 
1.8.1 Gram-positive cell envelope 
As discussed in Section 1.2.1, the Gram-positive cell envelope is composed of a cytoplasmic membrane 
and a thick peptidoglycan cell wall, with no outer membrane present (Figure 1.18). Instead, there is a 
thick layer of peptidoglycan to protect the cell membrane from harsh environments and turgor pressure 




The composition of peptidoglycan was summarised in Section 1.2.2. The peptidoglycan layer in the 
Gram-positive cell envelope is approximately 20-80 nm in diameter with many layers compared with 
the peptidoglycan of Gram-negative bacteria which is less than 10 nm thick (Mai-Prochnow et al. 
2016). Threading through the layers of peptidoglycan are teichoic acids. These are long anionic 
polymers that are covalently linked to the peptidoglycan layer. Lipoteichoic acids are also present, 
which are anchored to the cytoplasmic membrane and run through the peptidoglycan layer (Silhavy et 
al. 2010). There are also a range of proteins found within the cell envelope and some are associated with 
the cytoplasmic membrane and peptidoglycan layer. Lastly, surface proteins such as adhesins allow 
adhesion to host cells. 
1.8.2 Comparison of Membrane Vesicle (MV) composition between Gram-negative and 
Gram-positive bacteria 
Recent evidence in the literature suggests that Gram-positive bacteria produce membrane vesicles 
(MVs). These are different to OMVs in cargo and composition due to differences in the membrane 
structure (Brown et al. 2015, Bitto et al. 2017). OMVs derived from Gram-negative bacteria are 
composed of the outer membrane and contain cargo from the periplasm. Gram-positive membrane 
vesicles, however, are composed of the cytoplasmic membrane only and cargo from the cytosol (Figure 
1.19). The term membrane vesicles (MVs) will be used to describe vesicles from Gram-positive bacteria 
as they are not outer membrane vesicles (OMVs). MVs may also be used as a term to describe both 
MVs from Gram-positive bacteria and OMVs from Gram-negative bacteria as it encompasses both. 
Figure 1.18 Gram-positive bacteria cell 
envelope 
The Gram-positive bacterial cell envelope 
is composed of the plasma membrane and 
a thick peptidoglycan cell wall. Image 



















1.8.2.1 Gram-positive MV composition and cargo 
In 2009, membrane vesicles were visualised on the surface of Staphylococcus aureus cells using TEM 
(Lee et al. 2009). The MVs were very similar in appearance to OMVs as they were nano-sized, 
spherical membranous structures of 20-100 nm in diameter (Lee et al. 2009). MVs were then purified 
from S. aureus using a method very similar to that used for OMV purification. The purified MVs were 
visualised by TEM and the size of the MVs was determined using dynamic light scattering. To 
determine the MV proteome, MV protein profiles were visualised by SDS-PAGE and proteins were 
characterised by microscopy (Lee et al. 2009).    
MVs from Gram-positive organisms, (such as Staphylococcus aureus), have been found to contain 
cytoplasmic proteins, metabolic enzymes, DNA polymerases, ribosomal proteins and virulence 
factors (Lee et al. 2009). Many of the virulence factors found in Gram-negative OMVs have also 
been found in Gram-positive MVs. These include toxins, haemolysin, adhesins and β-lactamases 
(Joffe et al. 2016). As with OMVs, it appears that Gram-positive cells have a specific sorting 
mechanism for packaging cargo into the MVs. In 2010, it was found that MVs from Bacillus 
anthracis contained toxins (edema factor, lethal factor and protective antigen), which were not 
present freely in the supernatant (Rivera et al. 2010). The protein profile of the MVs were also 
confirmed to be different from that of the cytoplasmic membrane and cytosol making it unique. 
Figure 1.19 Comparison of membrane vesicles formed from Gram-negative and Gram-positive 
bacterial membranes.  
There are significant differences in the composition of Gram-negative and Gram-positive bacterial 
membranes. This leads to variations in the composition of membrane vesicles produced and methods 
of MV biogenesis. This schematic summarises the OMV cargo and membrane composition of typical 





1.8.3 Models for Gram-positive MV biogenesis 
The method of MV biogenesis from Gram-positive bacteria is not fully understood. At first glance, it 
seems unclear how membrane vesicles can bud from the cytoplasmic membrane when the 
peptidoglycan layer is so thick. Three hypotheses of how membrane vesicles are formed from Gram-










1.8.3.1 Turgor pressure  
The first theory is that the turgor pressure produced after MVs are released from the cytoplasmic 
membrane is enough to force the MVs through the peptidoglycan cell wall. In this theory, there may be 
pore sizes within the cell wall which are large enough to allow MVs through or that there are certain 
parts of the cell wall which are thinner than others (Brown et al. 2015). 
1.8.3.2 Proteases degrade peptidoglycan 
MVs released by Gram-positive strains have been found to contain peptidoglycan-degrading enzymes. 
This may suggest that enzymes are secreted with the MVs which degrade the peptidoglycan layer, 
allowing the MVs to bud (Brown et al. 2015).  
1.8.3.3 MVs are transported through a channel 
One final hypothesis is that MVs are transported through the peptidoglycan layer using protein 
channels. This would allow the passage of MVs through the peptidoglycan layer without disrupting the 
cell wall (Brown et al. 2015). 
 
Figure 1.20 Hypotheses of MV formation in Gram-positive bacteria 
Three main hypotheses exist of how Gram-positive bacteria secrete membrane vesicles through such a 
thick layer of peptidoglycan. The first is that MVs can be forced through by turgor pressure (a), the 
second is that enzymes degrade the peptidoglycan cell wall to allow MVs to bud (b) and the third is that 
protein channels are used to guide MVs extracellularly (c). These hypotheses are not mutually exclusive 
and may all be possible. Image sourced from Brown et al. 2015.  
 
 




1.9 Using Streptomyces S4 as a model system to study MVs 
1.9.1 Introduction to Streptomyces  
Antimicrobial resistance (AMR) hinders the effective treatment and prevention of infections caused by 
microbes such as bacteria, fungi, viruses and protozoa. AMR is a serious threat to health globally as the 
infections can no longer be treated and may then be spread to others (World Health Organization, Fact 
sheets on AMR, 2018). Bacteria from the genus Streptomyces produce the majority of antibiotics used 
for medicine, agriculture and veterinary practice (Chater, 2016). With a global emergence of multi-drug 
resistant pathogens, the study of Streptomyces bacteria for new antimicrobial compounds has never been 
more important.    
 
Streptomyces are filamentous soil bacteria that play a key role in the decomposition and recycling of 
plants and fungi. Some have also developed symbiotic relationships with insects or plants and some 
have evolved pathogenic traits (Chater, 2016). Streptomyces are Gram-positive bacteria but are unusual 
as they grow as filamentous hyphae that resemble fungi. Streptomyces have a complex life cycle which 














In this life cycle, free spores germinate to form a substrate mycelium. These are networks of branching 
hyphae that grow by tip extension. When nutrients are depleted, these hyphae grow away from the 
substrate to reach nutrients. The hyphae can also grow upwards and outwards to form aerial mycelium. 
The unbranched cell at the tip of the aerial filament differentiates and eventually the aerial hyphae 
develop into chains of spores. Spores are dispersed into the environment and when settled in the soil, 
start to germinate, which restarts the life cycle (Angert, 2005). 
1.9.2 Streptomyces S4 
In this study, Streptomyces S4 was used, which has a symbiotic relationship with the leaf-cutting ants 
Acromyrmex octospinosus. These ants are highly evolved as they cultivate fungus in specialised 
chambers in their nests (Haeder et al. 2009), which they use as a food source. These ants bring leaves to 
Figure 1.21 Life cycle of 
Streptomyces coelicolor 
Diagram representing the 
stages of the S. coelicolor 
life cycle including the 
development of the 
substrate mycelium, aerial 
mycelium, spore 
development and 
dispersal. Image sourced 




the nest and cut them into smaller pieces to feed to the fungus, which later becomes their main food 
source. The ants maintain the fungal gardens and need to protect the garden from microfungal weeds. 
They do this by removing waste and secreting antifungal compounds from metapleural glands (Haeder 
et al. 2009). There is now evidence that there is a symbiosis between these ants and bacterial strains that 
produce antifungal compounds. One example of this is the strain Streptomyces S4, which is known to 
produce antifungal agents (Haeder et al. 2009). 
 
Streptomyces S4 contains biosynthetic gene clusters which lead to the synthesis of the antifungal 
compounds candicidin (Barke et al. 2010) and antimycin (Seipke et al. 2011). Candicidin is a polyene 
antifungal that is known to be highly effective against Candida albicans. Ergosterol is the main sterol in 
the cytoplasmic membrane of fungi. Candicidin binds to ergosterol, which affects the permeability and 
membrane integrity. This leads to a rapid efflux of potassium ions within the cell which causes death. 
Antimycins are a group of compounds that are toxic towards a range of pathogenic fungi including 
Candida albicans. Antimycins inhibit cytochrome c reductase, which is an enzyme in the mitochondrial 
electron transport chain. This disrupts the entire electron transport chain and inhibits cellular respiration 
which leads to cell death. Previous evidence has found that Streptomyces S4 produces both candicidin 
and antimycins but it is currently not known how they are released extracellularly. 
1.9.3 AmBisome (amphotericin B liposome) 
The AmBisome is a drug delivery system used to treat fungal infections. The AmBisome is a liposome 
which is an artificially made spherical vesicle formed of a phospholipid bilayer (Walker et al. 2018). 












The liposomes in the AmBisome preferentially bind to the fungal cell wall. The active amphotericin B 
is released from the liposome and travels to the fungal cell membrane. Amphotericin B is a polyene 
antifungal agent which binds to ergosterol in the fungal cell membrane. The exact mechanism of 
transport of the amphotericin B from the AmBisome to the fungal cell is unknown. However, it is 
hypothesised that this occurs because amphotericin B has a higher binding affinity for ergosterol 
compared with cholesterol (the main lipid component in the AmBisome) (Stone et al. 2016). 
Figure 1.22 The structure of 
the AmBisome  
The AmBisome is a liposome 
which is an artificially made 
spherical vesicle formed of a 
phospholipid bilayer. This 
liposome is decorated with 
the antifungal agent 
amphotericin B. Images 





Amphotericin B forms transmembrane channels within the fungal membrane which cause efflux of ions 
such as potassium, sodium, chloride and hydrogen from the cell. This loss of ions leads to cell death. 
Due to the known success of the delivery of Amphotericin B within a liposome to fungal cells, it led us 
to wonder if a similar process occurs in nature. This was tested by purifying membrane vesicles from 
Streptomyces S4 to see if any antifungal agents were present (Chapter 5). 
 
1.10 Therapeutic applications of membrane vesicles  
Interest in the MV field is growing and more methods are being developed to use bioengineered MVs 
for drug delivery and vaccines. MVs are often used by bacteria to secrete virulence factors so blocking 
MV production could be a target for preventing infection by these pathogens.  
1.10.1 Using MVs for development of vaccines 
MVs secreted by bacteria are naturally immunogenic and have the potential to be used as vaccines 
against a range of diseases. MVs also can be manipulated and engineered to display specific antigens 
needed for the vaccines against particular bacteria. An ideal vaccine should provoke a strong and 
specific immune response but in a way that is safe and has minimal adverse effects to the host. The 
immune response is triggered by pathogen-associated molecular patterns (PAMPs). PAMPs are unique 
and conserved motifs found in different pathogens and are recognised by the immune system as foreign. 
PAMPs are found on the surface of MVs and can activate the antigen presenting cells of the immune 
system. Another advantage of using MVs for vaccines is that they are non-replicating and cannot 
colonise the host or replicate and cause infection. They have also been shown to be thermostable and 
can withstand chemical treatment (Gerritzen et al. 2017). Antigens can be presented on the surface of 
MVs or within the MVs (luminal) when designing a vaccine. Surface exposed antigens activate antigen-
specific B cells of the adaptive immune response. Antigens within the lumen of MVs can be detected by 
cytotoxic T cells (Gerritzen et al. 2017).  
 
OMVs have been developed for use in the vaccination against the Neisseria meningitidis serogroup B, 
which causes bacterial meningitis. There are currently effective vaccines against the meningococcal 
serogroups A, C, W and Y, but there has been little success with group B. The meningococcal group B 
polysaccharide is very weakly immunogenic as the antigens have strong similarity to those expressed on 
human nerve tissues. This means that there is the potential to cause the production of autoantibodies 
which could be fatal (Hedari et al. 2014). This makes vaccines very difficult to produce and different 
strains can vary in their antigens. In 2013, OMVs were used to produce multicomponent OMV vaccines 
using antigens from various strains. The OMVs were engineered to express three recombinant proteins 
from the serogroup B strain and has been predicted to be effective against 78% of the Neisseria 
meningitidis serogroup B strains currently in Europe (Hedari et al. 2014). It is also safe to use and can 
be co-administered with other vaccines (Hedari et al. 2014). Findings from this project could be used in 




1.10.2 Using MVs for drug delivery 
OMVs produced by bacteria can be manipulated to include certain proteins/antigens of interest for drug 
delivery and vaccines. OMVs produced by various bacterial strains are studied to determine their 
composition and cargo compared with that of the periplasm, outer membrane and whole cell. Although 
the exact mechanism is unclear, certain proteins and lipids appear to be selected and excluded from 
packaging into OMVs. Knowledge of this has allowed the targeting of proteins of interest to OMVs by 
fusion with proteins known to be incorporated into OMVs. 
1.10.2.1 Using E. coli OMVs as recombinant protein delivery vehicles 
In 2009, a foreign antigen FLAG was targeted to OMVs of an engineered E. coli O157:H7 strain. FLAG 
is a short peptide of 8 amino acids that is used for detection and purification of the recombinant proteins 
it is added to. It is hydrophilic and its short length allows it to be present on the surface of the protein of 
interest with minimal disruption to protein function and transport throughout the cell. In this study, the 
FLAG peptide was fused to the β-barrel domain of OmpA which resided in the OM by chromosomal 
tagging. The peptide was located to the periplasmic side of the OM and was more protected from 
extracellular protease degradation (Figure 1.23). The study was successful as the OmpA protein 
containing the FLAG peptide was successfully delivered to the OMVs (Kim et al. 2009). Studies such 
as these establish models for targeting antigens of interest to OMVs for either drug delivery or vaccines.   
  
Figure 1.23 The incorporation of OmpA into E. coli OMVs 
Image sourced from Kim et al. 2009. In this paper, a foreign epitope (FLAG) was targeted to E. 
coli OMVs by fusion with OmpA. The polypeptide tag (FLAG) is an artificial antigen 
commonly used in recombinant DNA and protein technology. FLAG was fused to the β-barrel 




1.10.3 Effect of OMVs on the host immune response  
1.10.3.1 OMVs can modulate the innate immune response  
OMVs can stimulate a proinflammatory response from the host 
The innate immune response is the first line of response to prevent infection. The innate immune 
response is activated when PAMPs are detected. Host cells display pattern recognition receptors (PRRs) 
that detect specific PAMPs. Recognition of PAMPs leads to activation of the host innate immune 
response, which includes inflammation, recruitment of phagocytes and the complement cascade. OMVs 
are formed from the Gram-negative cell envelope and therefore contain PAMPs that are recognised by 
the hosts’ immune system. These include LPS, certain lipids, lipoproteins, virulence factors as well as 
OM and periplasmic proteins which are conserved in pathogens. PRRs are present on host cells of the 
innate immune system including dendritic cells and macrophages and so are activated by the presence 
of OMVs (Kuehn, Kesty. 2005). OMVs are often one of the main factors that initiate an inflammatory 
response in macrophages and host epithelial cells (Chatterjee, Chaudhuri. 2012). 
 
Interaction of OMVs with the complement cascade 
The complement system plays a key role in the immune response. The complement proteins circulate as 
inactive precursors that are activated in response to PAMPs. A cascade is produced where the binding 
of one protein causes the binding of the next protein and so on. The final product is a membrane attack 
complex, which causes cell lysis of bacterial cell membranes. In order to prevent this, OMVs from the 
Gram-negative bacteria Morexella contain the virulence factors UspA1 and UspA2, which bind to one of 
the essential proteins in the complement system called C3 to inactivate it. Without C3, the complement 
cascade is inhibited and no membrane attack complex is formed to lyse pathogens (Tan et al. 2007)). 
 
In contrast to this, Neisseria meningitidis OMVs were found to cause high complement activation 
compared to LPS on N. meningitidis cell OM. This research indicated that the major complement 
activation with meningococcal septicaemia may be due to the immune response reacting to the OMVs 
produced by N. meningitidis rather than the cells themselves (Bjerre et al. 2002). The immune system 
reacting to the OMVs instead of the cells is beneficial as they can evade the immune system response 
more easily. 
1.10.3.2 OMVs modulate the adaptive immune response 
Detection of OMVs 
The adaptive immune response is slower to respond to infection than the innate immune response. 
However, it is a specific response, which is unique to the pathogen. The adaptive immune response is 
carried out by lymphocytes including B and T cells. B cells are produced in the bone marrow and 
generate antibodies, which are specific to the pathogen detected. This opsonises the bacterial cells for 
phagocytosis. T cells can be divided into CD4+ (known as helper T cells) and CD8+ (known as 
cytotoxic T cells). CD4+ T cells induce other cells of the immune response including B cells and CD8+ 




the host. The adaptive immune response can react to OMVs in the same way as it would to a pathogen 
as they contain many of the same PAMPs. 
 
OMVs can contain superantigens 
Neisseria lactamica are commensal Gram-negative bacteria that colonise the nasopharynx area. N. 
lactamica have been found to produce OMVs that contain a mitogen on their surface. Mitogens 
stimulate mitosis and the mitogen associated with N. lactamica OMVs was found to activate B cell 
proliferation, independent of T cells. This mitogen/antigen found on N. lactamica OMVs was found to 
have properties of a superantigen which results in excessive activation of the immune system (Vaughan 
et al. 2010). Superantigens cause activation of high frequencies of T cells or B cells, which are not 
specific for particular antigens. In this case, naive B cells are stimulated to produce polyclonal 
antibodies, which have low affinity for removing the OMV-producing pathogen. This leads to a non-
specific immune response and allows the OMV-producing bacteria to evade specific adaptive immune 
responses (Vaughan et al. 2010). 
1.10.3.3 Example of using of E. coli OMVs for cancer therapy 
In 2014, OMVs were used in the cell-specific delivery of drugs. A mutant strain of E. coli was 
engineered to produce OMVs which were later loaded with a small interfering RNA (siRNA) by 
electroporation. The siRNA chosen was known to target kinesin spindle protein mRNA. Kinesin spindle 
protein plays a critical role in mitosis and its inhibition leads to cell cycle arrest at mitosis then cell 
death. The OMVs were targeted to cancerous cells using a HER2-specific affibody in the membrane. 
HER2 is a transmembrane receptor, which is overexpressed in certain cancers such as breast, ovarian 
and gastric carcinomas (Gujrati et al. 2014). HER2 is therefore used as a target for cancer therapies. In 
order to target the OMVs to the cancerous cells, a genetic fusion was made between the ClyA monomer 
(known to be packaged into OMVs) and an anti-HER2 affibody. OMVs produced from this strain 
displayed the HER2 ligand on their surfaces to target them to cancer cells where the siRNA could be 
delivered. The study appeared to be successful as the OMVs caused cytotoxic effects against cancerous 
cells that overexpressed HER2. 
 
The E. coli OMVs were engineered to have low immunogenicity and minimal endotoxicity to human 
cells. In order to do this, the E. coli K-12 strain used (W3110) had a msbB mutation. This mutation 
causes the cell to produce defective, penta-acylated LPS and reduces the toxicity towards host cells 
compared to the usual hexa-acylated LPS. These findings agreed with a previous study that reported that 
hexa-acylated LPS stimulates the production of TNFα from THP1 cells more than penta-acylated LPS 
(Hajjar, et al. 2002). It is also thought that the expression of the HER2 affibody on the surface of the 
OMVs may have prevented the innate immune response by shielding the OMV PAMPs.  
 
The results of this study were promising as the OMVs appeared to successfully target tumour tissue 
(due to the HER2 affibody) and release the siRNA. Once released, the siRNA induced cytotoxic effects 




the host with only very weak immunogenic responses (Gujrati et al. 2014). The use of attenuated 
bacterial strains with minimal virulence factors and toxicity could be used in the future to produce 
therapeutic OMVs for use in vaccines or drug delivery. 
1.11 Project aims and unanswered questions 
One of the main project aims was to compare the cargo identified within membrane vesicles from a 
range of bacterial strains and to speculate on the function of the molecules packaged (ie. are the 
secretion of these molecules beneficial to the OMV-producing cell?). Another essential aim of the 
project, was to bioengineer bacterial cells to produce OMVs containing a target protein of interest. This 
could ultimately be beneficial for therapeutic applications, such as cell-specific drug delivery or 
development of vaccines. 
1.11.1 What are the best methods to purify and characterise OMVs? 
The first aim (addressed in Chapter 3) was to develop a cost-effective method to purify OMVs 
reproducibly, giving the best yield possible. There is no universal protocol for OMV purification in the 
literature (Klimentová et al. 2015) so this needed to be developed. The isolated OMVs should be intact 
with as few contaminants from the bacterial cell as possible. OMV characterisation methods were 
sourced and developed from previous studies in the literature (McCaig et al. 2013, Klimentová et al. 
2015). This included using electron microscopy, SDS-PAGE, Western blotting, mass spectrometry, 
protein quantification and dynamic light scattering. 
1.11.2 What are the differences in (O)MV composition, cargo and function from both 
Gram-negative and Gram-positive bacterial strains?  
Membrane vesicles were studied in the Gram-negative bacteria E. coli and P. aeruginosa and the Gram-
positive organism Streptomyces S4. 
 
1.11.2.1 Using E. coli to study OMV biogenesis 
One of the ultimate project aims was to manipulate a bacterial strain of interest into producing OMVs 
with specific cargo for therapeutic use. The E. coli genome has been sequenced and annotated across a 
broad range of strains and the information is widely available (for example, the EcoCyc database). E. 
coli K-12 strains and E. coli B strains are very commonly used as a model organism in the scientific 
community. This made E. coli a good candidate for bioengineering to enable targeted expression of 
recombinant proteins for delivery and inclusion in OMVs and there are also previous studies that have 
been successful (Gujrati et al. 2014, Kim et al. 2009). Additionally, the study may give insight into 
which molecules pathogenic E. coli package into OMVs, which could potentially have clinical 
relevance. 
 
1.11.2.2 P. aeruginosa 
P. aeruginosa can form biofilms in the lung of CF patients and are known to communicate during the 




produce OMVs which have been found to contain virulence factors such as toxins and β-lactamases. 
OMVs from P. aeruginosa were studied as a Gram-negative bacterial comparison for E. coli OMVs 
with an aim to compare and contrast OMV cargo in another pathogenic and clinically relevant strain.   
 1.11.2.3 Streptomyces S4 
At the outset of the project, there had been reports that Gram-positive bacteria produced extracellular 
membrane vesicles (MVs). This was originally shown in Mycobacterium ulcerans (Marsollier et al. 
2007) and summarised by Brown et al. 2015, Kim et al. 2015 and Liu et al. 2018. MV production had 
also been documented in Streptomyces coelicolor (Schrempf et al. 2011) and Streptomyces lividans 
(Schrempf & Merling 2015). In both publications it was shown that the Streptomyces species produced 
visible exudates that were enriched in MVs and contained a range of proteins, lipids and bioactive 
molecules such as actinorhodin (a benzoisochromanequinone dimer polyketide antibiotic produced by S. 
coelicolor) and undecylprodigiosin (an alkaloid produced by S. lividans).   
 
In this study, Streptomyces S4 was used which has a symbiotic relationship with the leaf-cutting ants 
Acromyrmex octospinosus. These attine ants are highly evolved as they cultivate fungus in specialised 
chambers in their nests (Haeder et al. 2009) which they use as a food source. Streptomyces S4 contains 
biosynthetic gene clusters which leads to the synthesis of the antifungal compounds candicidin (Barke et 
al. 2010) and antimycin (Seipke et al. 2011). Unlike both S. lividans and S. coelicolor, S4 does not 
produce highly coloured and visible exudates but it was known that candicidin and antimycin were 
secreted extracellularly and produce a visible zone of inhibition when plated with C. albicans (Barke et 
al. 2010). We reasoned that the antifungals may be packaged into MVs to facilitate their diffusivity and 
targeting. This was particularly applicable to candicidin which is a complex and highly insoluble 
molecule. Streptomyces S4 mutants were also available which were unable to produce antimycin 
(ΔantC), candicidin (ΔfscC) and a double mutant which was unable to produce antimycin or candicidin 
(ΔantC ΔfscC). This enabled us to investigate whether the biosynthesis of either candicidin or antimycin 
was specifically linked to MV biogenesis in Streptomyces S4.  
1.11.3 Can we target a protein of interest to be incorporated into bacterial MVs?  
During these studies, E. coli K-12 clearly demonstrated an enrichment of FimA into OMVs. For this 
reason, fusion of GFP and mNeon green to FimA were chosen to trial targeting a chosen protein to the 
OMVs. However, at the outset of the project, it was not clear whether fusion of a protein to FimA alone 
was sufficient to facilitate correct targeting. We trialled this with FimA monomer protein which was 
tagged with either GFP (chromosomal FimA-GFP fusion) or Neon Green (exogenously expressed 




Chapter 2: Materials and Methods 
2.1 Materials 





Chemical name Supplier Product code
Acetic acid Fisher Scientifc A0360 
Acetone Fisher Scientifc A0560
Agar technical No3 Oxoid LP0013
Ammonium sulphate Acros Organics 205870010
Bacto peptone BD Chemicals 211677
Bacto tryptone BD Chemicals 211705
Bacto yeast extract BD Chemicals 212750
Bovine serum albumin Sigma-Aldrich A2153
Butanol Fisher Scientifc B4850
Calcium chloride, anhydrous Sigma-Aldrich C1016
Casein enzymic hydrolate Sigma-Aldrich 22090
Chloroform Fisher Scientifc C4960
D-glucose anhydrous Fisher Scientifc G/0500/61
D-Mannitol Sigma-Aldrich M9546
Ethanol (absolute, 99.8+%) Fisher Scientifc E0650
Glucose Fisher Scientifc G05002
Glycerol Fisher Scientifc G/0600/17




Hydrochloric acid (HCl) Fisher Scientifc H1150
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Melford MB1008
Malt extract Oxoid LP0039
Methanol Fisher Scientifc M4000
OptiPrep (density gradient medium) Sigma-Aldrich D1556
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich 78830
Phosphate buffered saline Oxoid BR0014G
Protein assay dye reagent concentrate (Bradford 
assay)
Bio-rad 5000006
Sodium bicarbonate Sigma-Aldrich S5761
Sodium chloride Fisher S/3160/60
Sodium dodecyl sulphate (SDS) Melford B2008
Sucrose Fisher S/8600/60
Trichloroacetic acid (TCA) Sigma-Aldrich T4885
Tris (hydroxymethyl methylamine) Fisher T/P630/60
Tryptone soy broth Sigma-Aldrich 22092




Table 2.2 Enzymes, substrates and inhibitors 
 
 
Table 2.3 SDS-PAGE reagents 
 
 















Enzymes and Substrates Supplier Product code
4-Nitrophenyl acetate Sigma-Aldrich N8130 
Mini Protease Inhibitor Cocktail tablets Sigma-Aldrich 11836153001 ROCHE
Protease from Streptomyces griseus Sigma-Aldrich P5147 
Proteinase K Sigma-Aldrich P6556
Trypsin Sigma-Aldrich 59430C-100ML
SDS-PAGE Supplier Product code
InstantBlue Protein Stain Expedeon ISB1L
NuPAGE 4-12% Bis-Tris Protein Gels, 1.0 
mm, 10-well
Thermo-Fisher NP0321BOX
NuPAGE MOPS SDS Running Buffer 20x Thermo-Fisher NP0001
NuPAGEMES SDS Running Buffer 20x Thermo-Fisher  NP0002
Pierce Silver Stain Kit Thermo-Fisher 24612
Precision Plus Protein Dual Color Standards Bio-rad 1610374
Reducing sample buffer (4x) Invitrogen NP0008
Wet transfer/Western blotting Supplier Product code
BCIP/NBT tablets Sigma B5655
Milk (Instant Dried Skimmed) Tesco N/A
PVDF membrane 0.2 µm pore Roche 3010040001














Clonality Host Antibody Specificty
Anti-FimA monoclonal FimA (18 kDa)
Professor Hultgren, 
Washington 
University in St. 
Louis
Polyclonal Rabbit
"Gel slice antibodies were made by 
treating rabbits with material from 
gel slices containing FimA (from 







University in St. 
Louis
Polyclonal Rabbit
"Whole pili antibodies were made 
by treating rabbits with non-
denatured UTI89 type 1 pilus preps"
Anti-Flagellin Flagellin (51 kDa) Abcam #ab93713 Polyclonal Rabbit
This antibody is specific for 
bacterial Flagellin (FliC). Reacts 
with Flagellin from: E. coli, 
Salmonella anatum, Salmonella 
selandia







N/A Promega #S372B Polyclonal Goat
Heavy and light chains for all IgG 
subclasses. Immunoaffinity-purified 
using immobilized antigens and 




mNeon green        (34 
kDa)
Chromotek #32F6 Monoclonal Mouse
 The antibody recognizes 
mNeonGreen at the N-terminus, C-
terminus, or internal site of the 
fusion protein  
Anti-OmpA antibody










N/A Sigma #A3687 Polyclonal Goat





Table 2.6 Reagents for TEM 
 




Table 2.8 Reagents for Mass Spectrometry 
 
Table 2.9 Antibiotics/Antifungals used 
 
Table 2.10 Reagents used for cloning techniques 
 
  
Electron Microscopy Supplier Product code
Gelatin capsules Agar Scientific G29208
Glutaraldehyde fixative Agar Scientific AGR1011
Immunogold conjugate 10 nm particle size BBI solutions EM.GMHL.10
Immunogold conjugate 15 nm particle size BBI solutions EM.GAR15
LR White Medium Grade Resin Agar Scientific AGR1281
Paraformaldehyde Agar Scientific R1018
Uranyl acetate Agar Scientific AGR1260A
Mass Spectrometry Supplier Product code
4-HCCA matrix solution Aldrich 14,550-5
Acetonitrile (ULC/MS - CC/SFC) Biosolve 12041
Ammonium bicarbonate (LCMS grade) Fluka 40867
DTT Melford MB1015
Formic acid (LC/MS grade) Fisher Scientific A117-50
Iodoacetamide Sigma-Aldrich I6125
Peptide Calibration Standard II Bruker 8222570
Trypsin (Sequencing Grade Modified Trypsin) Promega V511A
Water (HPLC grade) Fisher 10449380




Confocal Microscopy Supplier Product code
ProLong Gold antifade mountant Life Technologies P36930
Lectin from Triticum vulgaris  (wheat) 
FITC conjugate
Sigma-Aldrich L4895
Cloning materials Supplier Product code
1 KB DNA ladder Promega G5711
10x Ligase buffer Promega C1268
10x NEB buffer Cutsmart New England BioLabs B7204S
10x Promega enzyme buffer Promega R9991
10x T4 Polynucleotide Kinase 
Reaction Buffer 
New England BioLabs B0201S
2x PCRBIO Taq Mix Red PCR Biosystems PB10.13
6x loading dye New England BioLabs B70245
AscI restriction enzyme New England Biolabs R0558S
EcoRI restriction enzyme New England BioLabs R0101S
Ethidium bromide Sigma E7637
NdeI restriction enzyme New England BioLabs R0111S
PstI restriction enzyme Promega R611A
Q5® High-Fidelity 2X Master Mix New England BioLabs M0492S
T4 DNA ligase Promega M180A




2.2 Equipment list 
2.2.1 Autoclave:  
Classic Prestige Medical autoclave sterilises by heating contents at 121ºC for 11 mins (1.4 bar pressure).  
2.2.2 Vacuum pump 
The vacuum pump was used for sterilisation of 150 mL volumes and above. 
Table 2.11 Comparison of the different filters used for sterilisation 
2.2.3 Thermo Scientific Barnstead Easypure II system 
Double deionised water was filtered through a Barnstead D3750 irradiated hollow fibre filter (pore size 
0.2 µm, resistance 18.2 MΩ.cm). This is referred to as ‘MQ water’ throughout the thesis. 
Table 2.12 Centrifuges used throughout this project 
 
2.2.4 Spectrophotometers 
• UV-Vis spectrophotometer: Shimadzu UV-1800 spectrophotometer was used to measure the 
optical density of cultures (at 600 nm) and protein concentration by Bradford assay (at 595 
nm). Plastic 1 mL cuvettes were used with a 1cm path length. 
• Cary Spectrophotometer: The spectrophotometer Agilent Technologies Cary 60 UV-Vis was 
used to draw UV-Vis spectrum to detect candicidin and antimycin. 500 μL samples were 
loaded on to the spectrophotometer in UV quartz cuvettes (Sigma-Aldrich Z276723-1EA).   
• NanoDrop Spectrophotometer: DNA and protein concentration were quantified using the 
NanoPhotometer 50 (Implen). 
2.2.5 SDS-PAGE, protein transfer and Western blotting 
• SDS-PAGE tank: XCell SureLock Mini-Cell Electrophoresis System 
• Western blot wet transfer tank: Mini Trans-Blot (Bio-Rad). 
Centrifuge used Rotor used Centrifuge tubes/Sample size
 Eppendorf Centrifuge 5415 R F45-24-11  1.5 mL microcentrifuge tubes
  Beckman Coulter Optima LE-80K 
Ultracentrifuge 
Type 70 Ti 26.3 mL polycarbonate ultracentrifuge tube
Beckman Coulter TL-100 Ultracentrifuge TLA-100.3 750 µL sample volume in 3 mL ultracentrifuge tube
Beckman Coulter. Avanti J-265 centrifuge JLA-16.250 250 mL polycarbonate centrifuge tube
Sigma 2K15 centrifuge  #12149 15 mL or 50 mL Falcon tubes









0.2 Nalgene Rapid-Flow SFCA 150 Sterilise buffers/solutions
0.2 Nalgene Rapid-Flow PES 500 OMV purification




• Agarose gel preparation and tank: Agarose gels were prepared using the multiSUB Midi 
electrophoresis unit, 10 x 10 cm UV Tray, 2 x 16 sample combs, loading guides and dams. Gels 
were run on the Fisherbrand multiSUB Midi Horizontal Gel System. 
• SDS-PAGE gel and Western blot photos: Photos were taken using the G:Box Chemi XX6 
machine by SynGene and associated software. 
2.2.6 Mass Spectrometry  
Proteins of interest on silver stained gels were identified using Bruker ultrafleXtreme MALDI-
TOF/TOF mass spectrometer and associated software.  
2.2.7 Dynamic Light Scattering (DLS)  
The Litesizer 500 Anton Paar was used to characterise the OMVs using the DLS mode. 
2.2.8 Sonication 
Sonication was performed using the Soniprep 150 (MSE).  
2.2.9 Microplate reader 
Growth curves were produced by culturing E. coli in CELLSTAR 48 Well Cell Culture Plates (Greiner 
Bio-One, #677 180). Two identical microplate readers were used to generate growth curves at 25ºC and 
37ºC concurrently. The microplate readers used were SPECTROstar Nano (BMG Labtech) with 
associated SPECTROstar Nano software.  
2.2.10 Microscopy 
• Electron microscopy: Jeol transmission electron microscope model JEM 1230. Photos taken 
using a Gatan multiscan digital camera and operated at an accelerating voltage of 80 kV. 
• Confocal microscopy: Zeiss lsm 880 with airscan with associated Zen Black software. 
• Light microscopy: GXM L2800 Premium Compound Microscope at 400x magnification and 
photos were taken using the associated camera.  
2.2.11 Imaging of agar plates 
Photos of plates taken using aCOLyte (Synbiosis). 
2.2.12 Cloning 
• UV transilluminator: BioView UV transilluminator was used to locate DNA bands for gel 
extraction.  





2.3 Media and buffers 
All media and buffers were stored at 4ºC unless otherwise stated. 
2.3.1 MQ water 
In all solutions prepared for experiments, double deionised water was used. This was filtered further 
using Thermo Scientific Barnstead Easypure II system. 
2.3.2 Media and buffer sterilisation 
All media and PBS buffers were autoclaved or filter sterilised using filters of 0.2 µm pore size (Cole-
Parmer). For volumes over 100 mL, Nalgene filters with a 0.2 µm pore size and a vacuum pump were 
used. 
2.3.3 Media  
All media described below were prepared by addition of components listed to the desired volume of 
MQ water, mixed well then autoclaved. Agar technical No 3 was added (20 g/L) to media before 
autoclaving for preparation of agar plates.  
 
Table 2.13 Media recipes 
 
Table 2.14 Media supplements  
 
 
Media supplement stocks were stored at -20ºC. Chloramphenicol stock was mixed into ‘hand hot’ LB 
agar then plates were poured and left to set for 20-30 mins. Agar plates were left to dry next to a Bunsen 
burner for a minimum of 30 mins and stored at 4ºC. 
Media name Media recipe and preparation details
Lysogeny broth (LB)-Lennox 10 g/L Bacto tryptone, 5 g/L Bacto yeast extract, 5 g/L sodium chloride
Yeast Extract Peptone Dextrose 
(YPD) 
20 g/L glucose, 20 g/L Bacto peptone, 10 g/L Bacto yeast extract
Tryptone Soy Broth (TSB) 30 g/L TSB pre-made powder
Yeast Extract-Malt Extract 
Medium (YEME) 
3 g/L Bacto yeast extract, 3 g/L Malt extract, 5 g/L Bacto peptone, 10 g/L 
glucose
Mannitol Soya (MS) Agar plates
20 g/L soya flour (Holland and Barrett), 20 g/L mannitol, 20 g agar. Media 
was autoclaved twice before pouring to ensure there were no spores
Milk (casein) agar plates
28 g/L skimmed milk powder, 5 g/L casein enzymic hydrolysate, 2.5 g/L 
yeast extract, dextrose 1 g/L dextrose, 15 g/L agar, final pH at 25ºC 7.0. 
Heat to boiling to dissolve then sterilise by autoclaving. Mix well after 
autoclaving and pour.
Supplement






25 mg/mL in ethanol, 
absolute
N/A 25 µg/mL
IPTG Melford #MB1008 1 M in sterile MQ water






2.3.4 Buffer and Solution preparations 
Table 2.15 Buffer and solution recipes  
 
 
2.3.4.1 Preparation of 4% (w/v) formaldehyde fix for EM 
To prepare 4% (w/v) formaldehyde in PBS, 8% (w/v) paraformaldehyde was prepared then mixed 1:1 
with 2X concentrated PBS. 2 g paraformaldehyde was dissolved in 20 mL water total in a glass beaker. 
The mixture was heated to 65-70ºC with continuous stirring. When condensation had formed on the 
beaker, 2-3 drops of 1 M sodium hydroxide in water was added until the solution changed from white 
and cloudy to clear. Once dissolved, the solution was left to cool to room temperature. MQ water was 
added to make the total volume 25 mL then 25 mL 2X PBS was added to make a final solution of 4% 
(w/v) formaldehyde in 1X PBS. Fix was stored at 4ºC.  
  
Buffer category Buffer name Buffer preparation details
HEPES buffer 10 mM HEPES/0.85% NaCl, adjusted to pH 7.4 and filter sterilised
HEPES buffer with CaCl2
10 mM HEPES/0.85% NaCl/20 mM CaCl2, adjusted to pH 7.4 and filter 
sterilised
Phosphate buffered saline 
(PBS)
  1 tablet dissolved in 100 mL MQ water and autoclaved
100% TCA stock 
A 100% stock solution of TCA was prepared by adding 227 mL sterile 
MQ water to 500 g powder as described by the Trichloroacetic acid 
SigmaUltra datasheet (T9159)
Western transfer buffer 25 mM Tris and 192 mM glycine (no pH adjustment)
TBS 137 mM sodium chloride, 10 mM Tris and 0.1% Tween 20 pH 7.4. 
TBST 137 mM sodium chloride, 10 mM Tris and 0.1% Tween 20 pH 7.4. 
TEM
TBST for immunogold 
labelling
20 mM Tris, 500 mM NaCl, 0.1% BSA, 0.05% Tween 20, pH 7.2. Made 
fresh on the day
PMSF stocks
200 mM stocks of PMSF in absolute ethanol were prepared and stored at 
-80ºC. Immediately prior to use in a Proteinase K test, stocks were 
diluted to 50 mM using HEPES buffer
SDS stocks Various concentrations of SDS were prepared in MQ water





 200 mM Tris-HCl, 500 mM sucrose, 1 mM EDTA, pH 8.0. Add 
protease inhibitor cocktail tablet immediately before use and store at 4ºC
T salts
 75 mM CaCl2, 6 mM MgCl2 and 15% glycerol in MQ water (filter 
sterilised)
Magnesium chloride 0.1 M MgCl2, 15% glycerol in MQ water (filter sterilised)




 1 M Tris, 50 mM EDTA, 28.6 mL glacial acetic acid, pH 8.27
General use buffers
Cloning reagents 









2.4 Microbial strains 
Table 2.16 Microbial strains used in this study 
   
   
Strain name Strain characteristics and additional information Reference/Source for further information
Burkholderia cenocepacia 
J2315 
Pathogenic strain originally isolated from a cystic 
fibrosis patient
Dr. Vittorio Venturi, International Centre for 
Genetic Engineering (Holden et al.  2009)
Candida albicans SC5314
Commonly used Candida albicans wild type strain 
from which most laboratory strains are derived 
(pathogenic)
Dr Luisa Sordi, University of Kent (Candida 
Genome Database)
Clinical isolate 1 (E.coli 
MS207)
Bacteraemia isolate belonging to clonal group ST685
Strain originates from East Kent Hospitals 
University NHS Foundation
Clinical isolate 2  (E.coli 
MS10)
EEC958: Uropathogenic strain (UPEC) strain 
belonging to clonal group ST131 
Dr Mark Shepherd, University of Kent (Totsika 
et al.  2011)
Clinical isolate 3 (E.coli 
MS1)
CFT073: Uropathogenic strain (UPEC) belonging to 
clonal group ST73 
Dr Mark Shepherd, University of Kent (Welch 
et al. 2002
Clinical isolate 4 (E.coli 
MS343)
83972: Asymptomatic bacteriuria strain 
Dr Mark Shepherd, University of Kent. 
(Klemm et al . 2006)
Clinical isolate 5 (E.coli 
MS190)
Bacteraemia isolate belonging to clonal group ST162
Strain originates from East Kent Hospitals 
University NHS Foundation
Clinical isolate 6 (E.coli 
MS234)
Bacteraemia isolate belonging to clonal group ST69
Strain originates from East Kent Hospitals 
University NHS Foundation
E. coli B, wildtype 
Wild type (Parental) strain of E. coli B strains such 
as BL21
Keio collection #2507 (Baba et al. 2006)
E.coli ∆fimA (JW4277-1) BW25113 ΔfimA782::kan Keio collection #11065 (Baba et al.  2006)
E.coli ∆fimB ( JW4275-1) BW25113 ΔfimB780::kan Keio collection #11063 (Baba et al.  2006)
E.coli ∆fimC (JW4279-1) BW25113 ΔfimC784::kan Keio collection #11066 (Baba et al. 2006)
E.coli ∆fimD ( JW5780-1) BW25113 ΔfimD785::kan Keio collection #11607 (Baba et al . 2006)
E.coli ∆fimE ( JW4276-1) BW25113 ΔfimE781::kan Keio collection #11064  (Baba et al.  2006)
E.coli ∆fimF ( JW4281-1) BW25113 ΔfimF786::kan Keio collection #11067 (Baba et al. 2006)
E.coli ∆fimG (JW4282-2) BW25113 ΔfimG787::kan Keio collection #11770 (Baba et al. 2006)
E.coli ∆fimH (JW4283-3) BW25113 ΔfimH788::kan Keio collection #11068 (Baba et al.  2006)
E.coli ∆fimI (JW5779-1) BW25113 ΔfimI783::kan Keio collection #11573 (Baba et al.  2006)
E.coli ∆fimZ  (JW5073-1) BW25113 ΔfimZ745::kan Keio collection #11159 (Baba et al . 2006)
E.coli ∆fliC ( JW1908-1) BW25113  ΔfliC769::kan Keio collection #9586 (Baba et al. 2006)
E.coli AAEC278
E.coli MG1655 ∆(fimBE)-sacB Neo . Allelic 
exchange intermediate strain produced in the 
construction of 'E.coli  with fimbriae locked on' 
strain.  In this strain, the invertible element (fimS ) is 
in the 'on' position to produce T1F. The fim  fragment 
has been replaced by the sacB Neo gene cassette
Dr. Ian Blomfield, University of Kent, 
#AAEC278 (McClain et al. 1993)
E.coli  BL21
E.coli B strain derivative. fhuA2 [lon] ompT gal 
[dcm] ΔhsdS. Competent E.coli  B strain for routine 
non-T7 expression
New England BioLabs #C2530H
E.coli  BL21 (DE3)
 E.coli B strain derivative. fhuA2 [lon] ompT gal (λ 
DE3) [dcm] ∆hsdS. λ DE3  = λ sBamHIo ∆EcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
Identical to E.coli BL21 except this strain contains 
the λDE3 lysogen that carries the gene for T7 RNA 
polymerase under control of the lacUV5 promoter
New England BioLabs #C25271
E.coli DH5α 
NEB® 5-alpha Competent E. coli (High Efficiency). 
Derivative of DH5α cells used for routine non-T7 
expression




   
   
Strain name Strain characteristics and additional information Reference/Source for further information
E.coli FimB-LacZ fusion
E.coli WT MG1655 ∆lacZYA ∆fimB (-457 to +209 
relative to fimB ORF) FimB-LacZ translational 
fusion. This strain contains a deletion of the Lac 
operon (lacZYA ) and fimB and an insertion of a 
FimB-LacZ fusion protein. T1F production locked 
off is FimB is no longer functional.
Dr. Ian Blomfield, University of Kent, 
#BGEC056 (El-Labany et al. 2003)
E.coli  fimbriae locked on
E.coli MG1655 fimB-am6 fimE-aml8 (produced 
from intermediate strain AAEC278). T1F production 
locked on. The invertible element (fimS ) is locked 
on due to the modifications in the parental 
intermediate strain (AAEC278)
Dr. Ian Blomfield, University of Kent, 
#AAEC356 (McClain et al. 1993)
E.coli parental (BW25113)
E. coli  K-12 strain derivative. Contains six 
mutations: Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
λ-, rph-1, Δ(rhaD-rhaB)568,  hsdR514. The E. coli 
K-12 BW25113 parent strain is the common 
background genotype used for the generation of the 
E. coli Keio Knockout Collection
Keio collection #7636 (Baba et al.  2006)
E.coli WT MG1655
E.coli K-12 derivative. Contains 2 mutations: λ-, 
rph-1 . Used as the wild-type strain to produce 
E.coli FimB-LacZ fusion strain and E.coli with 
fimbriae locked on
Keio collection #6300 (Baba et al. 2006)
E.coli ΔflhA (JW1868-1) BW25113 ΔflhA732::kan Keio collection # 9554 (Baba et al.  2006)
E.coli ΔfliD  (JW1909-1)   BW25113 ΔfliD770::kan Keio collection #9587 (Baba et al.  2006)
E.coli ΔfliS  (JW1910-1) BW25113 ΔfliS771::kan Keio collection #9588 (Baba et al. 2006)
E.coli Δlon (JW0429-1) BW25113 Δlon-725::kan Keio collection #8592 (Baba et al. 2006)
E.coli ΔlrhA ( JW2284-6) BW25113 ΔlrhA771::kan Keio collection #11785 (Baba et al. 2006)
E.coli ΔompT (JW0554-1 ) BW25113 ΔompT774::kan Keio collection #8680 (Baba et al.  2006)
MG1655 with GFP-FimA 
protein fusion
ASC129 (MG1655 fimAΩGFPmut2 ) 
Professor Sander Tans, AMOLF, The 
Netherlands (Tans et al. 2009)
Pseudomonas aeurginosa 
PA01
Clinical isolate. Two P. aeruginosa pathogenicity 
islands (PAPI-1 and PAPI-2) are absent from 
PA01 which means it is less virulent than PA14.




Clinical isolate. Two P. aeruginosa  pathogenicity 
islands (PAPI-1 and PAPI-2) are present in the 
genome of PA14  which is a highly virulent clinical 
isolate




Commonly used laboratory strain derived from S. 
cerevisiae S288C 
EuroSCARF #Y00000
Streptomyces S4  ∆fscC
S4 fscC null mutant: this strain does not produce 
Candicidin
Professor Matt Hutchings UEA (Seipke et al. 
2011)
Streptomyces  S4 ∆antC
S4 antC  disruption mutant: this strain does not 
produce Antimycin
Professor Matt Hutchings UEA (Seipke et al. 
2011)
Streptomyces  S4 ∆antC 
∆fscC
S4 strain containing knockouts of both fscC  and 
antC  genes meaning that there is no production of 
Candicidin or Antimycin
Professor Matt Hutchings UEA (Seipke et al. 
2011)
Streptomyces  S4 WT
Wild type Streptomyces  S4 strain: originally isolated 
from attine ant nests





2.5 Microbial growth and storage conditions 
2.5.1 Preparation of bacterial glycerol stocks 
50% autoclaved glycerol (in MQ water) was mixed with stationary phase bacterial culture in a sterile 
cryotube vial in a 1:1 ratio. All strains were stored at -80oC. 
2.5.2 Preparation of Streptomyces S4 spore stocks 
Streptomyces S4 strains were supplied by Professor Matt Hutchings from the University of East Anglia. 
Strains were spread on MS agar plates and incubated for 1 week at 30ºC to form a lawn of spores. 1 mL 
of sterile 10% (v/v) glycerol (in MQ water) was added to the surface of the plate and mixed using a 
sterile swab. Any residual liquid from the plate was removed to form the -20ºC spore stock. 1 mL 10% 
(v/v) glycerol was also used to rinse any spores from the sterile swab. This stock was split into aliquots 
and stored at -20ºC.  
2.5.3 Culture conditions 
Cultures were grown in conical flasks containing at least one-fifth of their own volume of medium or 
500 mL to 1 L of medium in a 2 L baffled flask. Cultures were incubated at 37oC, shaking at 180 RPM 
for 18 hrs unless otherwise stated. Cultures were inoculated into LB from either a -80 °C glycerol stock 
or from colonies on a freshly streaked agar plate. Bacteria were streaked from -80 °C glycerol stocks 
and agar plates were inverted and incubated overnight at 37oC unless otherwise stated. 
2.5.4 Measuring optical density 
Culture optical density was measured at 600 nm using a Shimadzu UV-1800 spectrophotometer in 
plastic 1 mL cuvettes with a 1 cm path length. 
2.5.5 E. coli growth curves on the microplate reader (25ºC and 37ºC) 
Growth curves were produced for the following E. coli strains: BL21 (DE3), Parental BW25113, FimB-
LacZ fusion, ∆fimA and ∆fimC. Each strain was grown to stationary phase at 37ºC, 180 RPM overnight.  
Two 48 well plates were prepared in duplicate containing the following samples: 
• Growth curves in LB: Each strain was diluted to OD600 0.1 using LB before addition of 500 
μL to each well. There were 4 repeats for each strain.  
• Growth curves in LB + 1.5 M ammonium sulphate: Ammonium sulphate was slowly added 
to E. coli strains at OD600 0.1 so that cells were cultured in LB with 1.5 M ammonium 
sulphate. 500 μL was added to each well and each sample was done in triplicate.  
• Growth curves in chloramphenicol: Chloramphenicol stock was added to E. coli strains at 





One of the 48 well plates was run on the microplate reader at 37ºC and the other was at 25ºC. OD600 
readings were taken every 8 mins and the growth curve graphs were generated using Microsoft Excel.  
 
2.6 OMV standard purification protocol 
2.6.1 Standard protocol for purifying OMVs from Gram-negative bacteria 
The strain of interest was inoculated into 500 mL to 1L LB media and incubated at 37°C, 180 RPM for 
18 hrs in 2 litre baffled flasks. The bacterial culture was pelleted by centrifugation at 12,000 RPM 
(14,515 x g) for 10 min at 4°C. The supernatant (containing OMVs) was extracted and filtered through a 
0.2 µm PES membrane filter for Pseudomonas aeruginosa strains or 0.45 µm PES membrane filter for 
E. coli strains. This was to remove any whole bacterial cells or large bacterial fragments. To ensure that 
all live bacterial cells had been removed, 500 μL-1 mL of filtered supernatant was spread onto LB agar 
plates and incubated for 24-48 hrs at 37°C to check for growth. OMVs were precipitated out of solution 
by slowly adding 1.5 M ammonium sulphate then incubated overnight at 4°C with gentle stirring. The 
OMVs were pelleted by centrifugation at 16,000 RPM (25,805 x g) for 30 mins at 4°C. The resulting 
OMV pellets were resuspended in 1-5 mL 10 mM HEPES/0.85% NaCl, pH 7.4 for further analysis. P. 
aeruginosa OMV samples were filter sterilised once more using 0.2 µm pores to give a cleaner sample. 
OMVs resuspended in 10 mM HEPES buffer were stored at 4ºC then at -20ºC for future use in SDS-
PAGE gels or Western blotting. 
2.6.2 Standard protocol for purifying OMVs from competent cells containing desired 
plasmid 
1 colony from a successful transformation was inoculated into 50 mL LB containing 25 µg/mL 
chloramphenicol in a 250 mL flask then incubated at 37°C, 180 RPM overnight. The OD600 of cultures 
of interest were recorded and flasks were prepared as described in Table 2.17. Flasks were incubated at 
37ºC, with shaking at 180 RPM for 18 hrs.  















Volume of  
1M IPTG 
added (µL)
1A - Parental strain + IPTG 500 5 0.5 250
1B - Parental strain - IPTG 500 5 0.5 0
2A) ΔfimA strain + IPTG 500 5 0.5 250




The OD600 was monitored and cells were induced with 0.4 mM IPTG at an OD600 of 0.25-0.3 (early 
stationary phase). Cells were grown to mid-late exponential phase (Figure 2.1). When the induced cells 
had reached an OD600 of approximately 1.0, OMVs were purified using the standard protocol for 
Gram-negative bacteria (Section 2.6.1). Flask 1B is a negative control of Flask 1A and Flask 2B is a 
negative control of Flask 2A with no addition of IPTG. Once Flasks 1A and Flask 2A had reached the 
correct OD600, OMVs were purified immediately and with their respective negative controls.   
 
 
2.6.3 Standard protocol for purifying MVs from Streptomyces S4 strains 
20 μL of spore stock was added to 1 mL sterile MQ water and spread on to a sterile MS agar plate. The 
plate was incubated at 30ºC for 5-7 days. Colonies were inoculated into 12.5 mL YEME:TSB (both 
media mixed 1:1) and incubated at 30ºC, 180 RPM for 72 hrs. 5 mL of each culture was inoculated into 
500 mL LB in 2 litre baffled flasks then incubated at 30°C, 180 RPM for 72 hrs. OD600 of each culture 
was determined using a range of dilutions and confirmed to be approximately 3.0 for each strain. The 
bacterial culture was pelleted by centrifugation at 5000 x g for 30 mins at 4ºC and the supernatant was 
removed to be filtered through a 0.45 µm PES membrane filter. MV purification protocol from this 
point onwards was as described above in Section 2.6.1.   
2.6.4 Ultracentifugation 
For ultracentrifugation, the OMV pellets were resuspended in 4.5 mL 45% (v/v) OptiPrep in 10 mM 
HEPES/0.85% NaCl, pH 7.4. 4 mL was layered on to the bottom of a 26.3 mL polycarbonate 
ultracentrifuge tube (Beckman). A gradient of 4 mL of 40%, 35%, 30%, 25% and 20% (v/v) OptiPrep in 
10 mM HEPES buffer was prepared and slowly added in layers on top of the OMVs in 45% OptiPrep. 
Tubes were balanced by addition/removal of the 20% OptiPrep layer. Ultracentrifugation was 
performed at 111,000 x g for 2 hrs at 4 °C for P. aeruginosa strains or 50,000 RPM (183,960 x g) for 3 
hrs at 4ºC for E. coli strains. Ultracentrifuge tubes were incubated at 4ºC overnight to allow each layer 
Figure 2.1 Growth curve of E. coli parental strain and ΔfimA at 37 °C. Strains were grown in triplicate, 
error bars represent 1 Standard Deviation from the mean 
E. coli ΔfimA 





to settle. Without disturbing the ultracentrifuge tube, each layer was removed sequentially then kept at 
4°C for further analysis. 240 μL of the sample of interest was precipitated using 60 μL TCA using the 
standard protocol prior to loading on an SDS-PAGE gel. In order to visualise the OMVs by TEM, the 
OptiPrep needed to be removed from the samples. Each sample of interest was diluted with PBS so that 
the percentage of OptiPrep was now 2-3 % in each sample. The OptiPrep was then removed by 
centrifugation at 16,000 RPM (25,805 x g) for 3 hrs at 4ºC. Each pellet was resuspended in 1.5 mL 10 
mM HEPES buffer. 1.2 mL OMVs in HEPES was centrifuged at 13,200 RPM (14,220 x g) for 30 mins 
at 4ºC and finally resuspended in 12 μL 10 mM HEPES buffer. 10 μL of this sample was added to the 
EM grids for visualisation of the OMVs. 
2.6.5 Alternative techniques to remove flagella 
OMVs were purified from 500 mL culture using the standard protocol and were resuspended in 5 mL 10 
mM HEPES buffer. 
The following methods were compared: 
1. Standard method: 1 mL OMVs in 10 mM HEPES buffer were centrifuged at 4ºC for 30 mins, 
13,200 RPM. The resulting OMV pellet was resuspended in 30 μL 10 mM HEPES buffer. 
2. Low speed spin: 1 mL OMVs in 10 mM HEPES buffer was centrifuged at 6000 x g at 4ºC for 30 
mins. The resulting OMV pellet was resuspended in 30 μL 10 mM HEPES buffer. 
3. Proteinase K: 900 μL OMV sample was mixed with 100 μL Proteinase K sample (100 µg/mL in 
HEPES /CaCl2 buffer). Samples were incubated at 37ºC for 30 mins. 5 mM PMSF was added to inhibit 
the protease and incubated at 37ºC for another 30 mins. OMV were centrifuged at 13,200 RPM (14,220 
x g) for 30 mins at 4 °C. The resulting OMV pellet was resuspended in 30 μL 10 mM HEPES buffer. 
4. OMVs before filtration through a 0.45 µm membrane filter: 2 mL OMVs in 10 mM HEPES 
buffer were centrifuged at 4ºC for 30 mins, 13,200 RPM.  The pellet was resuspended in 30 μL 10 mM 
HEPES buffer.  
5. OMVs after filtration through a 0.45 µm membrane filter: 2 mL OMVs in 10 mM HEPES buffer 
was filtered through a 0.45 µm membrane. The sample was centrifuged at 4ºC for 30 mins, 13,200 
RPM.  The pellet was resuspended in 30 μL 10 mM HEPES buffer. 
6. Addition of proteases from Streptomyces griseus. A protease stock of 10% (w/v) was prepared in 
10 mM HEPES buffer with CaCl2. This was then diluted to give other concentrations of proteases from 
1% to 0.1%. OMVs resuspended in HEPES were incubated with proteases of the relevant 
concentrations at 37ºC for 30 mins. The samples (450 μL) were centrifuged at 4ºC for 30 mins, 13,200 
RPM (14,220 x g) and the pellet was resuspended in 20 μL 10 mM HEPES buffer in preparation for 
TEM. 
2.6.6 Alternative techniques to remove fimbriae 
As ultracentrifugation was unsuccessful, alternative techniques were compared to see if OMVs could be 
isolated from the co-purified fimbriae in E. coli K-12 strains. OMVs were purified from 500 mL culture 
using the standard protocol and were resuspended in 5 mL 10 mM HEPES buffer. 




1. OMVs untreated: 500 μL OMV in 10 mM HEPES buffer 
2. OMVs heat treated at 95ºC for 30 mins: 500 μL OMVs in 10 mM HEPES buffer were heated 
at 95ºC for 30 mins 
3. OMVs sonicated: OMVs were subject to 6 cycles of sonication for 30 seconds then resting for 
30 seconds at 30% power (maximum is 40%)  
2.6.7 Lipid extraction  
Lipids and proteins were separated in OMV samples using chloroform-methanol extraction method 
(Ferrez, et al. 2003). 1 mL E. coli OMVs were mixed with 4 mL chloroform-methanol mixture (2:1 
v/v). Briefly, the mixture was vortexed for 20 seconds then centrifuged at 2500 x g for 10 mins. The 
aqueous layer (top layer, mostly methanol and water) was discarded. The interphase layer (containing 
OMV proteins) was extracted and transferred to a new 1.5 mL microfuge tube. Samples were spun in a 
vacuum centrifuge to remove all surrounding liquid and OMV proteins were resuspended in 10 mM 
HEPES buffer for Proteinase K test. As a control, 1 mL 100 µg/mL BSA was added to 4 mL of 
chloroform-methanol mixture and was treated in the same way as the OMVs. 
2.7 Outer membrane and periplasmic protein extractions 
Outer membrane proteins and periplasmic proteins were isolated using Tris-sucrose-EDTA (TSE) 
buffer extraction (Quan et al. 2013). This method was chosen as it appears to be an efficient method of 
extracting outer membrane and periplasmic proteins with minimal contamination of proteins from the 
inner membrane and cytoplasm (Quan et al. 2013). Isolation of periplasmic proteins, OM proteins and 
OMVs were performed on the same E. coli culture concurrently for direct comparison. In each case, the 
colony of interest was inoculated into 750 mL LB and grown overnight. 500 mL of this culture was 
used to purify OMVs and 100 mL was used for the periplasmic and OM extraction.  
 
Briefly, 100 mL fresh overnight culture was diluted to be OD600 1.0. The bacterial cells were harvested 
by centrifugation at 3000 x g for 20 mins at 4ºC and the supernatant was discarded. The cell pellet was 
carefully resuspended into 1 mL TSE buffer then incubated on ice for 30 mins. This sample was then 
centrifuged at 16,000 RPM for 30 mins at 4ºC and the supernatant was transferred to a new microfuge 
tube suitable for ultracentrifugation. The supernatant at this stage contained the soluble extracted 
bacterial envelope proteins. To separate outer membrane proteins from periplasmic proteins, the 
supernatant was centrifuged at 43,000 RPM for 1 h at 4 °C (TL-100 Ultracentrifuge rotor Beckman). 
The pellet from this step contained the outer membrane proteins and the supernatant contained the 





2.8 Protein manipulation techniques 
2.8.1 Bradford assay 
The concentration of protein in both cells and OMV samples were determined using a Bradford assay. 
A standard curve was produced using a range of BSA concentrations between 0-1000 µg/mL diluted in 
MQ water. 20 μL of the BSA standard at each concentration was vortexed with 1 mL 1x Bradford 
reagent and incubated at room temperature for 15 mins. The Absorbance of the samples were read at a 
wavelength of 595 nm and a standard curve was constructed. The Bradford assay was performed using 
the same procedure as for the BSA standards and the protein concentration (µg/mL) was calculated 
from the standard curve. Standards and OMV/cell samples were performed in triplicate and an average 
was taken.  
2.8.2 Standardisation of protein samples for SDS-PAGE gel 
All samples were standardised to the same protein concentration prior to loading on an SDS-PAGE gel 
unless otherwise stated. A Bradford assay was performed to determine the protein concentration of all 
samples. The sample with the lowest concentration of protein was determined and all other samples 
were diluted to be the same. Once all samples were the same protein concentration, they were either 
loaded on to an SDS-PAGE gel or TCA precipitated to concentrate (see method below). Any empty 
lanes on an SDS-PAGE gel were filled with 10 mM HEPES buffer (details in Section 2.15) and 4x 
reducing sample buffer (RSB).   
2.8.3 TCA-precipitation of OMVs 
Purified OMVs (resuspended in HEPES) were vortexed with cold 100% TCA stock solution to make a 
final concentration of 20% TCA. Samples were incubated on ice for 30 mins then centrifuged for 30 
mins, 13,200 RPM (14,220 x g) at 4 °C. The supernatant was removed and 0.5 mL cold acetone was 
added. After briefly vortexing, the samples were centrifuged for 15 mins, 13,200 RPM (14,220 x g) at 4 
°C. The supernatant was removed and each OMV pellet resuspended in 10 mM HEPES buffer (details 
in Section 2.15) and 4x RSB in a 3:1 ratio. 
2.8.4 SDS-PAGE 
SDS-PAGE gels were run using the Novex Xcell II Mini-Cell system for Electrophoresis with pre-cast 
10 well 4-12% Bis-Tris gels. SDS-PAGE gels were run using 1x MOPS or 1x MES SDS running 
buffer. Each sample was mixed with the appropriate volume of 4X reducing sample buffer (RSB) and 
heated to 95 °C for 5 mins prior to loading. 20 μL of each sample was loaded into each well. 0.2 μL 
markers were used each time to estimate protein size when the SDS-PAGE was due to be silver stained. 
5-10 μL markers were used when staining with Coomassie. Gels were run at 165 V for 48 mins (MES 
running buffer) or 55 mins (MOPS running buffer). 




SDS-PAGE gel was placed in 25 mL InstantBlue and left on a shaker for 1 hour at room temperature. 
2.8.4.2 Detection of proteins via silver staining 
SDS-PAGE gels were developed using the Pierce Silver Stain kit as described in the manufacturer’s 
protocol. All steps below were carried out on an orbital shaker. Briefly, SDS-PAGE gels were subject to 
2 x 5 min washes in MQ water then 2 x 15 min washes minimum in Gel Fix (30% ethanol, 10% acetic 
acid, 60% MQ water). Gels were washed for 2 x 5 mins in 10% (v/v) ethanol then 2 x 5 mins in MQ 
water. Gels were sensitised for 1 min (in 50 μL sensitiser in 25 mL MQ water) then washed 2 x with 
MQ water for 1 min. Gels were stained for 30 mins minimum in Staining Solution (0.5 mL Enhancer 
with 25 mL Silver Stain solution). After 2 x 20 second washes with MQ water, gels were developed 
using Developer Solution (0.5 mL Enhancer with 25 mL Developer solution) for 1-3 mins. Once bands 
appeared, the reaction was stopped using 5% (v/v) acetic acid for 10 mins. After imaging, gels were 
stored long term in 5% (v/v) acetic acid or MQ water at 4ºC. 
2.8.4.3 Imaging of SDS-PAGE gels and Western blots 
Gels and blots were imaged using Syngene G:BOX and associated software. 
2.8.4.4 Densitometry analysis of protein profiles on SDS-PAGE gel 
Densitometry analysis was performed using Image J (Miller, 2010). 
2.8.4.5 Extraction of FimA monomer protein from an SDS-PAGE gel 
An SDS-PAGE gel was run containing protein markers and OMVs from E. coli with fimbriae locked on 
strains. After running, the SDS-PAGE gel was cut in half. One half (containing 1 lane of protein 
markers and 1 lane of the OMV sample) was silver stained so that the FimA protein could be visualised 
(at 18 kDa). This was called the ‘stained FimA’ sample. The other half of the gel containing 1 lane of 
protein markers and 1 lane of OMVs was not stained. However, using the protein markers and other 
stained half of the gel, the location of FimA at 18 kDa could be estimated and this was extracted. This 
sample was called the ‘unstained FimA’ sample as no silver staining had taken place. The excised gel 
pieces were cut as small as possible and were incubated with 1 mL elution buffer (50 mM Tris-HCl, 150 
mM NaCl, and 0.1 mM EDTA, pH 7.5) at 30 °C, shaking at 180 RPM. The samples were centrifuged at 
5000 x g for 10 minutes and the supernatant, (containing the extracted protein), was removed.  
2.8.5 Wet transfer 
An SDS-PAGE gel was run of the samples as described above including 5-10 µL protein markers. 
Transfer from the SDS-PAGE gel to PVDF membrane was performed using the Bio-Rad electro 
transfer cell equipment using the manufacturer’s instructions.  
2.8.5.1 Western blot protocol for anti-OmpA antibody 
All steps below were carried out on an orbital shaker. After transfer, the membrane was blocked in 10% 




in 5% (w/v) BSA in TBST). Membranes were then subject to 3 x 15 min washes in 1X TBST then 
incubated for 1 hour with 10 mL secondary antibody (diluted in 5% BSA in TBST). Membranes were 
then subject to 3 x 5 min washes in 1X TBST then 2 x 5 min washes in 1X TBS. Bands were developed 
in the dark using BCIP/NBT substrate for 1-10 mins and the reaction was stopped by washing in MQ 
water. See Table 2.18 for further information about PVDF membranes and secondary antibodies used 
for each primary antibody. 
2.8.5.2 Western blot protocol for all other antibodies 
All steps below were carried out on an orbital shaker. After transfer, the membrane was blocked in 5% 
(w/v) milk in TBST for 30 mins then incubated overnight at 4ºC with primary antibody diluted in 5% 
milk in TBST (see Table 2.18 for details of dilutions for each primary antibody). Membranes were then 
subject to 4 x 5 min washes in 1X TBST then incubated for 1 hour with of secondary antibody (diluted 
in 5% milk in TBST). Membranes were then subject to 4 x 5 min washes in 1X TBST. Bands were 
developed in the dark using BCIP/NBT substrate for 1-10 mins and the reaction was stopped by 
washing in MQ water. 
Table 2.18 Dilutions for primary and secondary antibodies during Western blotting and PVDF 
membrane types used for transfer 
 
 
2.8.5.3 Imaging of Western blots 
Gels and blots were imaged using Syngene G:BOX and associated software. 
2.8.6 Mass spectrometry (matrix-assisted laser desorption/ionisation, MALDI) 
All preparation for the mass spectrometry described below was performed in Kevin Howland’s 
laboratory (UKC). Microfuge tube preparation: Before use microfuge tubes used in this procedure 
were rinsed with ethanol and air-dried overnight in a foil covered beaker to reduce keratin 
contamination. Band excision: SDS-PAGE gels containing the bands of interest were subject to 2 x 10 
min washes with MQ water. Bands of interest were then carefully excised from the SDS-PAGE with a 
clean washed scalpel and cut further into 1 mm x 1 mm squares. The extracted gel pieces were 
incubated overnight at 4ºC in 500 μL MQ water in a clean microfuge tube. Reduction and alkylation: 
All solutions used were prepared on the day and all centrifugation steps were performed at 5000 RPM 
for 1 min at room temperature. Firstly, the gel pieces were centrifuged and the MQ water was removed. 
Antibody name











size used with 
antibody (µm)
Anti-FimA monoclonal 1 in 5000 Rabbit Anti-rabbit (Sigma) 1 in 5000 0.2
Anti-FimA polymer 1 in 5000 Rabbit Anti-rabbit (Sigma) 1 in 5000 0.45
Anti-Flagellin 1 in 10,000 Rabbit Anti-rabbit (Sigma) 1 in 5000 0.45
Anti-GFP antibody 1 in 3333 Mouse
Anti-mouse secondary 
antibody (Promega)
1 in 5000 0.45
Anti-Neon green 
antibody
1 in 1000 Mouse Anti-mouse (Promega) 1 in 5000 0.45




Gel pieces were incubated in 1 mL 50 mM NH4HCO3:acetonitrile (1:1) for 15 mins then spun down to 
remove liquid. Gel pieces were shrunk by addition of 100 μL acetonitrile for 15 mins then centrifuged 
and all liquid removed. 50 μL 10 mM DTT in NH4HCO3 was added to cover the gel pieces then 
incubated at 56ºC for 30 mins. Gel pieces were spun down and any excess liquid was removed. The gel 
pieces were then shrunk briefly by incubation in acetonitrile for 2 mins. Acetonitrile was removed and 
55 mM iodoacetamide in 50 mM NH4HCO3 was added. Iodoacetamide is light sensitive so gel pieces 
were incubated for 20 mins in the dark. Gel pieces were then washed in 100 μL 50 mM 
NH4HCO3:acetonitrile (1:1) then 50 mM NH4HCO3 then acetonitrile in the same way as described 
above and all excess liquid was removed. In-gel Digestion: Gel pieces were rehydrated in 20 μL 
digestion buffer (25 mM NH4HCO3, 10% acetonitrile and 10 ng/μL Trypsin) and incubated on ice for 
30 mins. Any remaining liquid was removed and gel pieces were rehydrated in 10 μL 25 mM 
NH4HCO3, 10% acetonitrile (no Trypsin) and incubated at room temperature overnight for digestion. 
Extraction of peptides: 5 μL acetonitrile was added to the gel pieces and sonicated for 15 mins in an 
ultrasound bath. Gel pieces were briefly centrifuged and the supernatant was collected and transferred to 
a fresh microfuge tube. 10 μL 50% acetonitrile, 5% formic acid solution was added to the gel pieces and 
sonicated for 15 mins in an ultrasound bath. Gel pieces were spun down and the supernatant was 
transferred to the same microfuge tube as in the previous step. These combined supernatants were stored 
at 4ºC if samples were to be analysed in the next 24 hrs or stored at -20ºC.  
Analysis of samples 
Proteins were identified using Bruker ultrafleXtreme MALDI-TOF/TOF mass spectrometer and 
associated software. Samples to be identified were added to the MTP Anchorchip MALDI-TOF plate 
(Bruker). 0.5 μL sample (prepared above) was added to the MALDI-TOF plates in known coordinates 
and left to air dry. 1 μL matrix solution (0.7 mg/mL α-Cyano-4-hydroxycinnamic acid dissolved in 
solvent mixture 85% acetonitrile, 15% water, 0.1% TFA and 1 mM NH4H2PO4) was then added on top 
of each sample and left to air dry. 0.5 μL Peptide Calibration Standard solution was added to the plate 
and left to air dry. The plate was loaded on to the instrument and the following settings were used: 
Polarity: positive, Laser frequency: 2 kHz, Ion sources: 25 kV and 22.35 kV, Lens: 7.5 kV, Pulsed 
ion extraction: 80 nS, Peptide Calibration Range: 700-3500 Da, Data sampling rate: 4 Gs/s. For 
each sample 3500 shots were summed and saved. Protein was identified by a Peptide Mass Fingerprint 
(PMF) search in the Mascot database. A match is significant if it has a score greater than 70.  
2.9 Microscopy  
2.9.1 Transmission Electron Microscopy (TEM) 
2.9.1.1 Preparation of copper and gold grids used for TEM  






Table 2.19 Comparison of grids used for TEM 
  
2.9.1.2 Standard TEM protocol to visualise OMVs 
OMVs resuspended in 10 mM HEPES buffer were concentrated for EM by centrifugation at 13,200 
RPM (14,220 x g) for 30 mins at 4°C. The OMV pellets were then resuspended in 10-15 μL 10 mM 
HEPES buffer. 10 μL purified OMVs were added to a copper EM grid and left to settle for 10 mins. 
OMVs were then fixed by adding 10 μL of 4% (w/v) formaldehyde in PBS and the grids were left for 
10 mins. The grids were subject to 4 x 1 min washes in MQ water then negatively stained using 2% 
(w/v) uranyl acetate in PBS. Grids were air dried for 20 mins and loaded on to the EM for analysis.  
2.9.1.3 Time lapse experiment to observe OMV biogenesis 
Colonies of P. aeruginosa PA14 and E. coli BL21 (DE3) were inoculated into 25 mL LB and incubated 
for 18 hrs at 37ºC, 180 RPM. 15 mL was centrifuged at 3000 RPM for 8 mins at room temperature. The 
bacterial pellets were resuspended in 15 mL PBS then subject to two washes in PBS (3000 RPM for 8 
mins). The bacterial pellet was resuspended in 10 mL fresh LB and the OD600 of the culture was 
measured. Cells were diluted in LB to give an OD600 of 0.1. 10 μL of cells in LB was added to gold 
carbon coated EM grids and incubated at 37ºC. Grids were fixed at various time points over 22 hrs by 
adding 10 μL 5% (v/v) glutaraldehyde in 200 mM CAB (sodium cacodylate arsenic pH 7.2) for 5 mins. 
The grids were then washed in 20 μL 2.5% (v/v) glutaraldehyde in 100 mM CAB for 2 mins then 30 
mins. The grids were then subject to 3 x 1 min water washes. Grids were air dried for 20 mins then 
loaded on to the EM for analysis (JEOL 1230) at 80 KV. 
2.9.1.4 Immunolabelling OMVs using anti-OmpA antibody 
Purified E. coli BL21 (DE3) OMVs were concentrated 10x by centrifugation at 13,200 RPM (14,220 x 
g) for 30 mins at 4ºC then resuspended in 10 mM HEPES buffer. 10 μL OMVs were added to each grid 
and left to settle for 10 mins. Grids were fixed by washes in 20 μL 2% (w/v) formaldehyde + 0.5% (v/v) 
glutaraldehyde in 100 mM CAB pH 7.2 for 1 min then 30 mins. Grids were then subject to 2 x 5 min 
washes in 100 mM CAB then 2 x 5 min washes in TBST. Grids were washed in 2% (w/v) BSA in 
TBST for 1 min then 30 mins. Grids were then incubated with anti-OmpA antibody (Antibody Research 
Corporation 111120) diluted 1 in 50 in TBST. An identical grid was used as a negative control and was 
incubated in TBST only. Grids were left in primary antibody at 4ºC overnight. The next day, grids were 








Used to visualise purified (O)MVs. Default 
grid type used unless otherwise stated 
Gold Formvar/carbon 400 Immunogold labelling (O)MVs
Gold None 400
Immunogold labelling cells and (O)MVs 




(BBI solutions EM.GAR15) which was diluted 1 in 50 in TBST. Grids were washed in secondary 
antibody for 1 min then left for 30 mins. Grids were subject to 5 x 1 min washes in TBST then 5 x 1 
min washes in Milli-Q water. Lastly, grids were negatively stained using 2% (w/v) uranyl acetate in 
PBS then air dried for 20 mins. Grids were loaded on to the EM for analysis (JEOL 1230) at 80 KV. 
2.9.1.5 Embedding bacterial cells in resin for immunogold labelling and TEM analysis 
Colonies were inoculated into 12.5 mL LB and incubated at 37 °C, 180 RPM for 20 hrs. 1 mL overnight 
culture was harvested by centrifugation at 13,000 RPM for 2 mins. Cells were fixed in 1.5 mL 2.5% 
(v/v) gluteraldehyde in 100 mM sodium cacodylate buffer pH 7.2 (CAB) for 3 hrs with gentle rotation 
at 20 RPM. Fixed cells were pelleted by centrifugation at 13,000 RPM for 2 mins then washed twice in 
100 mM CAB buffer, followed by final resuspension in 1.5 mL CAB. Cells were pelleted by 
centrifugation at 13,000 RPM for 2 mins then resuspended in 1.5 mL 50% (v/v) ethanol. Resuspended 
cells were mixed with gentle rotation at 20 RPM for 10 mins. This was repeated so that the cells were 
washed in 70% (v/v) ethanol, 90% (v/v) ethanol and 3x washes in 100% ethanol to remove all water. 
Cell pellet was finally resuspended in 1.5 mL LR White Resin Medium Grade (Agar scientific, 
AGR1281) and left spinning on the rotor overnight at room temperature. Cells were pelleted by 
centrifugation at 13,000 RPM for 2 mins, the supernatant was removed and the cells were resuspended 
in fresh LR White Resin (Agar Scientific). This was repeated once more. Cells resuspended in resin 
were left spinning at 20 RPM at room temperature for 5 hrs. Cells were then added to Gelatin capsules 
(Agar Scientific G29208). They allow resin polymerisation in the absence of oxygen as they are sealed. 
Cells were pelleted (13,000 RPM for 2 mins) and resuspended in 0.5 mL resin. The cells (resuspended 
in resin) were then added to the capsules and fresh resin was used to top up the capsules to the point of 
overflowing to leave as little air is in the capsule as possible. The capsules were placed into new 1.5 mL 
Eppendorfs (cut in half) so they could be microfuged at 1000 RPM for 5 mins so that the cells were at 
the bottom of the capsule. Capsules were incubated at 60ºC for 22 hrs to allow polymerisation of resin 
inside the gelatin capsules. The gelatin capsules were cut off the resin using a Teflon coated razor blade. 
The bottom of the resin capsule contained the cell sample (was visible as a LB-coloured pellet). The top 
part of the resin (away from the sample) was filed down to the flat then the sample was labelled with 
permanent marker. The resin pieces were stored in a Petri dish for sectioning and EM at a later date. 
2.9.1.6 Embedding OMVs in resin for immunogold labelling and TEM analysis 
E. coli strains were grown in 750 mL LB and purified using the standard OMV purification protocol for 
E. coli. The final OMV pellet was resuspended in 1 mL 10 mM HEPES buffer. 800 μL E. coli OMVs 
were harvested by centrifugation at 13,200 RPM (14,220 x g) for 30 mins at 4 ºC. OMVs were then 
fixed in 1.5 mL 2.5% gluteraldehyde in 100 mM sodium cacodylate buffer pH 7.2 (CAB) for 1.5 hrs 
with gentle rotation. Fixed OMVs were pelleted by centrifugation at 13,200 RPM (14,220 x g) for 30 
mins then washed twice in 100 mM CAB, followed by final resuspension in 25 μL CAB. 25 μL of fixed 
OMVs were added to PCR tubes immersed in a 54°C water bath. After warming, 25 μL of pre-heated 
3% (w/v) agarose solution in 100 mM CAB was added to the OMV suspension and mixed thoroughly 




then transferred into a pre-warmed frame constructed from two glass microscope slides separated by an 
acetate gasket, held together by bulldog clips. The slides were incubated at 4ºC for 10 mins to set. The 
microscope slides were separated and the agarose gel was cut into small (~2 mm) squares with a 
razorblade. The agarose pieces were transferred to a petri dish into a droplet of 0.1% Alcian blue in 1% 
acetic acid (v/v). Agarose squares were then transferred to a glass vial and washed twice in 3 mL 100 
mM CAB. Using this process, agarose pieces were washed in 50% (v/v) ethanol, 70% (v/v) ethanol, 
90% (v/v) ethanol and finally 3x in 100% ethanol. All 100% ethanol was removed and agarose pieces 
were left in approximately 3 mL resin overnight at room temperature so that all remaining ethanol 
evaporated. All resin liquid was removed around the agarose pieces then fresh resin was added. This 
was repeated and the agarose pieces were left in resin for 5 hrs. This was then added to gelatin capsules 
which were filled with resin to the top until overflowing. 1 blue agarose piece was added to the bottom 
of the gelatin capsule filled with resin. Capsules were incubated at 60ºC for 22 hrs to allow 
polymerisation. The gelatin capsules were cut off the resin using a Teflon-coated razor blade. The 
bottom of the resin capsule contained the OMV sample (visible due to the blue dye) and the top part of 
the resin (away from the sample) was filed down to the flat then labelled with permanent marker. The 
resin pieces were stored in a Petri dish for sectioning and EM at a later date. 
2.9.1.7 Sectioning and visualisation of embedded samples  
Sectioning was performed by Ian Brown (UKC) on a RMC MT-XL ultra-microtome with a diamond 
knife. Sections were added to un-coated 300 mesh gold grids (Ian Brown). Grids were washed in 2% 
(w/v) BSA in TBST for 1 min then 30 mins. Grids were incubated in 15 μL primary antibody in TBST 
at 4°C overnight. See Table 2.20 for further details on the primary and secondary antibodies used. 















Anti-FimA monoclonal 1 in 50 Rabbit




and Anti-GFP antibody 
mix
1 µL FimA 
antibody, 1 µL 




Anti-mouse 10 nm gold 
(BBI solutions) then anti-
rabbit 15 nm gold 
1 in 50
Anti-FimA polymer 1 in 50 Rabbit
Anti-rabbit 15 nm gold 
(BBI solutions )
1 in 50
Anti-Flagellin 1 in 50 Rabbit
Anti-rabbit 15 nm gold 
(BBI solutions )
1 in 50
Anti-GFP antibody 1 in 50 Mouse
Anti-mouse 10 nm gold 
(BBI solutions )
1 in 50
TBST only (anti-mouse 
negative control)
N/A N/A
Anti-mouse 10 nm gold 
(BBI solutions )
1 in 50
TBST only (anti-rabbit 
negative control)
N/A N/A







Grids were subject to 5 x 1 min washes in TBST then incubated in secondary immunogold conjugated 
antibody for 30 mins. For the samples probed with both anti-FimA monomer and anti-GFP primary 
antibodies, grids were incubated in anti-mouse secondary antibody for 15 mins then anti-rabbit 
secondary antibody for 15 mins. Grids were subject to 5 x 1 min washes in TBST then 5 x 1 min washes 
in TBST. Grids were incubated in 4.5% (v/v) uranyl acetate in 1% (v/v) acetic acid solution for 15 mins 
then washed in a stream of MQ water. Lastly, grids were stained by incubation in Reynolds lead citrate 
for 3 mins then washed in a stream of MQ water. Grids were air dried for 30 mins then loaded on to the 
EM for analysis. For further details about antibodies used, see Section 2.1. 
2.9.2 Confocal microscopy  
Confocal microscopy for Streptomyces S4 cells and MVs 
Streptomyces S4 cells were inoculated into 12.5 mL YEME:TSB (two media mixed in a 1:1 ratio) and 
incubated at 30ºC, 180 RPM for 48 hrs. 1 mL cells were pelleted by centrifugation at 13,200 RPM 
(14,220 x g) for 30 mins so that both cells and OMVs were pelleted together. The supernatant was 
removed and 1 mL 2% (w/v) paraformaldehyde in PBS was used to fix cells. Cells were pelleted again 
and 1 mL 100 µg/mL WGA-FITC (Sigma L4895) was mixed with the cells and incubated in the dark 
for 1 hour. 15 μL cells were added onto a 1.5 mm thickness coverslip before being inverted into a drop 
of ProLong Gold antifade mountant (Life Technologies, P36930) on a glass slide. Slides were incubated 
at room temperature in the dark overnight to cure. Samples were visualised the next day by confocal 
microscopy (Zeiss lsm 880 with airscan with associated Zen Black software) under the supervision of 
Matt Lee. A scale bar was added to images using Fiji (Image J). The only modification to the protocol 
when using Streptomyces S4 MVs was that there was an additional concentration step after the 
incubation with WGA-FITC for 1 hour. MVs were pelleted by centrifugation at 13,200 RPM (14,220 x 
g) for 30 mins then resuspended in 15 μL PBS which was added to the glass slide in the same way as 
above. 
2.9.3 Light microscopy 
Light microscopy for fimbriae agglutination assay 
Each E. coli strain was inoculated into LB and incubated at 37ºC for 18-24 hrs, 180 RPM. 
Saccharomyces cerevisiae was inoculated into YPD and incubated at 30ºC for 18-24 hrs, 180 RPM. 5 
μL of overnight E. coli strain was mixed with 5 μL Saccharomyces cerevisiae on a glass microscope 
slide. Yeast cell agglutination was visualised using GXM L2800 Premium Compound Microscope at 




2.10 Protease studies 
2.10.1 Proteinase K test 
Purified OMV samples were treated with a working concentration of 10 µg/mL Proteinase K 
(resuspended in HEPES/CaCl2 buffer, details in Section 2.15) and/or varying concentrations of SDS (in 
MQ water). The OMVs were incubated in the presence and absence of Proteinase K and SDS for 30 
mins while shaking at 37°C, 180 RPM. PMSF was added to every sample to inhibit Proteinase K (0.5 
mM working concentration) then samples were incubated for another 30 mins while shaking at 37°C, 
180 RPM. Samples were then TCA precipitated to concentrate then run on an SDS-PAGE gel for 
analysis. For pre-lysed OMVs, OMVs were heated for 95°C for 30 mins then left at room temperature 
to cool before Proteinase K addition. 
 
 
Table 2.21 Description of the contents of each sample in a Proteinase K test 
 
2.11 Detergent studies 
2.11.1 E. coli and Streptomyces S4 detergent studies 
Various concentrations of SDS were added to E. coli/Streptomyces S4 MVs then incubated for 60 mins 
at 37 ºC, shaking at 180 RPM. Samples were TCA precipitated and finally resuspended in 30 μL 10 mM 








10 mM HEPES 
buffer)
100µg/mL Proteinase 
K (or substituted with 
10 mM HEPES/CaCl2 
buffer)




2 OMVs - Prot K - SDS 168 µL OMVs 24 µL HEPES/CaCl2 48 µL water 
3 OMVs + Prot K - SDS 168 µL OMVs 24 µL Proteinase K 48 µL water 
4 OMVs - Prot K + SDS 168 µL OMVs 24 µL HEPES/CaCl2 48 µL 20% SDS
5 OMVs heated to 95°C + Prot K 168 µL OMVs 24 µL Proteinase K 48 µL water 
6 OMVs + Prot K + SDS 0.02% 168 µL OMVs 24 µL Proteinase K 48 µL 0.02% SDS
7 OMVs + Prot K + SDS 1% 168 µL OMVs 24 µL Proteinase K 48 µL 5% SDS
8 OMVs + Prot K + SDS 2% 168 µL OMVs 24 µL Proteinase K 48 µL 10% SDS
9 OMVs + Prot K + SDS 4% 168 µL OMVs 24 µL Proteinase K 48 µL 20% SDS




2.12 Cloning / DNA manipulation techniques 
2.12.1 Plasmid design and cloning overview 
The plasmid pJB005 was donated by Dr Alex Moores (UKC) for use in cloning. See Figure 2.2 for 
plasmid map and details. The vector is a derivative of the pCA24N plasmid with mNeonGreen fused at 




















Aim: To re-introduce the fimA and fimC genes back into E. coli ΔfimA/ΔfimC strains using the pJB005 
plasmid. The resulting proteins are a FimA-mNeon Green fusion protein and a FimC-mNeon Green 
fusion protein. Figure 2.3 gives an overview of the cloning procedure. 
 
 
2.12.1.2 Cloning Oligos into pJB005 plasmid overview 
Aim: To create an mNeon Green protein with the FimA signal peptide sequence on the N-terminus of 
the protein. Figure 2.4 gives an overview of the cloning procedure. 
 
  
Figure 2.3 Overview 
for cloning fimA and 














2.12.2 Primer design and preparation 
The following primers (listed in Table 2.22) were ordered from Integrated DNA Technologies (IDT). 
Further information of primer design can be found in Appendix A.1-A.2. 
Table 2.22 List of primers ordered from IDT with brief descriptions of their use 
 
 
2.12.2.1 Primer stocks (-80 ºC freezer) 
DNA was resuspended in sterile MQ water to make a 100 µM stock solution (stored at -80ºC). 
2.12.2.2 Working stocks of DNA (-20 °C) 
-80°C primer stocks were diluted to be 10 µM DNA which were then stored at -20°C.   
2.12.3 Transformation of DNA 
2.12.3.1 Preparation of competent cells    
The following strains from The Coli Genetic Stock Center (Keio collection) were made chemically 
competent with the guidance of Dr Alex Moores (UKC). The desired strain was inoculated into 10 mL 
LB and grown overnight at 37°C, 180 RPM. 50 μL of this culture was inoculated into 50 mL LB and 
was incubated at 37°C, 180 RPM until an OD600 0.5 was reached. 3.75 mL pre-warmed sterile 100% 
glycerol was added slowly to the flask 5 mins before reaching OD600 0.5. After OD600 0.5 was 
reached, the cells were chilled on ice for 10 mins. The cells were centrifuged for 10 mins at 4000 RPM, 
4°C and the supernatant discarded. Cells were resuspended gently in 50 mL of ice-cold magnesium 
chloride solution (see Section 2.15 for details). Cells were pelleted by centrifugation for 8 mins at 3800 
RPM and the supernatant was discarded. The cell pellet was resuspended gently in 12.5 mL ice cold T 
Primer name Primer description Primer sequence (5' - 3')
pJB.gene.seq.f




Reverse primer for insert in plasmid 
pJB005 including mNeon green protein
CTAATTAAGCTTGGCTGCAGGT 
fimA .full.f




































salts (containing CaCl2 and MgCl2, see Section 2.15 for details) and incubated on ice for 20 mins with 
occasional mixing. Cells were pelleted at 4ºC at 3600 RPM for 6 mins then the cells were finally 
resuspended gently into 2.5 mL T salts. Competent cells were split into aliquots of 200 μL into pre-
chilled tubes and stored immediately at -80 ºC. All steps above were performed in a sterile environment 
and cells remained on ice for as long as possible.      
2.12.3.2 Transformation protocol 
Competent cells were thawed on ice for 20-30 mins before addition of exogenous DNA. 1 μL of 
purified plasmid (approximately 150 ng/µL) was mixed with 50 μL competent cells then incubated for 
30 mins on ice. 50 μL competent cells only were used as a negative control. The cells were then heat 
shocked at 42ºC for 45 seconds to allow uptake of exogenous DNA through the disrupted membrane. 
Cells were then incubated on ice for 2 mins for recovery and retention of the exogenous DNA. 500 μL 
sterile LB was added to each reaction then incubated at 37ºC for 1 hour. 50 μL was then spread on a LB 
plate containing 25 µg/mL chloramphenicol for selection of cells containing the desired plasmid. To 
concentrate the cells further, 450 μL cells were centrifuged at 3500 RPM for 3 mins. The supernatant 
was removed and cells were resuspended in 50 μL LB and spread on to LB plate containing 25 µg/mL 
chloramphenicol. All plates were incubated at 37ºC overnight. 
2.12.4 DNA isolation  
2.12.4.1 Isolation of genomic DNA 
Genomic DNA from E. coli MG1655 was supplied by Dr Alex Moores (UKC). 
 
2.12.4.2 Isolation of fimA and fimC inserts from genomic DNA 
 





25 2x Q5 Master Mix
2.5 Forward primer (10 µM)
2.5 Reverse primer (10 µM)
19 MQ water




2.12.4.3 Isolation of plasmid DNA 
A sterile pipette tip was used to pick up a colony of interest from a successful transformation. This 












Cells were grown in LB with 25 µg/mL chloramphenicol overnight (37ºC, shaking at 180 RPM). 5 mL 
of culture was used and plasmid DNA was isolated using QIAprep® Spin Miniprep Kit (Qiagen). 
Isolated plasmid DNA was eluted using either 50 μL sterile MQ water or 50 μL supplied EB buffer (10 
mM Tris·HCl, pH 8.5). DNA concentration was determined by using a NanoDrop Spectrophotometer. 
  
2.12.5 Preparation of plasmid and inserts for ligation (fimA/fimC inserts) 
2.12.5.1 Preparation of pJB005 plasmid for ligation  
Undigested pJB005 plasmid was provided by Dr Alex Moores (UKC).  
2.12.5.2 Plasmid digestion with restriction enzymes NdeI and AscI 
The reaction was set up as follows (Table 2.24). NdeI restriction enzyme was added and the mixture 
was incubated for 1 hour at 37°C. AscI was then added and incubated for another 1 hour at 37°C. NdeI 
enzyme needs 3 base pairs or more on each side of the cleavage site to recognise the sequence (NEB 
catalogue 2013-2014, page 330). For this reason, NdeI was added first then AscI was added 1 hour later. 
Table 2.24 Digestion of plasmid with restriction enzymes NdeI and AscI 
  
Volume (µL) Component
3 10x NEB Cutsmart enzyme buffer
7 pJB005 plasmid (to make 1 µg DNA)
18 Sterile MQ water
1 NdeI restriction enzyme (20 Units/µL)
1




the isolation of 








2.12.5.3 Gel extraction of plasmid to prevent re-ligation 
6 μL 6x loading dye was added to the 30 μL reaction above and ran on a 1% agarose gel. 12 μL was 
loaded into 3 consecutive wells. The location of the plasmid was determined using a UV box and the 
bands from all 3 lanes were extracted using a scalpel. The plasmid was extracted using QIA quick gel 
extraction kit (Qiagen) and quantified using the NanoDrop spectrophotometer. The extracted plasmid 
was used immediately for ligation.       
2.12.5.4 Preparation of fimA and fimC inserts for ligation (restriction digest) 
Gel extraction of fimA and fimC insert DNA 
fimA and fimC inserts were extracted from genomic DNA as described above. In order to purify 
fimA/fimC only (and no other genomic DNA), a gel extraction was performed. 30 μL of the PCR 
reaction was mixed with 6 μL 6x loading dye and ran on a 1% (w/v) agarose gel. 15 μL was loaded into 
2 consecutive wells. The location of the DNA was determined using a UV box and the bands from both 
lanes were extracted using a scalpel. The plasmid was extracted using QIA quick gel extraction kit 
(Qiagen) and quantified using the NanoDrop spectrophotometer. The extracted insert DNA was used 
immediately for ligation.       
 
Digestion with restriction enzymes NdeI and AscI 
The reaction was set up as follows (Table 2.25) and incubated for 2 hrs at 37 °C. 
Table 2.25 Digestion of inserts with restriction enzymes NdeI and AscI 
 
PCR clean up 
Immediately after digestion, restriction enzymes were removed using QIAquick PCR Purification Kit. 
 
2.12.6 Preparation of plasmid and inserts for ligation (Oligo insert) 
2.12.6.1 Preparation of pJB005 plasmid for ligation  
Plasmid digestion with restriction enzymes NdeI and AscI 
The reaction was set up as follows (Table 2.26). NdeI restriction enzyme was added and the mixture 




6 10x NEB Cutsmart enzyme buffer
45 fimA/fimC extracted DNA (to make 1 µg) 
7 Sterile MQ water
1 NdeI restriction enzyme  (20 Units/µL)




Table 2.26 Restriction digest of pJB005 plasmid with restriction enzymes NdeI and AscI 
 
 
PCR clean up  
Restrictions enzymes were removed from the DNA after digestion using the QIAquick PCR Purification 
Kit (Qiagen) using the manufacturer’s instructions.  
2.12.6.2 Preparation of Oligos for ligation  
Phosphorylation 
Oligos were phosphorylated using the reagents listed in Table 2.27 and incubated at 37°C for 45 mins. 
Table 2.27 Phosphorylation of Oligo DNA 
 
Annealing forward and reverse Oligos 
50 μL forward primer oligo for FimA signal peptide was mixed with 50 μL associated reverse primer 
oligo for FimA signal peptide. 11 μL annealing buffer was added and the tube was added to a heat block 
and incubated at 95ºC for 5 mins. The heat block was then turned off and left to cool to room 
temperature 
 
2.12.7 Ligation protocol 
2.12.7.1 Ligation of plasmid with fimA and fimC insert 






3 10x NEB Cutsmart enzyme buffer
7 pJB005 plasmid (to make 1 µg DNA)
18 Sterile MQ water
1 NdeI restriction enzyme (20 Units/µL)
1





6 Oligo DNA (10 µM)
5 10 mM ATP 
5 10x T4 Polynucleotide Kinase Reaction Buffer
37 Sterile MQ water

















All tubes were centrifuged briefly to spin down then incubated at 4ºC overnight. 50 µL DH5α 





0 Digested PCR insert 
1 Digested vector (5 ng/µL)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)




1 Digested PCR insert
1 Digested vector (5 ng/µL)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)




3 Digested PCR insert
1 Digested vector (5 ng/µL)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)




5 Digested PCR insert
1 Digested vector (5 ng/µL)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)




2.12.7.2 Ligation of plasmid with Oligo DNA 
Ligation of plasmid with Oligo DNA was performed as described below in Table 2.29. 






All tubes were centrifuged briefly to spin down then incubated at 4ºC overnight. 50 µL DH5α 
competent cells were transformed with 5 μL ligation reaction. 
2.12.8 DNA analysis techniques 
2.12.8.1 Colony PCR 
Colony PCR reactions were set up as described in the Table 2.30 below. A negative control was run 
using undigested plasmid only (no colonies). See Appendix A.3-A.4 for results. 









Annealed Oligos (annealed Oligos diluted 1 in 6 with 
sterile MQ water)
0.5 Digested pJB005 plasmid (5 ng/µL DNA)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)
7 Sterile MQ water
Volume (µL) Component
0.5 Digested pJB005 plasmid (5 ng/µL DNA)
1 10x ligase buffer (Promega C1268)
1 T4 DNA ligase (Promega M180A)
7.5 Sterile MQ water
Volume (µL) Component
12.5 2x PCRBIO Taq Mix Red (PCR Biosystems)
1.25 Forward primer for plasmid (10 µM)
1.25 Reverse primer for plasmid (10 µM)
10 MQ water
0
Colony of interest (colony taken from patch and mixed 
straight into the colony PCR reaction)
Volume (µL) Component
12.5 2x PCRBIO Taq Mix Red (PCR Biosystems)
1.25 Forward primer for plasmid (10 µM)
1.25 Reverse primer for plasmid (10 µM)
9 MQ water




Colony PCR reactions were added to the PCR machine and ran using settings in Table 2.31 below. 







2.12.8.2 Agarose gel electrophoresis 
1% or 2% (w/v) agarose gels were made by dissolving agarose in 1x TAE buffer by heating in a 
microwave. Once fully dissolved, this was then poured into a gel mould (Fisher Scientific) and left to 
set for 20-30 mins. 5 μL DNA 1KB ladder (Promega) was loaded into the first well of all gels to 
estimate DNA fragment sizes. 6x loading dye was added to samples (unless the reaction contained Taq 
polymerase) and 5 μL was loaded into each well unless otherwise specified. Gels were run at 150 V for 
25 mins then stained for 30 mins in 0.5 µg/mL ethidium bromide in MQ water. Bands were visualised 
using G:Box machine by SynGene and associated software. 
 
2.12.8.3 Double digest of plasmid to confirm insert  
pJB005 plasmid containing fimA insert 
The reactions were set up as follows (Table 2.32) and incubated for 1 hour at 37 °C.  
 




pJB005 plasmid containing fimC insert 
The reactions were set up as follows (Table 2.33) and incubated for 1 hour at 37 °C. 
 












1. Initial denaturation 95 3 1
2a. Denaturation 95 1
2b. Annealing 53 1
2c. Elongation 72 2
3. Final extension time 72 5 1





1 pJB005 with fimA  insert (160 ng/µL)
1 10x Promega enzyme buffer
1 PstI restriction enzyme (10 Units/µL)
1 NdeI restriction enzyme  (20 Units/µL)




1 pJB005 only (empty vector)
1 10x Promega enzyme buffer
1 PstI restriction enzyme (10 Units/µL)
1 NdeI restriction enzyme (20 Units/µL)




1 pJB005 with fimC  insert  (214 ng/µL)
1 10x Promega enzyme buffer
1 AscI restriction enzyme (10 Units/µL)
1 EcoRI restriction enzyme (20 Units/µL)




1 pJB005 only (empty vector)
1 10x Promega enzyme buffer
1 AscI restriction enzyme (10 Units/µL)
1 EcoRI restriction enzyme (20 Units/µL)




2 μL 6x loading dye was added to each sample. 5 μL was then loaded into each well of a 1% agarose gel 
and stained using ethidium bromide. See Appendix A.5-A.6 for results. 
 
2.12.8.4 DNA sequencing 
Samples were shipped to Genewiz for Sanger Sequencing. Plasmids to be sequenced were diluted to 
100 ng/μL using autoclaved MQ water. These were sent with the relevant primers which were diluted to 
5 µm (5 pmol/μL). All inserts were confirmed as the correct sequence. See Appendix A for results.   
 
2.13 Streptomyces S4 specific techniques 
2.13.1 Bioassay of Streptomyces S4 cells and MVs on C. albicans 
























2.13.1.1 Preparation of Streptomyces S4 WT MVs with various number of washes in 10 mM 
HEPES buffer (Figure 2.7). 
  






2.13.1.2 Effect of Streptomyces S4 cells on C. albicans growth 
Streptomyces S4 colonies (from MS plates) were inoculated into TSB:YEME (two media mixed 
together in a 1:1 ratio) and incubated at 30ºC, 180 RPM for 72 hrs. 5 μL of this culture was spotted at 
the centre of an LB agar plate and left to soak/dry for 2 hrs. Plates were incubated at 30ºC for 72 hrs. C. 
albicans was added to the plates and the zones of inhibition (ZOI) were measured. All plates were 
prepared in triplicate and the average ZOI and standard deviation was calculated for each strain. 
2.13.1.3 Effect of candicidin and antimycin on C. albicans growth 
Candicidin (Bioaustralis) and antimycin (Sigma) were resuspended in ethanol to give 1 mg/mL 
concentration. These stocks were then diluted with ethanol to give various concentrations ranging from 
1 mg/mL to 1 µg/mL. All candicidin stocks were stored at -20ºC and antimycin at 4ºC. 10 μL 
candicidin/antimycin at each concentration was added to LB plates and left to soak/dry for a minimum 
of 2 hrs at room temperature. 10 μL ethanol only was used as a negative control.  C. albicans was added to 
the plates and the zones of inhibition (ZOI) were measured. All plates were prepared in triplicate and 
the average ZOI and standard deviation was calculated for each concentration of antifungal. 
2.13.1.4 Effect of Streptomyces S4 MVs on C. albicans growth 
5 μL or 10 μL purified MVs (depending on experiment) were added to LB plates and left to soak/dry for 
a minimum of 2 hrs at room temperature. C. albicans was added to the plates and the zones of inhibition 
(ZOI) were measured. 
2.13.1.5 C. albicans addition to plate 
C. albicans was streaked from the -80 ºC glycerol stock on to a YPD agar plate and incubated for 18-24 
hrs at 37°C. Colonies were inoculated into YPD media and incubated at 37ºC for 18-24 hrs in 
preparation for the experiment. 5 μL MVs/cells/antifungals were added to LB plates and left to soak/dry 
for a minimum of 2 hrs at room temperature. The OD600 of C. albicans was measured then diluted to 
OD600 1.0. Cells were centrifuged at 5000 RPM for 5 mins and the supernatant was discarded. C. 
albicans cell pellets were resuspended into 50 mL ‘hand hot’ LB agar (0.5% w/v) then 10 mL was 
slowly added to each plate. Plates were incubated at 37ºC for 18 hrs and the diameter of the ZOI 
measured using a ruler in mm. All plates were prepared in triplicate and the average ZOI and standard 
deviation was calculated for MVs from each strain. 
2.13.2 Identification of candicidin in Streptomyces S4 MVs 
2.13.2.1 Butanol extraction 
Streptomyces S4 MVs were purified from all 4 strains using the usual protocol (Section 2.6.3). After the 
final spin at 16,000 RPM (25, 805 x g) to pellet the MVs, the following 3 methods were used to extract 






























Analysis of candicidin/antimycin by UV-Vis spectrophotometer 
UV-Vis spectrum was determined using the Cary spectrophotometer.   






Chapter 3  
Optimisation of techniques for OMV purification 
and characterisation 
3.1 Introduction 
3.1.1 Optimisation of OMV purification procedure 
In order to complete the project aims outlined in Section 1.11, optimisation of OMV isolation and 
characterisation was essential. The aim was to optimise a method to purify OMVs reproducibly, giving 
the best yield possible. The purified OMVs should be intact with as few contaminants from the bacterial 
cell as possible. Methods were also developed to characterise the purified OMVs and determine the 
differences in OMV composition and cargo between different bacterial strains and compared with the 








Figure 3.1 Summary of different methods of OMV purification used in the literature  
Bacterial strains are cultured (1) then centrifuged to remove whole cells. OMV production can be 
increased if the cells are under stress. The supernatant from the centrifugation is filtered to remove any 
whole cells (2). OMVs can be concentrated by precipitation (for example with ammonium sulphate) or 
ultrafiltration (3). Lastly, OMVs can be purified further using either gel filtration or density gradient 





The starting point to develop this protocol was to optimise one that had been successfully used to purify 
OMVs by a previous student of Dr Gary Robinson (Dr Luisa de Sordi). This protocol involved growing 
the bacteria of interest overnight in LB, centrifuging the culture then filtering the supernatant through a 
PES membrane filter to remove any remaining bacterial cells. The supernatant was treated with 1.5 M 
ammonium sulphate to precipitate the OMVs so that they could be concentrated with another 
centrifugation step at 16,000 RPM (25,805 x g). Lastly, any remaining contaminants were removed 
using buoyant density ultracentrifugation. Ultracentrifugation is often the final step in OMV isolation 
protocols as it separates the OMVs from any contaminating proteins or extracellular appendages which 
may have been co-purified with the OMVs (such as Type 1 fimbriae or flagella). If performed correctly, 
OMVs settle into a lower-density region of the gradient whereas any contaminating proteins, flagella or 
fimbriae remain in the bottom layer.  
 
3.1.2 Methods of OMV characterisation 
During this study, OMVs were purified from one Burkholderia cenocepacia strain, two Pseudomonas 
aeruginosa strains (Chapter 3), thirty-three E. coli strains (Chapters 3-4) and four Streptomyces S4 
strains (Chapter 5). In order to ultimately manipulate membrane vesicles for therapeutic purposes, the 
OMVs must first be characterised from each strain using the techniques described below. Evidence is 
also needed to show that the purified OMVs are genuine, entire and that the cargo within is still 
functional (e.g. treatment with proteases). 
3.1.2.1 Visualisation of OMVs by Transmission Electron Microscopy TEM 
Purified OMVs were visualised using electron microscopy (EM) and compared to those found in the 
literature to confirm that they were the correct size, shape and appearance. To observe OMV biogenesis, 
E. coli BL21 (DE3) cells and P. aeruginosa (PA14) cells were grown in LB on gold EM grids and fixed 
at various time points over 24 hours. The cells were examined using TEM and photos were taken at 
each time point. Lastly, immunolabelling using an anti-OmpA antibody was applied to OMVs purified 
from E. coli BL21 (DE3). OmpA is a major protein in the outer membrane of E. coli and is known to be 
found on the surface of E. coli OMVs (Figure 3.2). Detecting OmpA on the surface of purified OMVs is 
evidence of successful isolation. 
Figure 3.2 The incorporation of 
OmpA into E. coli OMVs 
Image sourced from Kim et al. 2009. 
In this paper, proteins of interest were 
targeted to E. coli OMVs by fusion 





3.1.2.2 Proteome analysis of OMVs 
SDS-PAGE  
The protein profiles of OMVs purified from various bacterial strains were visualised using SDS-PAGE 
gels, which were silver stained. The protein profile of the purified OMVs was compared to that of the 
whole cell, periplasmic proteins and outer membrane proteins. This provides evidence that the OMVs 




Bands of interest in OMVs were excised from the SDS-PAGE gels and identified by mass spectrometry.  
 
Western blotting 
Western blots were performed to detect OmpA in purified OMVs from various strains of E. coli. This 
evidence complements the immunogold labelling images of E. coli OMVs using the anti-OmpA 
antibody.  
3.1.2.3 Evidence that purified OMVs are intact: Proteinase K treatment of OMVs 
The Proteinase K test was used to confirm that isolated OMVs are intact and to distinguish which 
proteins are outside the OMVs or within the lumen. This test is based on an experiment found in the 
literature (Figure 3.3). The principle is that the enzyme Proteinase K will degrade most proteins outside 
of the OMVs. However, proteins within the lumen of the OMVs will be protected from Proteinase K 
degradation. OMVs were incubated with Proteinase K in the presence and absence of SDS. SDS is a 
detergent and lyses OMVs which allows Proteinase K into the interior lumen of the OMVs where it can 
degrade proteins.  
  
Figure 3.3 Proteinase K test on OMVs from Francisella novicida in the literature 
OMVs were treated (or untreated) with 10 μg/ml Proteinase K in the presence or absence of 0.02% (w/v) 
SDS to disrupt vesicle integrity. OMVs were incubated for 1 hour at room temperature then 0.1 mM 
PMSF was added to inhibit the protease. The white arrows indicate which proteins in the OMVs are 
susceptible to Proteinase K digestion when no SDS is added (comparing lanes 1 and 2). Experiment, 
methodology and image sourced from McCaig et al. 2013 




3.1.2.4 Quantification of OMVs 
Bradford assay 
OMVs can be quantified by measuring either the protein or lipid components in the sample. Proteins in 
OMV samples can be quantified using a Bradford assay (Bradford, 1976). This method was used 
throughout the project to quantify OMVs and standardise the samples prior to loading on an SDS-PAGE 
gel. 
3.1.2.5 Dynamic light scattering (DLS) 
DLS is used to determine the number, intensity and size distribution of nanosized particles in a solution. 
Brownian motion is the random movement of particles in a solution due to constantly colliding with 
solvent molecules around them. Smaller particles move faster than larger molecules in solution. DLS is 
based on measuring the Brownian motion of particles in a solution which can be used to determine 
particle size.   
 
During DLS, the sample in the cuvette is illuminated by a laser beam. The particles (for example OMVs 
resuspended in buffer) scatter the light of the laser beam in all directions. The scattered light is detected 
at a certain angle which is known as the scattering angle θ. Here, a photon detector analyses the 
fluctuation of the scattered light (Figure 3.4 a). The DLS can analyse the scattered light and use this 
information to estimate particle size distribution and numbers. Smaller particles give faster fluctuations 




















Figure 3.4 Diagram showing the main principle of DLS technique 
Diagram to show the main components of Dynamic Light Scattering (DLS). Firstly, the sample in the cuvette 
is illuminated by a laser beam. The particles scatter the light of the laser beam in all directions. A photon 
detector analyses the fluctuation of the scattered light (a). Smaller particles give faster fluctuations of 







This technique has been used to estimate the size of E. coli OMVs in the literature (Bielaszewska et al. 
2017). The Litesizer 500 (Anton Paar) used in this study gives a value called the Mean Intensity for 
each sample run using the DLS setting. This gave the mean light intensity detected in kcounts/s and was 
trialled to quantify the OMVs. 
 
3.1.3 Bacterial strains used to study OMVs 
Table 3.1 Brief introduction to the bacterial strains used in Chapter 3. See Section 1.11 for rationale for 





Strain name Strain characteristics/additional information 
B. cenocepacia 
J2315 
Pathogenic strain isolated from a cystic fibrosis patient
E. coli B Parental          
(B strain) 
E. coli B wildtype strain. Parental strain of E. coli BL21 and BL21 
(DE3)
E.coli  BL21                
(B strain)
Competent E.coli  B strain for routine non-T7 expression.  Deficient in 
proteases Lon and OmpT. No flagella or fimbriae produced. Resistant 
to phage T1 
E.coli  BL21 (DE3)       
(B strain)
Identical to E.coli BL21 except this strain contains the λDE3 lysogen 
that carries the gene for T7 RNA polymerase under control of the 
lacUV5 promoter
E.coli FimB-LacZ 
fusion                          
(K-12 strain)
This strain contains a deletion of the Lac operon (lacZYA ) and fimB 
and an insertion of a FimB-LacZ fusion protein. Fimbriae production 
is locked off as FimB is no longer functional
E.coli  fimbriae 
locked on                              
(K-12 strain)
Fimbriae production locked on. The invertible element (fimS ) is 
locked on due to the modifications in the parental intermediate strain 
E.coli WT MG1655 
(K-12 strain)
Used as the wild type strain to produce E.coli FimB-LacZ fusion strain 
and E.coli with fimbriae locked on
E.coli WT Parental 
BW25113                                
(K-12 strain)
The parental strain of the Coli Genetic Stock Center Keio collection 
(from which the knock-out strains are derived) 
E.coli ΔfimA                    
(K-12 strain)
Strain contains a knockout of the protein FimA which is the main 
structural subunit of Type 1 fimbriae
E.coli ΔfliC               
(K-12 strain)
Strain contains a knockout of the protein Flagellin (FliC) which is the 
main structural subunit of flagella
P. aeurginosa PA01
Two P. aeruginosa pathogenicity islands (PAPI-1 and PAPI-2) are 
absent from PA01  which is less virulent than PA14
P. aeurginosa PA14
Two P. aeruginosa  pathogenicity islands (PAPI-1 and PAPI-2) in the 




3.1.4 Main chapter aims 
1. To determine a reproducible and cost-effective method of isolating OMVs, which can be applied to 
all Gram-negative bacterial strains 
2. To determine if OMVs can be purified with no contaminants from the bacterial cell. For example, can 
co-purification of proteins, flagella or fimbriae from the bacterial supernatant be prevented? 
3. To gain strong evidence that the purified OMVs are genuine, entire and still functional 
4. To compare the composition and cargo of OMVs between bacterial strains  
5. To determine which proteins are enriched and excluded in OMVs from a range of strains  
 
3.2 Results 
3.2.1 Optimisation steps for OMV purification 
The initial OMV purification protocol was taken from the thesis of Dr Luisa de Sordi. The protocol was 
optimised to give the standard OMV purification protocol below (Figure 3.5). After centrifugation at 
16,000 RPM (25,805 x g), an OMV pellet is produced which is often visible. This pellet was either 
resuspended in 10 mM HEPES buffer for further analysis or resuspended into 45% (v/v) OptiPrep so the 
OMVs could be purified further by ultracentrifugation. 
















Figure 3.5 Standard OMV purification protocol 
An OMV purification protocol was optimised and used as the standard for all experiments unless otherwise 
stated. This flow chart is a simplified summary of the OMV purification procedure. Ultracentrifugation 




3.2.1.2 How reproducible is the OMV purification protocol?  
OMVs purified from E. coli BL21 (DE3) on five different dates were compared. This was to confirm 
that the OMV purification protocol developed was reproducible.  Firstly, the TEM images of the OMVs 
were compared (Figure 3.6) and then the protein profile of the purified OMVs (Figure 3.7a). Protein 
densitometry plots were also generated using Fiji (Image J) to compare the protein profile of the MVs 





Figure 3.6 Comparison of OMVs purified from E. coli BL21 (DE3) on five separate occasions  
TEM images of OMVs from E. coli BL21 (DE3) purified on five separate occasions. ‘Purification 1’ 
was performed on 30/06/16 (a, f). ‘Purification 2’ was performed on 14/02/17 (b, g). ‘Purification 3’ 
was performed on 23/01/17 (c, h). ‘Purification 4’ was performed on 06/12/16 (d, i). ‘Purification 5’ 
was performed on 17/01/17 (e, j). 
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The SDS-PAGE gels showed that the OMV protein profile is different to that of the cells. The protein 
profile is almost identical each time OMVs are purified from E. coli BL21 (DE3) meaning that the 
purification protocol is reproducible. Each time, the E. coli cells grew to an OD600 of approximately 
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Figure 3.7 Comparison of the protein profiles of OMVs purified from E. coli BL21 (DE3) on five 
separate occasions  
OMVs from E. coli BL21 (DE3) purified on five separate occasions. ‘Purification 1’ was performed on 
30/06/16. ‘Purification 2’ was performed on 14/02/17. ‘Purification 3’ was performed on 23/01/17. 
‘Purification 4’ was performed on 06/12/16. ‘Purification 5’ was performed on 17/01/17. A Bradford 
assay was performed and all samples were standardised to be the same protein concentration. TCA 
precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel 
was run then silver stained to visualise the MV protein profile (a). The prominent band at around 37 kDa 
had previously been identified as OmpF (see Appendix B.1 for details). OMVs were quantified using a 






The only major difference in the protein profiles is the extra band between 100 and 150 kDa in 
Purification 1 and is faintly visible in Purifications 4 and 5, which has not been identified. The 
prominent band in the E. coli BL21 (DE3) OMV protein profile at around 37 kDa had previously been 
identified as OmpF (see Appendix B.1). OmpF is a porin protein located in the outer membrane. One of 
its functions is to allow diffusion of small hydrophilic molecules across the membrane and into the 
periplasm (Duval et al. 2009). An enrichment of OmpF in OMVs is expected as it is an outer membrane 
protein.  
 
3.2.1.3 Are any live bacterial cells present in the purified OMV sample when using this 
protocol? 
During the OMV purification procedure, the cells are centrifuged at 12,000 RPM (14,515 x g) and the 
supernatant (containing the OMVs) is filtered through a PES membrane filter to remove any whole 
bacterial cells. Each time, 1 mL of filtered supernatant was spread on to a LB agar plate and incubated 
at 37°C for 24-48 hours to confirm that there was no growth. 1.5 M ammonium sulphate was then 
slowly added to the supernatant to precipitate the OMVs. The addition of 1.5 M ammonium sulphate to 
LB was shown to fully inhibit the growth of five strains of E. coli (Figure 3.8). These two checks 
strongly indicate that the OMV samples used in every study did not contain any live bacterial cells.  
 
  
Figure 3.8 Addition of 1.5 M ammonium sulphate to LB inhibits the growth of five E. coli strains 
Growth curves were produced by culturing E. coli in 48 well cell culture plates. Two identical microplate 
readers were used to generate growth curves at 25ºC and 37ºC concurrently. Addition of 1.5 M ammonium 
sulphate (AS) to LB was shown to inhibit the growth of the following E. coli strains at 25ºC: BL21 (DE3), 
WT Parental BW25113, ΔfimA, ΔfimC and FimB-LacZ fusion. For graphs with error bars of 1 standard 
deviation and growth curves at 37ºC see Appendix B.2. 
 
 
ΔfimC in LB 
BL21 (DE3) in LB 
BL21 (DE3) in LB + 1.5 M AS
WT Parental BW25113 in LB 
WT Parental BW25113 in LB 
+ AS 
ΔfimC in LB + 1.5 M AS 
ΔfimA in LB 
ΔfimA in LB + 1.5 M AS 
FimB-LacZ fusion strain in LB 
FimB-LacZ fusion strain in LB + 




3.2.1.4 Does the type of membrane filter used affect the OMVs purified?  
In most OMV purification protocols, there is a filtration of the bacterial supernatant through a 
membrane filter of pore size 0.2 µm and 0.45 µm to remove any remaining live cells. 0.2 µm pore size 
was used with OMVs from P. aeruginosa as the OMVs were less than 200 nm in diameter. The larger 
pore size of 0.45 µm was used for E. coli cells as the OMVs found were often between 200-400 nm in 
diameter. A comparison of the OMVs purified using a polyethersulfone (PES) membrane filter was 
compared to a surfactant-free cellulose acetate (SFCA) membrane filter. PES membrane filters are 
commonly used for cell culture media and allow rapid filtration. SFCA membrane filters, however, are 
described as having the lowest protein binding so may improve the purity of the OMVs (Thermo-Fisher 
Nalgene Filter Brochure).  
 
To compare the OMV profile produced when using PES and SFCA membrane filters, 1 L of PA01 and 
PA14 culture supernatants were split into 2 x 500 mL. One half of the supernatant was filtered through a 
PES filter (Nalgene rapid-flow, Fisher 10300461) and the other half was filtered through a SFCA 
membrane filter (Nalgene rapid-flow, Fisher 10201371). After this step, the standard OMV purification 
protocol was then followed as usual and the OMVs were resuspended in 10 mM HEPES buffer (details 
in Section 2.15). The TEM images of the OMVs were first compared (Figure 3.9a) to assess the purity 
of the OMV sample (ie. to determine whether flagella and other debris were also present in the OMV 
sample). Next, the protein profiles of the OMVs were compared after purification with PES and SFCA 





















































Figure 3.9 Comparing the use of PES vs. SFCA membranes during the OMV purification process 
PA01 and PA14 cultures were grown overnight in 1 L LB. The cells were pelleted and the supernatant was 
extracted and split into two. One half of the supernatant was filtered through a PES membrane filter and 
the other half was filtered through a SFCA membrane filter. After this step, the standard OMV 
purification protocol was followed as usual and the OMVs were resuspended in 3 mL 10 mM HEPES 
buffer. The OMVs were concentrated then visualised using TEM (a). Samples were taken from various 
steps of the OMV purification procedure which is explained in b and d. A Bradford assay was performed 
and all samples from each strain were standardised to be the same protein concentration. TCA 
precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel 







The TEM images (Figure 3.9 a), showed no difference in the purity of the OMVs as there was flagella 
co-purified when using both filters. There was also no difference in the protein profile when using either 
filter (b-e). After reviewing the data, PES membranes were used for the OMV purification protocol as 
they are most cost effective and have a faster flow rate than SFCA membrane filters.   
 
3.2.1.5 Can flagella and fimbriae co-purified with OMVs be removed by buoyant density 
ultracentrifugation?  
Flagella and fimbriae can be co-purified with OMVs and this was initially studied in 3 strains (Figure 
3.10). TEM images were compared to see if it was possible to distinguish flagella and fimbriae in OMV 
samples be eye (Figure 3.10a-b). E. coli WT MG1655 is a K-12 strain which was studied extensively 
during this project and has been reported previously to express Type 1 fimbriae (Blumer et al. 2005). 
An E. coli FimB-LacZ (translational) fusion strain was used as a positive control for visualising flagella 
as fimbriae production is locked off. Also, an E. coli strain with fimbriae production locked on was used 
as a positive control for fimbriae production as there should be excessive fimbriae.  
 
These images (Figure 3.10b) can be used as a reference point for later decisions on how to differentiate 
between the two by eye. These images show that flagella are thicker and longer than fimbriae. They are 
also curvy/wavy whereas fimbriae are short, thin and straight appendages. As a final test, OMVs 
purified from E. coli WT BW25113 (a strain very closely related to MG1655 were fixed on to an EM 
grid. They were then immunogold labelled using an anti-polymerised FimA antibody and Flagellin. 
This confirmed the presence of fimbriae surrounding the OMVs and not flagella (Figure 3.10c). 


















Strain name Strain characteristics/additional information 
E.coli WT 
MG1655
Used as the wild-type strain to produce E.coli FimB-LacZ fusion strain and 
E.coli with fimbriae locked on
E.coli FimB-
LacZ fusion
This strain contains a deletion of the Lac operon (lacZYA ) and fimB and an 
insertion of a FimB-LacZ fusion protein. Fimbriae production is locked 
off as FimB is no longer functional.
E.coli  fimbriae 
locked on
Fimbriae production locked on. The invertible element (fimS ) is locked 
on due to the modifications in the parental intermediate strain (see Strain 






























Figure 3.10 TEM images of OMVs purified from three E. coli strains to compare co-purification of 
flagella and fimbriae 
The TEM images of OMVs from three E. coli strains were compared: E. coli MG1655, E. coli FimB-LacZ 
fusion and E. coli with fimbriae locked on (a). These images (b) can be used as a reference point for later 
decisions on how to differentiate between flagella and fimbriae by eye. As a final test, OMVs purified from 
E. coli WT BW25113 (a strain very closely related to MG1655) and were fixed on to an EM grid. They 
were then immunogold labelled using an anti-polymerised FimA antibody and Flagellin. This confirmed 





Ultracentrifugation to remove flagella co-purified with P. aeruginosa and E. coli OMVs 
The TEM images in Figures 3.9 and 3.10 indicate that OMVs are co-purified with flagella in the 
following strains: PA01, PA14 and E. coli FimB-LacZ fusion. OMVs were subject to buoyant density 
gradient ultracentrifugation by flotation through layers of OptiPrep. OMVs were resuspended in 45% 
(v/v) OptiPrep then the following layers of OptiPrep were added: 40%, 35%, 30%, 25% and 20% (v/v). 
If performed correctly, OMVs settle into a lower-density region of the gradient whereas any 
contaminating flagella or fimbriae remain in the bottom layer. After ultracentrifugation, a thin orange 
band could be seen within the ultracentrifuge tube (Figure 3.11a) which was suspected to contain the 
OMVs (blue arrow). All six layers of OptiPrep were extracted and then run on an SDS-PAGE gel to 
identify which layer contained the OMVs (Figure 3.11b). The OptiPrep layers of interest were then 


































Figure 3.11 Comparing the purity of OMV samples before and after buoyant density ultracentrifugation 
PA14 OMVs were subject to buoyant density ultracentrifugation using OptiPrep to separate them from any 
contaminating flagella. After ultracentrifugation, a thin orange band could be seen within the ultracentrifuge 
tube (a) which was suspected to contain the OMVs (blue arrow). All six layers of OptiPrep were extracted and 
a portion of the sample was TCA precipitated. The concentrated samples were run on an SDS-PAGE gel and 
silver stained to identify which layer contained the OMVs (b). The OptiPrep layers of interest were then 





Figure 3.11 shows the PA14 OMVs before and after ultracentrifugation. The layer of 30% OptiPrep 
contains purified OMVs without the contaminating flagella. This was also successful with PA01 OMVs 
(see Appendix B.3). Although this technique was successful with OMVs from P. aeruginosa, this 








Figure 3.12 Comparing the purity of OMV samples before and after buoyant density 
ultracentrifugation 
E. coli FimB-LacZ fusion strain OMVs were subject to buoyant density ultracentrifugation using OptiPrep 
to separate them from any contaminating flagella. All six layers of OptiPrep were extracted and a portion of 
the sample was TCA precipitated. The concentrated samples were run on an SDS-PAGE gel and silver 
stained to identify which layer contained the OMVs (a). The OptiPrep layers of interest were then visualised 
by TEM and the purity of the sample was compared before and after ultracentrifugation (b).   
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Instead of the OMVs settling into one layer of the OptiPrep gradient, the OMVs were spread across 
almost all OptiPrep layers and the contaminating flagella was still present. This would lead to a 
decrease in OMV yield if only one layer was chosen.  
3.2.1.6 Alternative methods to remove flagella from purified OMV samples 
Although ultracentrifugation was successful for separating P. aeruginosa OMVs from contaminating 
flagella, this was not successful for E. coli flagella. Three new methods were trialled to remove the 
contaminating flagella. The first method was an additional low speed spin of the purified OMVs at 6000 
x g for 30 minutes (Figure 3.13a). The second was addition of Proteinase K at 10 µg/mL (a). This 
concentration was chosen as it is known to degrade extracellular proteins without affecting the OMVs 
themselves (McCaig et al. 2013). The purified OMVs resuspended in 10 mM HEPES buffer (details in 
Section 2.15) were also subject to filtration through a membrane with 0.45 µm pore size to see if the 





Figure 3.13 Comparison of methods to remove the co-purified flagella in E. coli K-12 OMV samples 
OMVs were purified from 500 mL culture using the standard protocol and were resuspended in 5 mL 10 
mM HEPES buffer. The following methods were compared (shown in a): 1. Usual method: 1 mL 
OMVs in 10 mM HEPES buffer were centrifuged at 4ºC for 30 mins, 13,200 RPM. The resulting OMV 
pellet was resuspended in 30µL 10 mM HEPES buffer. 2. Low speed spin: 1 mL OMVs in 10 mM 
HEPES buffer was centrifuged at 6000 x g at 4ºC for 30 mins. The resulting OMV pellet was resuspended 
in 30µL 10 mM HEPES buffer. 3. Proteinase K: 900µL OMV sample was mixed with 100µL Proteinase 
K sample (100 µg/mL in HEPES/CaCl2 buffer). Samples were incubated at 37ºC for 30 mins then the 
protease was inhibited with PMSF. OMVs were centrifuged at 13,200 RPM (14,220 x g) for 30 mins at 
4°C. The resulting OMV pellet was resuspended in 30µL 10 mM HEPES buffer. The following methods 
were compared (shown in b): OMVs in 10 mM HEPES buffer were compared when additional filtration 






None of the methods trialled to separate OMVs from flagella in Figure 3.13 were successful. Lastly, 
OMVs were treated with a mix of proteases from Streptomyces griseus at varying concentrations 








The addition of this mix of proteases appeared to be successful at the removal of most flagella at a 
concentration of 0.5% (w/v) proteases. However, this mix of proteases produced many prominent bands 
on the SDS-PAGE gel ranging from approximately 10 kDa to 42 kDa. Bands at these molecular weights 
can obscure the protein profile of the OMVs on the SDS-PAGE gels. Additionally, the addition of 0.5% 
(w/v) proteases appeared to lyse the OMVs and degrade the OMV-associated proteins (see Appendix 
B.4 for Figures).      
 
 
3.2.1.7 Can ultracentrifugation be used to remove Type 1 fimbriae from purified E. coli OMV 
samples?  
OMVs were purified from the E. coli strain with fimbriae production locked on. This strain 
overexpresses fimbriae and produces flagella too. The OMV pellet was resuspended in 45% (v/v) 
OptiPrep then subject to ultracentrifugation to remove fimbriae (Figure 3.15). 
Figure 3.14 Using a mix of Streptomyces griseus proteases to remove the co-purified flagella in E. 
coli K-12 OMV samples 
A protease stock of 10% (w/v) was prepared in HEPES/CaCl2 buffer which was then diluted to give the 
other protease concentrations. OMVs resuspended in HEPES were incubated with proteases of varying 
concentrations at 37ºC for 30 mins. The samples (450 µL) were centrifuged at 4ºC for 30 mins, 13,200 












































Figure 3.15 Comparing the purity of OMV samples before and after buoyant density 
ultracentrifugation 
OMVs purified from E. coli with fimbriae production locked on strain were subject to buoyant density 
ultracentrifugation using OptiPrep. All six layers of OptiPrep were extracted and a portion of the sample 
was TCA precipitated. The concentrated samples were run on an SDS-PAGE gel and silver stained to 
identify which layer contained the OMVs (a). The OptiPrep layers of interest were then visualised by 






The SDS-PAGE gel in Figure 3.15a shows that the purified OMVs are spread between five of the 
OptiPrep layers (Lanes 5-9) instead of settling into one layer. The TEM images (Figure 3.15b) show 
that the contaminating fimbriae and flagella are still present and have not been separated from the 
OMVs.  
 
Both the SDS-PAGE gel and TEM images suggested that ultracentrifugation causes E. coli OMVs to 
spread between all six of the OptiPrep layers rather than settling within one layer. The fimbriae and 
flagella are also not separated from the OMVs in any sample tested. For this reason, E. coli OMVs were 
resuspended in 10 mM HEPES buffer (details in Section 2.15) for analysis in subsequent experiments 
rather than using ultracentrifugation so that no OMVs were lost. 
 
3.2.2 Visualisation of OMVs using Transmission Electron Microscopy (TEM) 
In this study, OMVs have been purified from a range of Gram-negative bacteria and visualised using 
TEM. OMVs are approximately 50 nm to 200 nm in diameter and are very similar to those found in the 
literature. Although there are small variations in size and staining intensity of the OMVs, OMVs from 
each bacterial strain generally appear the same (Figures 3.16-3.17). 
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Figure 3.16 Comparison of OMVs purified from a range of Gram-negative bacteria 
TEM analysis of purified OMVs from the following strains: E. coli WT MG1655 (a, j) E. coli 
FimB-LacZ fusion (b, k) E. coli with fimbriae locked on (c, l) E. coli BL21 (DE3) (d, m) E. 
coli BL21 (e, n) E. coli B strain (f, o) Burkholderia cenocepacia (g, p) Pseudomonas 
aeruginosa PA01 (h, q) Pseudomonas aeruginosa PA14 (i, r).  
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The purified OMVs from each strain were consistent, reproducible and are the correct size and 
appearance when compared to those in the literature. 
 
Figure 3.17 Comparison of OMVs purified from a range of Gram-negative bacteria from the 
literature 
TEM images of OMVs from Pseudomonas aeruginosa strains PA01 and PA14 sourced from Shan et al. 
2014 (a). Scale bars missing in the published images. TEM photo of P. aeruginosa PA01 biofilm OMVs 
sourced from Couto et al. 2015 (b). Scale bar missing in the published image. TEM image of P. 
aeruginosa PA01 OMVs sourced from Chutkan et al. 2013 (c). TEM image of B. cenocepacia OMVs 
from Martins et al. 2016 (d). TEM image of Uropathogenic E. coli OMVs sourced from Svennerholm et 
al. 2017 (e).  TEM images of OMVs purified from the probiotic E. coli strain EcN, serotype O6:K5:H1 (f) 
and E. coli ECOR12 which is a human commensal strain isolated from a stool sample (g). Images sourced 
from Fábrega et al. 2016. The final TEM image is of OMVs from a BL21 (DE3) ΔtolR(pET) strain and the 
image is sourced from (Bartolini et al. 2013) (h). This is referred to as the ‘empty OMV’ in the paper and 
is the negative control for expression of their recombinant protein of interest which is HtrA from 
Chlamydia muridarum.  
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3.2.2.1 Immunogold labelling of E. coli BL21 (DE3) OMVs using an anti-OmpA antibody  
OmpA is an outer membrane protein in E. coli that is known to be present on the surface of OMVs 
(Kim et al. 2009). Detecting OmpA on the surface of purified OMVs is evidence that OMVs have been 
purified successfully. Purified E. coli BL21 (DE3) OMVs were immunogold labelled using an anti-
















Figure 3.18 Immunolabelling E. coli BL21 (DE3) OMVs using anti-OmpA antibody.  
Purified E. coli BL21 (DE3) OMVs were concentrated 10x. 10 µL OMVs were added to each grid and 
grids were fixed by washes in 2% (w/v) formaldehyde + 0.5% (v/v) glutaraldehyde in 100 mM CAB 
pH 7.2. Grids were then washed in 100 mM CAB followed by washes in Tris-buffered saline with 
0.05% (v/v) Tween 20 (TBST). Grids were blocked in 2% (w/v) BSA then incubated with anti-OmpA 
antibody (diluted 1 in 50 in TBST). An identical grid was used as a negative control and that was 
incubated in TBST only. Grids were left in primary antibody or TBST only at 4ºC overnight. The next 
day, grids were washed in TBST then incubated in immunogold-conjugated anti-rabbit antibody 
(which was diluted 1 in 50 in TBST). Grids were incubated in secondary antibody for 1 min then left 
for 30 mins. Grids were subject to washes in TBST then MQ water. Lastly, grids were negatively 
stained using 2% (w/v) uranyl acetate in PBS then air dried for 20 mins. Grids were analysed by TEM. 









3.2.2.2 Visualising OMV biogenesis from E. coli BL21 (DE3) and Pseudomonas aeruginosa 
(PA14) cells 
In order to gain evidence of OMV budding from bacterial cells, E. coli BL21 (DE3) cells and PA14 
cells, (resuspended in LB), were grown on gold EM grids and fixed at various time points over 24 
hours. The cells at each time point were examined using EM and studied for evidence of OMV 
biogenesis (Figure 3.19). 
 
 
The OMV biogenesis images produced were similar to those found in the literature and appear to 
successfully show OMV biogenesis from the E. coli BL21 (DE3) and PA14 cells.  
Figure 3.19 Visualisation of OMV biogenesis from E. coli BL21 (DE3) and PA14 cells using EM 
E. coli BL21 (DE3) and PA14 cells were diluted to an OD600 of 0.1 in LB and added to a gold EM grid. 
The grids were incubated at 37ºC for 22 hrs and grids were fixed at various time points. Grids were 
negatively stained using 2% (w/v) uranyl acetate then visualised using EM at various magnifications. 
Figure 3.19 a-b shows E. coli BL21 (DE3) cells after 30 mins since addition to the gold EM grid. Figure 
3.19 c shows E. coli BL21 (DE3) cells 22 hrs after addition to the gold grid. Figure 3.19 d shows PA14 
cells 6 hrs after addition to the gold grid. Figure 3.19 e-f shows PA14 cells after 22 hrs after addition to 
the gold grid. Blue arrows indicate budding and released OMVs from cells. Figure 3.19 g shows OMV 
biogenesis from S. marcescens and is sourced from Li et al. 1998. Figure 3.19 h shows OMV biogenesis 
from H. pylori and is sourced from Parker et al. 2012. 
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3.2.3 How does the OMV protein profile compare across bacterial strains and species 
The protein profiles of OMVs purified from various bacterial strains were visualised using SDS-PAGE 



























OMVs from wild type E. coli K-12 strains (lanes 5-6) have a very different protein composition to 
OMVs from recombinant/engineered strains (lanes 7-10). OMVs from the wild type E. coli K-12 strains 
appear to be enriched with specific proteins (for example the prominent band at approximately 55 kDa 
in lanes 5-6). OMVs from E. coli B strains, however, appear to have many more proteins and at 
different molecular weights (lanes 7-10). Certain proteins also appear to be selectively included and 
excluded from P. aeruginosa and B. cenocepacia wild type OMVs compared with the engineered E. 
coli B strains (lanes 2-6 compared with lanes 7-10). The difference in OMVs produced from E. coli K-
12 and B strains was explored further (see Chapter 4, section 4.2.1). For further information on the E. 
coli BL21 strains in Lanes 8-10 see Appendix B.5. 
  
Figure 3.20 – Comparison of protein profiles of OMVs from various bacterial strains  
OMVs were purified from a range of B. cenocepacia, P. aeruginosa and E. coli K-12 and B strains. A 
Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. Proteins were separated using SDS-PAGE and silver stained to visualise OMV protein profiles. 







3.2.3.1 Comparison of the protein profile of OMVs and whole cells  
The protein profile of the OMVs was compared to the protein profile of the whole cell (Figure 3.21) to 
see which proteins are enriched and excluded from the OMVs. The protein profile of OMVs from E. 
coli FimB-LacZ fusion strain, PA01 and PA14 show that certain proteins are concentrated within the 
OMVs when compared to the cells. The prominent bands within OMVs from each strain were extracted 





Figure 3.21 Comparison of protein profiles of OMVs compared with the whole bacterial cell.  
OMVs were purified from E. coli BL21 (DE3), PA14, PA01 and E. coli FimB-LacZ fusion strain. 1 
mL of each overnight culture was saved from each strain to be used in the ‘cell’ lanes. All samples 
were standardised to the same protein concentration then TCA-precipitated prior to loading. Proteins 







3.2.3.2 Identification of proteins of interest by mass spectrometry 
Bands of interest were extracted from SDS-PAGE gels and identified by mass spectrometry (Table 3.2 
and Appendix B.6 for further detail).  
 
Table 3.2 Identification of OMV proteins by mass spectrometry 
Bands of interest were excised from silver stained SDS-PAGE gels then identified by mass 
spectrometry. Proteins were identified by a Peptide Mass Fingerprint (PMF) search in the Mascot 














Protein detected (using Peptide 
Mass Fingerprinting and 
SwissProt database unless 
otherwise stated)
Score (score 






E.coli  BL21 DE3 35 OmpF 125 (70) 39309 OMPF_ECOLI
38 Flagellar hook protein 100 (70) 42019 FLGE_ECOLI
52
Flagellin OS=Escherichia coli 
(strain K12)
255 (70) 51265 FLIC_ECOLI
55 Flagellin 257 (70) 51265 FLIC_ECOLI
17 FimA 71 (70) 18214 FIMA1_ECOLI
16
Type-1 fimbrial protein, A chain 
OS=Escherichia coli (strain K12)
71 (70) 18214 FIMA1_ECOLI
37
Outer membrane protein A 
OS=Escherichia coli O157:H7
93 (70) 37292 OMPA_ECO57
55 Antigen 43 120 (70) 106818 AG43_ECOLI
55 Antigen 43 148 (70) 106818 AG43_ECOLI
17 FimA 71 (70) 18214 FIMA1_ECOLI
49 B-type flagellin 241 (70) 49213 FLICB_PSEAE
40
Putative prophage major tail 
sheath protein
209 (70) 41339 Y807_PSEAB
32 Elastase 135 (70) 53882 ELAS_PSEAE
52 Aminopeptidase 108 (70) 57818
LAP_PSEAB or 
LAP_PSEAE
50 B-type flagellin 281 (70) 49213 FLICB_PSEAE





31 Chitin-binding protein 71 (70)





Putative prophage major tail 
sheath protein
135 (70) 41339 Y807_PSEAB
E.coli  WT MG1655











3.2.3.3 Identification of OmpA in E. coli OMV samples 
A range of E. coli OMV samples were probed with an anti-OmpA antibody (Figure 3.22a). A band is 
expected at 37 kDa according to the manufacturer’s guidelines. The whole E. coli cells were run 
alongside the OMVs as a positive control. The Western blot was also repeated using cell and OMV 
samples from E. coli BL21 (DE3), E. coli FimB-LacZ fusion protein, PA01 and PA14 (Figure 3.22b). 
Bands appeared at 37 kDa and 25 kDa for the E. coli strains but not for P. aeruginosa. This indicates 



























Bands at approximately 37 kDa were found indicating OmpA in all E. coli whole cells and OMVs 
(Figure 3.22a). A band was also present at approximately 25 kDa and there appears to be double 
banding at each of these molecular weights which could be due to the presence/absence of a signal 
peptide (see Section 3.3.2.3 for further discussion). OprF is the P. aeruginosa equivalent of OmpA in E. 
coli (Confer, Ayalew. 2013). The molecular weight of OprF is 37.6 kDa but has only 37.5% identity to 
OmpA in E. coli (see Appendix B.8). As expected, there were no bands at 25 kDa and 37 kDa in the P. 
aeruginosa cell or OMV samples (b). 
b 
Figure 3.22. Western blotting to detect OmpA in purified OMV and whole cell samples 
A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. E. coli and P. aeruginosa whole cells and OMV samples from each strain of interest 
used to run an SDS-PAGE gel. Proteins were separated using SDS-PAGE and then transferred to a 
PVDF membrane for Western blotting. The membrane was probed with an anti-OmpA antibody 










3.2.3.4 Enrichment of certain proteins within E. coli OMVs compared to the whole cell, outer 
membrane and the periplasm  
Previous SDS-PAGE gels and mass spectrometry results (Table 3.2) showed that OMVs from the E. 
coli K-12 strains appear to be heavily enriched with FimA (18 kDa) and/or Flagellin (51 kDa). In order 
to see if this cargo was enriched in other parts of the cell, six different strains of E. coli were subject to a 
periplasmic and outer membrane extraction protocol. The SDS-PAGE gels in Figure 3.23 indicated that 
the levels of FimA and Flagellin in the whole cell, periplasm and outer membrane are relatively low and 
















































The OMV protein profiles were found to be very different to the lysed cells, periplasmic proteins and 
OM proteins. It also appeared that certain proteins were enriched and/or excluded from the OMVs. For 
example, E. coli K-12 OMVs were enriched with (or excluded) the following proteins: FimA (18 kDa), 
Flagellin (51 kDa) and Antigen 43 α-chain (50 kDa). Interestingly, the presence of FimA and Flagellin 
appeared to be mutually exclusive in the OMVs except for the E. coli strain where fimbriae production 
is locked on (this is discussed further in Section 4.2.2). 
 
Lastly, the major outer membrane prolipoprotein Lpp was detected in high levels in the periplasmic and 
OM samples. This was expected as the Lpp protein is located in the periplasm and links the OM with 
the peptidoglycan layer (Schwechheimer, Kuehn. 2015). OMVs have been found to bud in locations 
where the Lpp link is absent. The major outer membrane prolipoprotein Lpp is not present in OMVs and 
so is absent in the OMV samples above (Schwechheimer, Kuehn. 2015). 
Figure 3.23 FimA and Flagellin are enriched in E. coli K-12 OMVs compared to levels in the 
periplasm and whole cell 
A Bradford assay was performed and all samples were standardised to be the same protein concentration. 
TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE 
gel was run and silver stained to visualise protein profiles of E. coli OMVs were compared to the whole cell, 
OM and periplasm. Samples were purified from the following E. coli strains: BW25113 Parental (a), ΔfimA 







3.2.4 Are the purified OMVs whole and intact?  
3.2.4.1 Proteinase K test: E. coli BL21 (DE3) OMVs 
The Proteinase K test is used to confirm that isolated OMVs are intact and to distinguish which proteins 
are outside the OMVs or within the lumen (see Section 3.1.2 for further information). E. coli BL21 and 
BL21 (DE3) OMVs were incubated with Proteinase K in the presence and absence of SDS (Figure 3.24 

























The sample in Lane 3 contains OMVs that have been treated with Proteinase K but no SDS. The bands 
in Lane 3 indicate which proteins are present within the lumen of the OMVs and are therefore protected 
from Proteinase K degradation (compared to Lanes 2 and 4).  However, when the OMVs were treated 
with both SDS and Proteinase K, the majority of the bands disappeared (lanes 6-9). SDS disrupts OMV 
membranes and allows Proteinase K access to the proteins within the OMVs. Figure 3.24 therefore 
provides evidence that the OMVs were present and intact. 
 
Figure 3.24 Proteinase K test on OMVs from E. coli BL21 (DE3) strain 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various 
concentrations of SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and samples 
were incubated for another 30 mins at 37ºC. TCA precipitation was used to concentrate samples prior to 


























As above, the sample in Lane 3 contains OMVs that have been treated with Proteinase K but no SDS. 
The bands in Lane 3 indicate which proteins are protected from Proteinase K within the lumen of the 
OMVs when compared to Lanes 2 and 4. When E. coli BL21 (DE3) OMVs were treated with both SDS 
and Proteinase K, the majority of the bands disappeared (Figure 3.25). In this case, the protein profile of 
Lanes 6-9 remains almost unchanged. However, when the OMVs are heated to 95°C before Proteinase 
K addition, many of the bands disappear. This evidence suggests that PA14 OMVs are resistant to 






Figure 3.25 Proteinase K test on OMVs from PA14  
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various 
concentrations of SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and 
samples were incubated for another 30 mins at 37ºC. TCA precipitation was used to concentrate 
samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to 
visualise the OMV protein profile. 
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The band in Lane 3 indicates that the main enriched protein in the OMVs (later confirmed as Flagellin) 
is protected from Proteinase K degradation within the lumen of the OMV. When SDS was added alone 
to the OMVs (with no Proteinase K), many new bands appeared (Lane 4). The hypothesis was that 
when the structure of the OMVs was disrupted by SDS, active proteases (that were originally contained 
within the OMVs) were now released extracellularly. These proteases could then degrade OMV proteins 




Figure 3.26 Proteinase K test on OMVs from E. coli FimB-LacZ fusion 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various concentrations 
of SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and samples were incubated 
for another 30 mins at 37ºC. TCA precipitation was used to concentrate samples prior to loading on an 
SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. The 










3.2.5 Do E. coli OMVs contain active proteases? 
E. coli FimB-LacZ OMVs were treated with various concentrations of SDS to determine the minimal 
concentration needed to disrupt the OMVs and release the proteases. OMVs were incubated with 
various concentrations of SDS at 37°C for 60 minutes (Figure 3.27a). The OMV samples before and 


































Figure 3.27 The effect of SDS on OMVs from E. coli FimB-LacZ fusion 
OMVs were incubated in the presence and absence of SDS of various concentrations for 60 mins at 37ºC. 
30 µl sample was mixed with 10 µl 4x Reducing sample buffer and heated at 95°C for 5 mins before 
loading on to an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the OMV 
protein profile (a). The brightness of the photo was increased by 10% for clarity. OMVs untreated with 
SDS (Lane 2) and OMVs treated with 1% SDS (Lane 6) were concentrated 3x by centrifugation at 13,200 





As found in Figure 3.26, the addition of SDS causes the extra bands to appear in each sample (Lanes 3-
9 of Figure 3.27a). Interestingly, the main Flagellin band in the OMV is still present and is not degraded 
by any released proteases. OMVs with no SDS treatment and OMVs treated with 1% (w/v) SDS were 
visualised by TEM and compared Figure 3.27b. The images indicate that once SDS was added to the 
OMVs, proteases were released that degraded the co-purified flagella. It seemed possible that the extra 
banding produced could be flagella-associated proteins, which were degraded when the OMV proteases 
are released.  
3.2.5.1 Evidence that E. coli FimB-LacZ fusion strain OMVs contain active proteases 
To test this theory further, OMVs were treated with SDS in the presence and absence of protease 
inhibitors (Figure 3.28). Lastly, a range of the bands produced by the incubation of OMVs with SDS 

























Figure 3.28 The effect of SDS on OMVs from E. coli FimB-LacZ fusion in the presence and 
absence of protease inhibitors 
OMVs were incubated in the presence and absence of 0.1% and 1% SDS for 60 mins at 37ºC. 10 mM 
HEPES buffer was prepared containing a Protease Inhibitor Cocktail (Roche) and this was used in the 
samples of Lanes 4, 5 and 7. 30 µl sample was mixed with 10 µl 4x Reducing sample buffer and heated 
at 95°C for 5 mins before loading on to an SDS-PAGE gel. The SDS-PAGE gel was run then silver 







All 12 bands above were detected as Flagellin by mass spectrometry (see Appendix B.11). Figure 5.28 
shows that the addition of the protease inhibitor prevented the appearance of the additional Flagellin 
bands (Lanes 4, 5 and 7). This indicates that there are proteases within the E. coli OMVs, which are 
released when SDS is added and the membrane is disrupted. It appears that the proteases degrade the 
co-purified flagella around the OMVs which causes the appearance of the extra Flagellin bands (as 
Flagellin is the main structural subunit in flagella). The Flagellin monomer within the OMVs (at 51 
kDa) is still protected, however, even after SDS addition. This is evidence that the Flagellin is protected 
somehow within the OMV separate to the proteases (discussed further in Section 3.3).   
3.2.5.2 4-Nitrophenyl acetate substrate  
The chromogenic esterase substrate 4-nitrophenyl acetate was used to quantify protease activity from 
purified OMVs. OMVs were incubated with the substrate in the presence and absence of 0.1% SDS at 
37°C for 60 minutes. As an additional negative control, OMVs were heated to 95ºC to inhibit any 
protease activity in the sample. Protease activity is detected by a colour change from clear to yellow 




















Figure 3.29 Detection of OMV proteases using 4-Nitrophenyl acetate substrate 
OMVs were incubated with the chromogenic esterase substrate (4-nitrophenyl acetate) in the 
presence and absence of 0.1% SDS at 37°C for 60 mins. As an additional negative control, 
OMVs were heated to 95ºC for 60 mins prior to the assay to inhibit any protease activity in the 
sample. Protease activity was detected by a colour change from clear to yellow which is 
measured by the increase in absorbance at 405 nm. The error bars represent 1 Standard 
Deviation from the mean. 
 




There was a large increase in absorbance at 405 nm when OMVs (resuspended in HEPES) were 
incubated with the 4-nitrophenyl acetate substrate. There was also no reaction at all with 10 mM 
HEPES buffer only (negative control). However, it was found that heating the OMVs to 95ºC for 1 hour 
did not have any effect on the absorbance detected which was unexpected. To explore this further, 1 mL 
samples were extracted from 3 different points in the OMV purification protocol (see Figure 3.30a) and 
used in the assay. Samples extracted from all points of the OMV purification protocol reacted with the 
substrate in the same way. After further investigation, it was found that that 4-nitrophenyl acetate 























The evidence showed that the protease activity of the OMVs could not be correlated to increase in 
absorbance using this method.  
b 
a 
Figure 3.30 4-Nitrophenyl acetate substrate reacts with LB and ammonium sulphate 
1 mL samples were extracted from 3 different points in the OMV purification protocol and used 
for the assay (a). OMVs were incubated with the chromogenic esterase substrate (4-nitrophenyl 
acetate) at 37°C for 60 mins. Protease activity was detected by a colour change from clear to 
yellow which is measured by the increase in absorbance at 405 nm. The assay was repeated with 
the following 4 samples: 10 mM HEPES buffer only, 10 mM HEPES buffer with 1.5 M 
ammonium sulphate added, LB media only and LB with 1.5 M ammonium sulphate added. 





3.2.6 What is the best method to quantify and compare the number of purified OMVs? 
The best method to quantify OMVs is widely debated (Wieser et al. 2014). In this project, Bradford 
assays were used to determine protein concentrations in OMV samples. This was used to standardise 
samples for loading on to SDS-PAGE gels and as a method to quantify OMVs isolated from different 
strains. Alternative methods of OMV quantification techniques were also trialled and are outlined 
below. 
3.2.6.1 Quantification of OMVs using a NanoPhotometer 50 (Implen) 
An alternative method of determining protein concentration was to use the NanoPhotometer 50 (Implen) 
using the Protein UV Bradford Assay setting. Known protein concentrations of BSA and lysed E. coli 
OMVs in HEPES were trialled on the NanoPhotometer. However, it was concluded that the 
NanoPhotometer N50 could not accurately detect low protein concentrations of 75 µg/mL and under 
(see Appendix B.12). Purified OMV samples can range between 20 µg/mL to 200 µg/mL protein. For 
this reason, the Bradford assay was used for determining all protein concentrations as it was more 
accurate. 
3.2.6.2 Characterisation and Quantification of OMVs using Dynamic Light Scattering (DLS) 
The Litesizer 500 was used to characterise OMVs using the DLS mode. The DLS was optimised to be 
used as an alternative method to quantify isolated OMVs and compare OMV production between 
various strains. Details of the DLS machine set up and optimisation are given in Appendix B.13. 
 
The Relative Frequency of the OMVs are given in 3 forms: 
1. Intensity weighted: this represents the size at which most light is scattered 
2. Volume weighted: this indicates the size where most of the vesicles are by volume 
3. Number weighted: this indicates how many vesicles there are at specific sizes 
 
Samples from the following E. coli strains were trialled on the DLS and the Relative Frequency of the 
OMVs was determined: 
1. E. coli B Parental strain 
2. E. coli BL21 strain 
3. E. coli BL21 (DE3) strain 
4. E. coli K-12 BW25113 Parental strain 
5. E. coli ΔfimA 
6. E. coli ΔfliC 
The DLS results for all three OMV samples purified from E. coli B strains showed very distinct peaks 
in the 100-300 nm region (Figure 3.31a). The average particle size for the E. coli B strains appeared to 
be correct as the TEM images showed that the OMVs can range from approximately 50-400 nm in 




Comparison of E. coli B strain OMV particle size using DLS  
  
Figure 3.31 Dynamic light scattering to analyse particle size of E. coli B strain OMVs 
The Litesizer 500 was used to calculate the Relative Frequency of OMVs (Intensity Weighted). 
OMVs resuspended in 10 mM HEPES buffer were purified from E. coli B strains: BL21 
(DE3), BL21 and B strain parental and 1 mL samples were run on the DLS. An average of all 
repeats was taken to generate a graph using Microsoft Excel for each strain showing the 
average size of the OMVs in nm (a). The particle size diameter was compared to the TEM 







Comparison of E. coli K-12 strain OMV particle size using DLS  
  
Figure 3.32 Dynamic light scattering to analyse particle size of E. coli K-12 strain OMVs 
The Litesizer 500 was used to calculate the Relative Frequency of OMVs (Intensity Weighted). 
OMVs resuspended in 10 mM HEPES buffer were purified from E. coli K-12 strains: ΔfimA, 
BW25113 and ΔfliC and 1 mL samples were run on the DLS. An average of all repeats was 
taken to generate a graph on Microsoft Excel for each strain showing the average size of the 
OMVs in nm (a). The particle size diameter was compared to the TEM images of OMVs from 







The OMVs from the E. coli K-12 strains were found to be approximately 100-200 nm in diameter in the 
TEM images (Figure 3.32b). However, OMV samples from the E. coli WT BW25113 strain and the 
ΔfliC strain show no peak at 100-200 nm (Figure 3.32a). Instead, peaks of 811 nm and 1034 nm were 
detected which is most likely to represent the co-purified Type 1 fimbriae. OMVs from the ΔfimA strain 
gave a peak of 333 nm and 1034 nm. The first of these peaks could represent the OMVs, however, this 
value seems high when compared to the TEM images. It is likely that flagella are being detected rather 
than the OMVs. 
3.2.6.3 Quantification of OMVs using DLS 
An attempt was made to quantify E. coli OMVs using the average mean intensity value of each 
sample. This has previously been used to compare light scattering in the literature (Simpanya et al. 
2008). Unfortunately, the mean intensity value for each replicate varied hugely which is reflected 
in the error bars of 1 Standard Deviation (Figure 3.33). The co-purification of flagella and fimbriae 
will also cause this value to be mis-representative of the OMV concentration. For this reason, the 
DLS was no longer used for OMV quantification.        
 
  
Figure 3.33 Dynamic light scattering to quantify purified E. coli OMVs 
OMVs resuspended in 10 mM HEPES buffer were purified from E. coli strains: BL21 (DE3), 
BL21, B strain Parental, ΔfimA, BW25113 and ΔfliC and 1 mL samples were run on the DLS. 
For each repeat of an individual OMV sample, a Mean Intensity is calculated. An average of 







3.3.1 Optimisation of the OMV purification protocol 
3.3.1.1 The OMV purification protocol developed is reproducible (Section 3.2.1) 
OMVs purified from E. coli BL21 (DE3) on five different dates were compared to confirm that the 
OMV purification protocol developed was reproducible. The TEM images and the protein profile 
densitometry plots of the purified OMVs were compared. The protein profile and TEM images were 
almost identical each time the OMVs were purified from E. coli BL21 (DE3). OMV yield was 
quantified by using the Bradford assay. The average protein yield was 26 µg/mL protein and all OMV 
samples were between 21 and 35 µg/mL protein. The protein profile of E. coli OMVs shows many 
proteins of all sizes. This agrees with other SDS-PAGE gels in the literature (Figure 1, Fantappiè et al. 
2014).  
 
3.3.1.2 Live bacterial cells are not purified using this OMV purification protocol (Section 3.2.1) 
During each OMV purification, 1 mL of PES membrane filtered supernatant was spread on to a LB agar 
plate and incubated at 37 °C for 24-48 hours to check that there was no bacterial growth. During the 
OMV purification protocol, 1.5 M ammonium sulphate was then slowly added to the supernatant to 
precipitate the OMVs. The addition of 1.5 M ammonium sulphate to LB was shown to fully inhibit the 
growth of five strains of E. coli (Figure 3.7).  
 
3.3.1.3 The choice of PES or SFCA membrane type does not affect the OMV sample purity, yield 
or proteome (Section 3.2.1) 
During OMV purification, there is a filtration of the bacterial supernatant through a membrane filter of 
pore size 0.2 µm or 0.45 µm to remove any remaining live cells. A 0.22 µm pore size was chosen to 
filter P. aeruginosa OMVs as the majority appear to be 200 nm or less. E. coli OMVs, however, can 
range up to 400 nm in diameter. A study in 2005 found that filtration of Neisseria lactamica OMVs 
through a 0.22 µm pore caused loss of approximately 50% of the OMVs (Gorringe et al. 2005). Care 
was taken to gain the highest yield of E. coli OMVs as possible so a 0.45 µm pore membrane filter was 
used.  
 
To test the type of membrane filter to use, PA14 and PA01 were filtered using PES and SFCA 
membranes to see if the OMV purification was enhanced or affected. The TEM images showed no 
difference in the purity of the OMVs as there was flagella was co-purified when using both filters. 
There was also no difference in the protein profile when using either filter. PES membranes were 
chosen for future OMV purifications as they are most cost effective and have a faster flow rate than 






3.3.1.4 Purified P. aeruginosa OMVs were separated from flagella by ultracentrifugation but this 
was not the case for E. coli OMVs (Section 3.2.1) 
The ultimate aim of the ultracentrifugation step was to purify OMVs without any contaminants from the 
cell. Ultracentrifugation of PA14 and PA01 OMVs was successful at removing contaminating flagella 
from the sample. However, this technique was not successful at separating E. coli K-12 OMVs from 
contaminating flagella. Both the SDS-PAGE gels and EM images suggested that the OMVs were spread 
between all six of the OptiPrep layers rather than settling within one layer. Furthermore, in every layer 
both OMVs and flagella were present so there was no benefit to ultracentrifugation of the OMVs. 
Further attempts to remove flagella and fimbriae from the OMV sample were unsuccessful. This 
included extra filtration steps, extra centrifugation steps and addition of proteases. For this reason, the 
E. coli OMVs pellets were resuspended in 10 mM HEPES buffer for analysis in subsequent experiments 
rather than using ultracentrifugation so that no OMVs were lost. It also appears that others in the 
literature struggle to separate OMVs from contaminating flagella and fimbriae even after 
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Figure 3.34 Comparison of OMVs purified from a range of Gram-negative bacteria from the 
literature 
TEM images of OMVs from: B. cenocepacia OMVs sourced from Martins et al. 2016 (a). Salmonella 
typhimurium OMVs sourced from Bitto et al. 2016 (b). Uropathogenic E. coli OMVs sourced from 







3.3.2 Success and limitations of OMV characterisation techniques 
Table 3.3 Characterisation methods used on purified OMVs (Section 3.2.2-3.2.6) 
OMV characterisation techniques used Figure number 
Visualisation of OMVs by transmission electron microscopy 3.10, 3.16 
Immunogold labelling of E. coli OMVs using an anti-OmpA antibody 3.18 
Visualisation of OMV biogenesis by growing E. coli and PA14 on EM grids 3.19 
Visualisation of OMV protein profiles using SDS-PAGE 3.20 
Comparison of the protein profiles of OMVs compared with whole cells, 
periplasmic proteins and OM proteins 
3.21, 3.23 
Mass spectrometry identification of OMV proteins Table 3.2 
Western blotting to detect OmpA in E. coli OMVs 3.22 
Evidence that purified OMVs are whole and intact (Proteinase K test) 3.24, 3.25, 3.26 
Evidence that purified E. coli OMVs contain active proteases 3.27, 3.28 
Quantification of OMVs by dynamic light scattering 3.31, 3.32, 3.33 
 
3.3.2.1 Purified OMVs were visualised by TEM and compared to those in the literature 
(Section 3.2.2) 
All evidence indicates that the purification protocol has successfully isolated OMVs from all bacterial 
strains tested. The EM images show OMVs of the expected size, shape and appearance when compared 
with those in the literature (see Figure 3.17). OMV biogenesis was observed by growing E. coli BL21 
(DE3) cells and Pseudomonas aeruginosa (PA14) cells on gold EM grids and fixing at various time 
points over 24 hours. When comparing the EM images to OMV biogenesis images in the literature, it 
appears that the experiment was successful (see Figure 3.19). Lastly, immunolabelling using an anti-
OmpA antibody was applied to OMVs purified from E. coli BL21 (DE3). OmpA was found on the 
surface/membrane of the OMVs as expected. However, this could be optimised further as there were too 
few immunogold labels. The OMV biogenesis experiment using E. coli BL21 (DE3) cells could also be 
repeated using immunogold labelling of OmpA.  
3.3.2.2 Analysis of the OMV proteomes from different bacterial strains (Section 3.2.3) 
The SDS-PAGE gels of the OMV protein profiles indicated that OMVs from the recombinant E. coli B 
strains contained a greater range of proteins than OMVs from the E. coli K-12, PA01 and PA14 strains. 
The non-recombinant (or ‘wild type’) strains produced OMVs which consistently contained large 
amounts of particular proteins and less of others. This suggests that certain proteins are selectively 
targeted to the OMVs in large concentrations and others are excluded. If a protein was to be targeted to 
OMVs for therapeutic purposes, it could be fused with one of the dominant proteins within these OMVs 
which are very prominent on the SDS-PAGE gels and consistently found in OMVs of that strain.  
 
Understanding of the natural packaging of cargo into the OMVs of wild type strains is essential to 
maximise the selectivity and yield of cargo for therapeutic purposes. Similarly, engineered strains such 
as E. coli BL21 (DE3) produce higher yields of OMVs than wild type strains but have more diversity in 




are not pathogenic in nature. All of these factors should be taken into consideration when choosing 
bacterial strains for drug delivery or vaccines. Table 3.4 outlines the main proteins found in P. 
aeruginosa OMVs and how the findings relate to the literature. The proteome of E. coli OMVs are 
discussed further in Chapter 4. 
 
Table 3.4 Proteins identified within P. aeruginosa OMVs 
 
 
One limitation of identifying bands of interest by mass spectrometry (MS) is that the proteins identified 
may not be truly OMV-associated and may have been co-purified along with the OMVs and still present 
within the sample. To ensure that proteins of interest are OMV-associated, Proteinase K tests were also 
performed on OMV samples to determine which proteins are protected within the OMVs. Flagellin and 
FimA became proteins of interest in E. coli OMVs (Chapter 4) so antibodies to each protein were 
purchased. These antibodies were used for Western blotting and immunogold labelling OMVs as extra 
evidence that these proteins are OMV associated along with the mass spectrometry data. Lastly, 
although MS is very sensitive, it does not show the relative abundance of each protein found which is 
another limitation.  
3.3.2.3 OmpA was detected in E. coli OMV samples by Western blotting (Section 3.2.3) 
Western blotting of E. coli OMV samples gave rise to two bands at 37 kDa and 25 kDa. OmpA in E. 
coli is known to have a molecular weight of approximately 37 kDa. The protein also contains a signal 
peptide which is 21 amino acids long and could give OmpA a 2-3 kDa difference when run on an SDS-
PAGE gel depending on if the signal peptide is present or absent. In the literature, 25 kDa and 27 kDa 





Further information about the 
protein identified
References
B-type flagellin PA01, PA14
Main structural component of 
flagella, used for motility. Virulence 
factor
Previously identified 
in PA01 biofilms 
and OMVs (Couto 
et al. 2015)
Putative prophage major 
tail sheath protein
PA01, PA14
OMVs are thought to be used as a 
‘decoy’ to sequester bacteriophages 
so that they cannot lyse the bacterial 





identified in PA01 
biofilms and OMVs 
(Couto et al. 2015)
Elastase PA01, PA14
Aminopeptidase PA01, PA14
Chitin-binding protein PA01, PA14
Known to be 
excreted 
extracellularly in 
PA01  biofilms 
(Couto et al. 2015)
"Seven secreted factors are
known to exist extracellularly [in 
PA01 biofilms] : elastase LasB, 
esterase EstA,
PasP, chitin binding domain 
protein CbpD, chitinase ChiC,
lactonizing lipase LipA, and an 
aminopeptidase (PA2939) of




proteins have also been found to be products of the ompA gene (Crowlesmith et al. 1980). However, the 
37 kDa band was the main focus when analysing the Western blots. 
3.3.2.4 Purified OMVs were whole and intact: Proteinase K test (Section 3.2.4) 
The bands remaining when Proteinase K is added to the OMVs (in the absence of SDS) indicated which 
proteins are within the lumen of the OMV. This is because these proteins were protected from 
degradation by Proteinase K within the OMVs.  However, when the OMVs were treated with both SDS 
and Proteinase K, the majority of the bands disappeared. This test provided evidence that the purified E. 
coli OMVs were present and intact before SDS addition. It also showed which proteins are OMV-
associated and which proteins to select for mass spectrometry. P. aeruginosa OMVs, however, appeared 
to be resistant to membrane disruption by SDS. Treatment with 5% SDS had no effect on the protein 
profile when Proteinase K was added compared with E. coli OMVs which are disrupted with as little as 
0.02% SDS. This could be investigated further using a range of detergents and comparing the lipid 
composition of E. coli and P. aeruginosa OMVs.  
3.3.2.5 Purified E. coli OMVs contained active proteases (Section 3.2.5) 
An initial Proteinase K test on the E. coli FimB-LacZ fusion strain OMVs indicated that active 
proteases were present within the OMVs (Figures 3.25). When these OMVs were incubated with SDS, 
it appeared that proteases were released which caused degradation of proteins to form additional bands 
on the SDS-PAGE gel. TEM images suggest that SDS caused lysis of the OMVs and release of active 
proteases which then degraded the surrounding flagella. All of the extra bands formed on the SDS-
PAGE gel were identified to be Flagellin by mass spectrometry which is the main structural subunit of 
flagella (Figures 3.2.7-3.2.8). 
  
Next, OMVs from a range of bacterial strains were incubated for 1 hour with a chromogenic esterase 
substrate (4-nitrophenyl acetate) (Figure 3.29-3.30). Unfortunately, it was discovered that the substrate 
was unexpectedly reacting with both LB and 1.5 M ammonium sulphate. For this reason, the colour 
change could not clearly be correlated with OMV protease activity. In order to characterise OMV 
proteases further, kits such as Sigma Protease Fluorescent Detection Kit PF0100 or Zymogram gels 
(Novex) could be used. If OMV protease activity directly correlates to OMV production, a colorimetric 
assay could potentially be developed to quantify OMVs and learn more about factors that trigger OMV 
release. 
3.3.2.6 There are limitations to the quantification of OMVs (Section 3.2.6) 
Bradford assay 
The best method to quantify OMVs is widely debated (Wieser et al. 2014). OMVs can be quantified 
using protein concentration or lipid concentration. Bradford assays are a reliable way to determine 
protein concentrations in OMV samples. This was used to standardise samples for loading on to SDS-





Quantification of OMVs using a NanoPhotometer 50 (Implen)  
The NanoPhotometer 50 (Implen) was trialled to quantify protein in OMVs. However, it was concluded 
that the NanoPhotometer could not accurately detect below 75 µg/mL of protein. As purified OMV 
samples can range between 20 µg/mL to 200 µg/mL, this method of quantification was not appropriate.  
 
Characterisation and Quantification of OMVs using DLS 
Lastly, The Litesizer 500 was used to characterise the OMVs using the DLS function. Although the 
DLS gave reproducible results for E. coli B strains, the DLS detected the co-purified fimbriae and 
flagella rather than the OMVs in E. coli K-12 strains. For this reason, the E. coli K-12 OMVs could not 
successfully be quantified and compared. A limitation of the DLS is that often values can be slightly 
larger than expected. The Litesizer assumes that all particles are spherical and so if there is movement 
of the OMVs during measurement or aggregation of OMVs, it may detect particles to be larger than 
their true size.  
3.3.3 Comparison of OMVs between different bacterial strains 
3.3.3.1 OMVs from wild type and recombinant strains have different protein profiles (Section 
3.2.3) 
The number of OMVs released from the engineered and proprietary BL21 strains was higher than E. 
coli WT strains when comparing numbers on the TEM images. Unfortunately, the quantification of E. 
coli K-12 and B strain OMVs using the Bradford assay are not directly comparable. This is because 
purified K-12 strain OMV samples also contain flagella and/or fimbriae so not all proteins quantified 
are OMV-associated.  
 
The SDS-PAGE gels of the OMV protein profiles indicated that OMVs from the recombinant E. coli B 
strains contained a greater range of proteins than OMVs, from the wildtype E. coli K-12, PA01 and 
PA14 strains. The non-recombinant strains produced OMVs which consistently contained large amounts 
of particular proteins and less of others. This suggests that certain proteins are selectively targeted to the 
OMVs in large concentrations for release and others are excluded. If a protein was to be targeted to 
OMVs, it could be fused with one of the dominant proteins within the OMVs of PA01/PA14/E. coli 
WT, which are very clear on SDS-PAGE gels and consistently found in OMVs of that strain.  
 
The OMV purification protocol and characterisation techniques developed in this Chapter were used 






Chapter 4  
E. coli K-12 strains package FimA and Flagellin 
into OMVs in a mutually exclusive way 
4.1 Introduction 
4.1.1 Brief comparison of E. coli K-12 and B strains 
E. coli K-12 strains and E. coli B strains are very commonly used as model organisms in the scientific 
community. E. coli is widely used in biotechnology due to its rapid doubling time, ease of manipulation 
and our extensive knowledge of the genome. One of the main differences between E. coli B strains and 
K-12 strains is that B strains are deficient in producing fimbriae and flagella. B strains are also deficient 
in certain proteases including Lon and OmpT (Bachmann, B.J. et al. 1972). The ultimate aim is to 
manipulate E. coli strains into producing OMVs with specific cargo for therapeutic use.  
4.1.2 E. coli pathogenicity and extracellular appendages 
As discussed previously in Section 1.6, E. coli cells express fimbriae and flagella during infection. Type 
1 fimbriae and flagella are crucial for colonisation of the urinary tract, but mediate opposing virulence 
objectives, as flagella are used for motility and fimbriae are used for adhesion to sites to cause infection. 
Previous studies in the literature indicate that pathogenic E. coli cells reciprocally regulate the 
expression of flagella and fimbriae (Cooper et al. 2012). However, this finding has never been applied 
to OMVs. In this study, FimA and Flagellin monomers were found in E. coli K-12 OMVs packaged in a 
mutually exclusive way which, has not yet been addressed in the literature. Polymerised FimA 
monomer forms the main structural subunit of Type 1 fimbriae and polymerised Flagellin monomer 
forms the main structural subunit of flagella. 
4.1.3 Coli Genetic Stock Center (CGSC): Keio collection series 
The Keio collection is a series of E. coli strains where individual genes were systematically deleted. The 
parent strain (from which all the knockout strains were made) is named ‘BW25113’ and is very closely 
related to E. coli K-12 MG1655 (Baba et al. 2006). To study the mutually exclusive packaging of FimA 
and Flagellin monomers into E. coli K-12 OMVs, a series of Keio collection knockout strains were 
used. Table 4.1 below briefly describes the role of each protein in the E. coli cell which can be used as a 





Table 4.1 Description of the Keio collection knockout strains used to study the mutually exclusive 
packaging of FimA and Flagellin. Note: T1F refers to Type 1 fimbriae. 
 
 
4.1.4 Main chapter aims: 
1. To compare OMV cargo and composition from a variety of both E. coli B strains and K-12 strains  
2. To gain insight into how specific proteins are enriched and/or excluded from E. coli OMVs 
3. To gain insight into the function of any cargo discovered (i.e. why would this be beneficial in vivo)  
4. To identify any target proteins of interest in OMVs, which could be used for therapeutic purposes e.g. 
drug delivery and vaccines. 
Strain name Function of the protein knocked-out Reference
E.coli ∆fimA 
(JW4277-1)
"FimA monomers comprise the bulk of the type 1 pilus structure"
E.coli ∆fimB 
( JW4275-1)
"The site-specific recombination that allows phase variation to occur requires two trans-acting 
factors located proximally upstream of fimS , encoded by fimB  and fimE ."  "FimB can bind to the 
fimS element to either switch from Phase-ON to Phase-OFF or vice versa, with a slight bias 
towards the Phase-OFF over the Phase-ON orientation."
E.coli ∆fimC 
(JW4279-1)
FimC is a periplasmic chaperone protein that helps translocate the fimbrial proteins through the 
periplasm until the FimC-Fim protein complex reaches the FimD usher. 
E.coli ∆fimD 
( JW5780-1)
"FimD is an integral outer membrane protein that serves as an usher, allowing surface localization of 
the nascently forming T1F"
E.coli ∆fimE 
( JW4276-1)
"The site-specific recombination that allows phase variation to occur requires two trans-acting 
factors located proximally upstream of fimS,  encoded by fimB  and fimE ". "FimE binds to switch 







"FimA does not mediate binding to the mannose containing receptor. An adhesin, encoded by the 
fimH  gene, is responsible for this binding"
E.coli ∆fimI 
(JW5779-1)




"Our results indicate that FimY and FimZ independently activate the PfimA promoter which controls 
the expression of the fim structural genes. FimY and FimZ were also found to strongly activate each 
other's expression and weakly activate their own expression."










“It is suggested that LrhA is a key regulator controlling the transcription of flagellar, motility and 
chemotaxis genes by regulating the synthesis and concentration of FlhD”
Lehnen et al. 
2002
E.coli ΔfliD 
(JW1909-1)   
“Flagella are crucial for bacterial motility and pathogenesis. The flagellar capping protein (FliD) 
regulates filament assembly by chaperoning and sorting flagellin (FliC) proteins after they traverse 
the hollow filament and exit the growing flagellum tip. In the absence of FliD, flagella are not 
formed”




“To prevent premature polymerization of newly synthesized flagellin molecules, FliS, the flagellin-
specific chaperone, binds flagellin and facilitates its export”




“The major filament protein (flagellin) and the filament-cap protein (FliD) bind to the FlhA 
cytoplasmic domain (FlhA-C) only in complex with their cognate chaperones (FliS and FliT).” 
“Deletion of flhA caused severely defective biofilm formation.”
Bange et al. 
2010          
Svensson et 
al.  2014
"FimF and FimG are associated with FimH adhesin, forming a fibrillum structure that anchors the 







4.2.1 Comparison of OMVs purified from E. coli B strains and K-12 strains 
4.2.1.1 TEM images of purified OMVs  
OMVs were purified from two recombinant E. coli B strains: BL21 and BL21 (DE3) and two E. coli K-
12 WT strains: E. coli WT MG1655 and E. coli FimB-LacZ fusion strain (see Table 3.1 in Section 3.1.3 
for strain introduction). OMVs were purified from the four strains above concurrently for a direct 
comparison. The TEM images (Figure 4.1), indicate that E. coli B strains (a, c) hypervesiculate 
compared to WT K-12 strains (b, d). Furthermore, purified OMVs from E. coli K-12 strains are co-
purified with flagella and/or fimbriae whereas E. coli B strain cells are deficient in flagella and fimbriae. 
This results in a purer OMV sample with no contaminants. For attempts at quantification of these OMV 


















4.2.1.2 Protein profile of E. coli OMVs (SDS-PAGE gel)  
In Section 3.2.5, E. coli OMVs were incubated with SDS which appeared to cause disruption to the 
membranes and allow release of proteases from the OMVs. These proteases degraded some of the 
OMV-associated proteins and changed the OMV protein profile. Although in this case the addition of 
SDS had no effect on the OMV protein profile, there was a clear difference in the banding profile of the 
recombinant (B strain) and WT (K-12 strain) OMVs (see Figure 4.2 and Appendix C.1 for the original 
sample labelling). 
Figure 4.1 Comparison of OMVs purified from E. coli B strain and K-12 strains 
TEM analysis of purified OMVs from four different E. coli strains: E. coli BL21 (a), E. coli WT MG1655 





























OMVs from E. coli B strains (lanes 3-6) have many proteins of all sizes with no particular protein band 
dominating the lane profile. However, OMVs from K-12 strains (in lanes 7-10) appear to have 1 main 
protein enriched in the OMVs and very few other proteins. One unexpected result was the difference in 
the banding pattern between E. coli WT MG1655 and E. coli FimB-LacZ fusion strain OMVs. In E. coli 
WT MG1655 OMVs, the prominent band at approximately 18 kDa was identified as FimA by mass 
spectrometry and the band at approximately 51 kDa was identified as Flagellin (see Appendix C.1). 
This finding was repeated three times for each band from three different gels. E. coli WT MG1655 
OMVs (lanes 7-8) are enriched with the protein FimA (18 kDa) but the Flagellin band (51 kDa) is 
missing entirely. In the E. coli FimB-LacZ fusion strain OMVs (lanes 9-10), Flagellin is present but 
FimA is absent. It appears that FimA and Flagellin are packaged in a mutually exclusive way when 
comparing OMVs from these two strains. 
 
4.2.1.3 What causes hypervesiculation in E. coli B strains compared to K-12 strains? 
E. coli B strains have a deletion of the ompT and lon gene which are present in the K-12 strains. E. coli 
Δlon and ΔompT strains were purchased from the Keio mutant collection at the Coli Genetic Stock 
Center (CGSC). The OMVs from these two mutant strains were compared to the Keio collection 
Figure 4.2 Comparison of the protein profile of OMVs purified from E. coli B strain and K-12 
strains. 
A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. FimA and 






parental strain BW25113. OMVs were also isolated from E. coli BL21, BL21 (DE3) and the parent of 
the E. coli B strains (see Section 2.4 for further information on strains used).  
 
As previously found, there appeared to be a higher number of OMVs purified from B strains compared 
to K-12 strains (see Figure 4.3 and Appendix C.2 for additional EM images). An overview of how to 
identify fimbriae and flagella by eye from EM images was developed in Section 3.2.1.5. E. coli B 
strains did not have any co-purified fimbriae or flagella. E. coli parental BW25113 strain OMVs were 
co-purified with fimbriae (g), E. coli ΔfimA OMVs were co-purified with flagella (f) and E. coli ΔfliC 
OMVs were co-purified with fimbriae. Interestingly, deletion of either ompT or lon resulted in the co-
purification of flagella instead of fimbriae (d, e). When either protease (OmpT or Lon) is absent, the cell 
switches from production of fimbriae to flagella. 
 
The protein profiles of the OMVs from all 8 strains were compared by SDS-PAGE and Western blotting 
(Figure 4.4). 
Figure 4.3 Comparison of OMVs purified from E. coli B strain and K-12 strains including 
Δlon and ΔompT  
TEM analysis of purified OMVs from a range of E. coli B and K-12 strains. B strains: E. coli B 
strain parental (a), E. coli BL21 (b), E. coli BL21 (DE3) (c). K-12 strains: E. coli ΔompT (d), 
E. coli Δlon (e), E. coli ΔfimA (f), E. coli WT Parental BW25113 (g), E. coli ΔfliC (h). 
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OMVs purified from E. coli B strains have many proteins with no particular one enriched in the OMVs. 
Interestingly, deletion of either the ompT or lon gene caused Flagellin to be packaged within the OMVs, 
while still packaging FimA monomer too (compare lanes 5-6 to lane 7). It also caused the E. coli cell to 
produce flagella instead of fimbriae and package Flagellin along with FimA monomer in OMVs.  
Figure 4.4 Comparison of the protein profile of OMVs purified from E. coli B strain and K-12 strains. 
OMVs were purified from a range of E. coli K-12 and B strains including ΔompT and Δlon. A Bradford 
assay was performed and all samples were standardised to be the same protein concentration. TCA 
precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. Proteins were 
separated using SDS-PAGE and silver stained to visualise OMV protein profiles (a). Purified OMV 
samples were probed using the following antibodies anti-FimA monomer, anti-FimA polymer and anti-
Flagellin (b). See Appendix C.3 for original Western blot images. 
b 
kDa 
FimA monomer (18 kDa) 
Flagellin (51 kDa) 





4.2.2 Evidence for Enrichment of FimA and/or Flagellin monomer into E. coli K-12 
OMVs 
4.2.2.1 OMVs were purified from an E. coli K-12 strain with fimbriae production locked on  
FimA is the main structural component of Type 1 fimbriae and is not usually found in a monomeric 
form. During the formation of Type 1 fimbriae, FimA enters the periplasm in an unfolded form and 
binds to the periplasmic chaperone FimC. FimC catalyses FimA folding then delivers it to the usher 
protein FimD. Lastly, the FimA monomer is incorporated into the Type 1 fimbriae (Nishiyama.et al. 
2005). Similarly, Flagellin is believed to bind to the chaperone FliS in the cytosol to prevent premature 
polymerisation of Flagellin monomers until they are needed for flagella biosynthesis (Muskotál et al. 
2006). To explore this further, OMVs were purified from an additional E. coli K-12 strain with fimbriae 
production locked on (further details this strain can be found in Section 2.4). Interestingly, OMVs from 

















Figure 4.5 Comparison of the protein profile of OMVs purified from E. coli MG1655 OMVs, 
FimB-LacZ fusion and E. coli with fimbriae production locked on  
A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. The bands 
at 18 kDa and 51 kDa have been identified as FimA and Flagellin in previous mass spectrometry of 






4.2.2.2 Immunogold labelling of embedded E. coli cells and OMVs to detect FimA and 
Flagellin monomer within the OMVs  
Further evidence was needed to confirm if the Flagellin and FimA bands in the SDS-PAGE gel reflected 
proteins packaged within the OMVs or whether the bands represented subunits of whole flagella or 
fimbriae which had been co-purified with the OMVs. Cells and OMVs from various E. coli strains were 
embedded in resin and sectioned to give a cross-section of the proteins inside the OMVs. Immunogold 
labelling was used to detect FimA and Flagellin monomer within the OMVs. Figure 4.6 shows 
immunogold labelled cells and OMVs purified from the Keio collection parental strain BW25113. Both 
FimA monomer and Flagellin monomer were detected within the whole cells (d and e). However, only 
FimA monomer was detected within the OMVs and not Flagellin (a and b). This confirms the findings 
in Figure 4.5. Lastly, it was noted that the immunogold labels present around the OMVs in Figure 4.6a 














4.2.2.3 How do the levels of FimA and Flagellin in OMVs compare to FimA/Flagellin levels in 
the whole cell and periplasm? 
Six different strains of E. coli were grown overnight in 750 mL LB. 500 mL of this culture was used to 
purify OMVs and 100 mL was used for periplasmic protein extraction. The ‘whole cell’ sample is the E. 
coli culture only. The SDS-PAGE gels indicated that the levels of FimA and Flagellin in the whole cell 
and periplasm are relatively low and that these proteins are specifically selected to be packaged in 
OMVs (Figure 4.7).  
 
a b c 
d e f 
Figure 4.6 Immunogold labelling of embedded E. coli parental BW25113 strain cells and OMVs 
TEM analysis of thin-sectioned cells and OMVs embedded in resin. The sections were immunogold 
labelled and probed with anti-FimA monomer antibody (a and d), anti-Flagellin antibody (b and e). As a 
negative control, the embedded OMVs were incubated in TBST only (no primary antibody). The samples 











Figure 4.7 FimA and Flagellin are enriched in E. coli K-12 OMVs compared to levels in the 
periplasm and whole cell 
A Bradford assay was performed and all samples were standardised to be the same protein concentration. 
TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE 
gel was run then silver stained to visualise protein profiles of E. coli OMVs were compared to the whole 
cell and periplasm. SDS-PAGE gel a shows the E. coli WT parental strain BW25113, E. coli FimB-LacZ 
strain and the E. coli fimbriae locked on strain. Gel b shows the ΔfimA strain, ΔfliC strain and ΔfimC strain. 
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The samples from Figure 4.7 were used for Western blotting to detect Flagellin and FimA monomers in 

































Figure 4.8 indicated that there was a clear enrichment of monomeric FimA and/or Flagellin in OMV 
purification samples compared with the periplasm and whole cell. The presence of FimA or Flagellin 
was also found to be mutually exclusive in the OMVs except for the E. coli strain where fimbriae 
production was locked on (c). The regulation of which protein was packaged had somehow been 
disrupted, which was explored further in Chapter 4.2.3. 
 
In the E. coli parental strain BW25113 (a), a faint band was present that appeared to be Flagellin within 
the periplasmic fraction. However, previous mass spectrometry results have identified this as an 
Antigen 43 subunit (50 kDa) rather than Flagellin (51 kDa). This band was also found in the ΔfliC 
periplasmic protein sample (e), which has also previously been identified as Antigen 43. Flagellin and 
Antigen 43 proteins have 41% amino acid identity (see Appendix C.5 for BLAST alignment). Antigen 
43 is composed of two protein subunits: α (50 kDa) and β (53 kDa) (Kjærgaard et al. 2000). As 
Figure 4.8 FimA and Flagellin are enriched in E. coli K-12 OMVs compared to levels in the 
periplasm and whole cell 
A Bradford assay was performed and all samples were standardised to be the same protein concentration. 
TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. Western blots 
were performed on periplasmic proteins, OMVs and proteins from the whole cell using anti-FimA 
monomer and anti-Flagellin antibodies. The presence of FimA and Flagellin was compared in the 
following strains: E. coli WT parental BW25113 (a), E. coli FimB-LacZ fusion protein (b), E. coli with 
fimbriae locked on (c), ΔfimA (d), ΔfliC (e) and ΔfimC (f). See Appendix C.4 for full photos of the Western 
blots. 
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Flagellin is 51 kDa, this makes differentiating between Flagellin and Antigen 43 bands difficult and 
cross-reactivity of the anti-Flagellin antibody with Antigen 43 is possible. For this reason, mass 
spectrometry was used to differentiate between Flagellin and Antigen 43 bands on SDS-PAGE gels if 
needed. 
 
4.2.2.4 Proteinase K test: Evidence for Flagellin monomer protection within E. coli K-12 OMVs 
As discussed in Section 3.2.4, the Proteinase K test confirms which proteins are present within the 
OMVs. To confirm the presence of FimA and Flagellin within E. coli K-12 OMVs, the Proteinase K test 
was applied. According to ExPASy peptide cutter tool (see Appendix C.6), Proteinase K will cause 251 
cleavages in Flagellin (FLIC_ECOLI) and 108 cleavages in FimA (FIMA1_ECOLI). When Proteinase 
K is added to the OMVs alone (without SDS), proteins within the lumen of the OMVs should be 
protected from degradation and the bands representing them will still be present on the SDS-PAGE gels. 
Any proteins outside the OMVs will be degraded and the bands will disappear on the SDS-PAGE gel. 
Figure 4.9 gives strong evidence that Flagellin is protected within OMVs from E. coli FimB-LacZ 
fusion strain (lane 3 compared to lanes 5-9).  
 







Figure 4.9 Proteinase K test on OMVs from E. coli FimB-LacZ fusion strain 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various concentrations of 
SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and samples were incubated for 
another 30 mins at 37ºC. TCA precipitation was used to concentrate samples prior to loading on an SDS-
PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. 
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4.2.2.5 Proteinase K test: Evidence for FimA monomer protection within OMVs 
 
Proteinase K test: OMVs from E. coli WT MG1655 strain 
The Proteinase K test was applied to OMVs from the WT MG1655 strain to confirm the presence of 
FimA within the OMVs as in Figure 4.9. Unexpectedly, the FimA monomer band remained unchanged 



























This result was unexpected as addition of Proteinase K to FimA (FIMA1_ECOLI) should cause 108 
cleavages (see Appendix C.6) and the FimA band should have disappeared. OMVs from E. coli with 
fimbriae production locked on contained Flagellin and FimA so the Proteinase K test was repeated 
using OMVs from this strain (Figure 4.11). The Proteinase K test successfully showed the protection of 
Flagellin within the OMVs that were structurally intact in Lane 3. However, the FimA monomer band 
remained undegraded by Proteinase K which was explored further. 
  
 
Figure 4.10 Proteinase K test on OMVs from E. coli WT MG1655 strain 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various 
concentrations of SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and 
samples were incubated for another 30 mins at 37ºC. TCA precipitation was used to concentrate 
samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to 































The conditions were optimised to allow degradation of FimA by Proteinase K. Addition of Proteinase K 
to FimA (FIMA1_ECOLI) should result in 108 cleavages but in this case the protein remains uncleaved. 
There were various hypotheses about why the FimA monomer was not degraded in these conditions. It 
could be that the protein was not in the correct conformation to be digested and that all the cleavage 
sites were inaccessible and protected within the protein. Alternatively, the FimA monomer could be 
protected from Proteinase K degradation due to its location within the OMV. For example, it could be 
compartmentalised within the OMV or FimA could be protected by being part of a compound which 
makes it inaccessible to proteases. Reference for the structure of FimA monomer can be found here: 
https://www.uniprot.org/uniprot/P04128. 
 
4.2.2.6 Optimisation of the Proteinase K test conditions in order to apply the test to OMV samples 
containing FimA monomer 
The following methods were trialled to degrade FimA monomer in the OMV samples: 
Figure 4.11 Proteinase K test on OMVs from E. coli WT with fimbriae locked on 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various concentrations 
of SDS for 30 mins at 37ºC. 5 mM PMSF was added to inhibit Proteinase K and samples were incubated 
for another 30 mins at 37ºC. TCA precipitation was used to concentrate samples prior to loading on an 
SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. 
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1. Temperature: Performing the Proteinase K test at 60ºC (instead of 37ºC) to aid FimA protein 
unfolding and allow Proteinase K easier access to the protein cleavage sites. 
2. Method of OMV lysis: OMVs were previously lysed by heating at 95ºC for 30 minutes. OMVs were 
also lysed by sonication to allow proteases full access to the FimA protein. The sonication conditions 
chosen were those used in a paper in the literature (Metruccio et al. 2016). 
3. Protease used: OMVs were treated with both Proteinase K and Trypsin alone and together. The 
concentration of proteases used was increased to be 10x more than those used in the literature for 
similar experiments (Mugita et al. 2017).  
4. Assay time: The proteases were incubated with the OMV samples for: 0, 30, 60, 120 and 180 
minutes.  
 
The Proteinase K test was repeated on OMVs from E. coli with fimbriae locked on with variations in 
the proteases used, protease concentration, reaction temperature and method of OMV lysis (Figures 4.12 
and 4.13). The FimA band remained unchanged in all conditions despite the Flagellin band degradation 

























Figure 4.12 Proteinase K test on OMVs from E. coli WT with fimbriae locked on 
The Proteinase K test was repeated on OMVs from E. coli with fimbriae locked on with variations in 
protease concentration, reaction temperature and method of OMV lysis (a). TCA precipitation was used to 
concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained 
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All the methods trialled were unsuccessful at degrading FimA. Previously, the FimA monomer band at 
18 kDa had been extracted and successfully verified by mass spectrometry. During the mass 
spectrometry procedure, the proteins were digested with trypsin and FimA had been successfully 
digested and identified. During the mass spectrometry procedure, the proteins were treated with 10 mM 
DTT in 50 mM ammonium bicarbonate and 55 mM iodoacetamide in ammonium bicarbonate. DTT 
disrupts the structure of proteins by reducing the disulphide bonds. Iodoacetamide then prevents 
reformation of disulphide bonds in proteins to keep them denatured. DTT and iodoacetamide were 
added to the OMV samples to denature the FimA monomer and allow Proteinase K access to the 
cleavage sites (Figure 4.14 and Appendix C.7) 
Figure 4.13 Proteinase K test on OMVs from E. coli WT with fimbriae locked on 
The Proteinase K test was repeated on OMVs from E. coli with fimbriae locked on with variations in 
protease concentration, reaction temperature and method of OMV lysis (a). TCA precipitation was used to 
concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained 
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Flagellin was degraded (at least partially) in all the conditions tested (Figure 4.14). However, the FimA 
monomer still remained uncleaved by Proteinase K or trypsin (see Appendix C.7). As Flagellin was 
very easily degraded and FimA monomer was not, the next hypothesis to test was whether FimA 
monomer was protected by lipids within the OMV in a different location to Flagellin. A lipid extraction 
was performed on the OMV samples to remove any lipid-protein interactions that could be protecting 
FimA. This ‘lipid-free’ OMV sample was then subject to digestion with Proteinase K and trypsin and 
was still unsuccessful (Figure 4.15). 
 
 
Figure 4.14 Proteinase K test on OMVs from E. coli WT with fimbriae locked on 
The Proteinase K test was repeated on OMVs from E. coli with fimbriae locked on with the addition of 
DTT, iodoacetamide and ammonium bicarbonate alone (a). TCA precipitation was used to concentrate 
samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to 
visualise the OMV protein profile (b). 
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Figure 4.15 Proteinase K test on the proteins of OMVs from E. coli WT with fimbriae locked on (all 
lipids extracted) 
The Proteinase K test was repeated on the lipid-free OMV sample from E. coli with fimbriae locked on 
using both Proteinase K (a) and Trypsin (b). TCA precipitation was used to concentrate samples prior to 
loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the  










It was known that the FimA band (18 kDa) was cleaved successfully by trypsin during mass 
spectrometry when the band was extracted from the SDS-PAGE gels. In order to recreate these 
conditions, OMV samples from E. coli with fimbriae locked on were run on an SDS-PAGE gel in 
duplicate. One lane was silver stained to locate the FimA monomer protein and the next lane was 
unstained and had not been processed using the silver staining procedure (see Section 2.8.4 for more 
details). This was to see if it was part of the silver staining procedure that made FimA susceptible to 
protease degradation. The bands containing FimA were extracted and the FimA protein was purified 
from the SDS-PAGE gel. This purified FimA was then subject to digestion by Proteinase K and trypsin 

























The FimA monomer protein that had been isolated from the SDS-PAGE gel was now susceptible to 
digestion by Proteinase K and trypsin. The silver staining process had no effect on whether the protein 
was digested as the FimA was still degraded in Lanes 3 and 8. In the only cases where digestion of 
FimA had been successful, the OMV samples have been TCA precipitated first before Proteinase K/ 
trypsin digestion. The final method trialled was to compare digestion of FimA monomer by Proteinase 
K before and after TCA precipitation for the SDS-PAGE gel (see Figure 4.17).  
Figure 4.16 Proteinase K test on the proteins of OMVs from E. coli WT with fimbriae locked on (all 
lipids extracted) 
The Proteinase K test was repeated on FimA protein that was isolated from the SDS-PAGE gel of OMV 
sample from E. coli with fimbriae locked on. The SDS-PAGE gel was run then silver stained to visualise 
























It appeared that TCA precipitation of the FimA monomer made it susceptible to Proteinase K 
degradation. TCA is an acid that disrupts hydrogen bonding and causes the denaturation of proteins as 
they lose their secondary structure (Koonz et al. 2014). This appears to denature FimA in a way that 
allows Proteinase K access to the cleavage sites that were previously sequestered. Although the FimA 
monomer could now be digested, this method could not be incorporated into the Proteinase K test 
because the OMVs would no longer be intact. Evidence that FimA is present within the OMVs by the 
Proteinase K test was not possible so EM and Western blotting studies with an anti-FimA monomer 
antibody was favoured.  
  
Figure 4.17 Proteinase K test on OMVs from E. coli WT with fimbriae locked on before and after 
TCA precipitation of the OMV proteins 
The digestion of FimA was compared before and after TCA precipitation. The SDS-PAGE gel was run 





4.2.3. Is the packaging of FimA and Flagellin into OMVs mutually exclusive? 
4.2.3.1 Comparison of OMVs from a variety fimbriae-associated protein knockouts and Flagellin 
The aim was to see if deletion of a range of proteins involved in Type 1 fimbriae synthesis affects the 
presence of FimA and/or Flagellin in the OMVs produced. This was also to gain insight into which 
proteins play a role in targeting FimA and Flagellin to the OMVs. Figure 4.18 shows TEM images of 
the OMVs purified from each knockout strain compared to the parent strain of the Keio collection 
(BW25113). Each E. coli cell generally has flagella or fimbriae expressed, which can switch depending 
on which protein is knocked out. Flagella or fimbriae are co-purified with the OMVs and can also be 
seen in the EM images. A description of how to distinguish fimbriae or flagella on the TEM images can 
be found in Section 3.2.1.5.  
The OMV samples were then ran on an SDS-PAGE gel to compare the protein profiles produced after 
each knockout (Figure 4.19). Bands of interest were identified by mass spectrometry and are labelled 
below (see Appendix C.8). The whole E. coli cells were also run on an SDS-PAGE gel to compare the 
protein profile to the OMVs (see Appendix C.8). The whole cells have many proteins with no particular 
band dominating the protein profile. This is opposite to the protein profile of the OMVs which are 
dominated by bands at 18 kDa and/or 50-51 kDa. 
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Figure 4.18 Comparison of OMVs from a variety of fimbriae-associated deletion mutants and 
Flagellin by TEM  
TEM analysis of purified OMVs from twelve different E. coli strains: a ΔfimA, b Parental BW25113, c 






Figure 4.19 Comparison of OMV protein profile from a variety of fimbriae-associated deletion 
mutants and Flagellin by SDS-PAGE 
 
OMVs were purified from twelve different E. coli strains from the Keio collection (CGSC) and three 
strains which had previously been studied (MG1655, FimB-LacZ fusion and fimbriae locked on strain). 
A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. Bands of 






The purified OMV samples from Figures 4.18 and 4.19 were used to produce Western blots, which 
were probed with the following antibodies: anti-Flagellin, anti-FimA monomer and anti-polymerised 
FimA (Figure 4.20). FimA monomer and Flagellin antibodies were used to test the hypothesis that 























The Western blots showed clear enrichment of FimA and/or Flagellin in E. coli K-12 OMVs compared 
with all other proteins. The packaging of FimA and Flagellin also appears to be mutually exclusive 
unless there’s a specific mutation to disrupt the regulation (summarised on Table 4.2). The hypotheses 
behind each result is discussed in Section 4.3.3. 
 
Figure 4.20 Comparison of OMV protein profile from a variety of fimbriae-associated deletion 
mutants and Flagellin by Western blotting 
OMVs were purified from twelve different E. coli strains from the Keio collection (CGSC). A Bradford 
assay was performed and all samples were standardised to be the same protein concentration. TCA 
precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. Purified OMV 
samples were probed using the following antibodies anti-FimA monomer, anti-FimA polymer and anti-








Table 4.2 Mutual exclusivity of FimA and Flagellin packaging in OMVs from various E. coli 
strains. The introduction to the fimbriae-associated proteins can be found in Section 4.1.3 and the 
















4.2.3.2 Purification of OMVs from E. coli strains containing a range of knock outs of flagella-
associated proteins 
 
OMVs were purified from E. coli strains containing deletions of various genes associated with flagella 
biosynthesis. Figure 4.21 shows TEM images of the OMVs purified from each knockout strain 
compared to the parent strain of the Keio collection (BW25113). Each E. coli cell generally has flagella 

































ΔfliC Yes No Yes
ΔfimA No Yes Yes
ΔfimC No Yes Yes
ΔfimB No Yes Yes
ΔfimE Yes Yes No
 ΔfimF No Yes Yes
ΔfimG Yes Yes No
ΔfimH Yes Yes No
ΔfimD No No Neither present
ΔfimI Yes Yes No
ΔfimZ Yes No Yes
WT MG1655 Yes No Yes
FimB-LacZ fusion No Yes Yes
Fimbriae locked on Yes Yes No
BL21 No No Neither present
BL21 (DE3) No No Neither present
Figure 4.21 Comparison of OMVs from a variety of flagella-associated deletion mutants by TEM 
TEM analysis of purified OMVs from four extra E. coli strains: a ΔfimA, b Parental BW25113, c ΔfliC, 
d ΔlrhA, e ΔfliD, f ΔfliS, g ΔflhA  
a b c 




The OMV samples were then ran on an SDS-PAGE gel to compare the protein profiles produced after 
each knockout (Figure 4.22a). Bands of interest were identified by mass spectrometry and are labelled 
below. Deletion of lrhA appeared to cause dysregulation of the packaging of FimA and Flagellin in 
OMVs as both were found together (Lane 5). These samples were then used to produce Western blots 
which were probed with the following antibodies: anti-Flagellin, anti-FimA monomer and anti-



























Figure 4.22 Comparison of OMV protein profile from a variety of flagella-associated deletion 
mutants by SDS-PAGE and Western blotting 
OMVs were purified from four additional E. coli strains from the Keio collection (CGSC). A Bradford 
assay was performed and all samples were standardised to be the same protein concentration. TCA 
precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-PAGE gel 
was run then silver stained to visualise the OMV protein profile. Bands of interest were identified by mass 
spectrometry and are labelled above (a). Purified OMV samples were used to perform Western blots which 
were probed using the following antibodies anti-FimA monomer, anti-FimA polymer and anti-Flagellin 

























The packaging of FimA and Flagellin also appeared to be mutually exclusive unless there’s a specific 
mutation to disrupt the regulation (summarised in Table 4.3). The introduction to the flagella-associated 
proteins can be found in Section 4.1.3. 
 
Table 4.3 Mutual exclusivity of FimA and Flagellin packaging in OMVs from various E. coli strains  
 
The reasons for the mutual exclusivity are discussed further in Section 4.3.3.  












ΔfliC Yes No Yes
ΔfimA No Yes Yes
ΔlrhA Yes Yes No
ΔfliD Yes No Yes
fliS Yes No Yes




4.2.4. Which conditions lead to packaging of FimA and Flagellin into E. coli K-12 OMVs? 
4.2.4.1 Packaging of FimA monomer into OMVs under different conditions 
OMVs were purified from E. coli WT parental strain (BW25113) at three different temperatures: 18ºC, 
25ºC and 37ºC to see if temperature affects the packaging of FimA monomer into OMVs. OMVs were 
also purified from three different points on the growth curve at 37ºC: early log phase, mid log phase and 
stationary phase (indicated on Figure 4.23a). This was to determine at which stage of bacterial growth 
FimA is packaged. Firstly, growth curves were produced by growing the E. coli parental strain 
(BW25113) at 25ºC and 37ºC using a microplate reader (Figure 4.23a).  
 
  
Figure 4.23 Growth of E. coli parental (BW25113) strain at 25ºC and 37ºC 
Growth curves were produced for E. coli parental (BW25113) strain at 25ºC and 37ºC, 180 RPM, 
overnight. The strain was diluted to OD600 0.1 using LB before addition of 500 μL to each well of the 48 
well sterile plates. OD600 readings were taken every 8 mins and the growth curve graphs were generated 
on Microsoft Excel using the raw data (a). The growth curve of each strain was done in triplicate and the 
average was taken. See Appendix C.11 for graphs with error bars of 1 standard deviation. The arrows on 
the growth curves indicate the time point that the OMVs were harvested at the following stages: early-log, 








The protein profile of the OMVs was visualised using SDS-PAGE and silver staining (Figure 4.24a). 
The same samples were used for a Western blot, probing with anti-FimA monomer antibody and FimA 































Figure 4.24b indicates that FimA is packaged into OMVs in mid-late log stage and stationary phase but 
not early log phase. Also, the Western blot shows that the more fimbriae there are (represented by 
polymerised FimA), the more FimA is packaged into the OMVs. Lastly, FimA is packaged into OMVs 
at 37°C and 25°C but not 18°C so is affected by changes in temperature. 
Figure 4.24 What conditions lead to the packaging of FimA into E. coli WT BW25113 OMVs? 
OMVs were purified from E. coli WT BW25113 at three different stages of growth and at 3 different 
temperatures. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. One SDS-PAGE gel was silver stained to visualise the OMV protein profile (a) the others were 
transferred to a PVDF membrane for a Western blot probing with the anti-FimA monomer and anti-







4.2.5. FimA and Flagellin are reciprocally regulated in some OMVs from clinical isolates 
OMVs were purified from 6 clinical isolates which were either isolated from the urine of patients with 
UTI infections or the blood from patients with bacteraemia caused by E. coli. See Appendix C.13 for 
the antibiotic resistance information of each clinical isolate strain. The purified OMVs were visualised 
by TEM and compared to OMVs from the E. coli WT Parental BW25113 strain, ΔfimA and ΔfliC 













Figure 4.25 TEM images and protein profiles of OMVs purified from six E. coli clinical isolates, 
BW25113, ΔfimA and ΔfliC strains 
TEM analysis of purified OMVs from the following E. coli strains: ΔfimA (a), Parental BW25113 (b), 
ΔfliC (c), Clinical isolate 1 (d), Clinical isolate 2 (e), Clinical isolate 3 (f), Clinical isolate 4 (g), Clinical 
isolate 5 (h), Clinical isolate 6 (i). A Bradford assay was performed and all samples were standardised to 
be the same protein concentration. TCA precipitation was used to concentrate samples prior to loading on 
an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the OMV protein profile. 
Bands of interest were identified by mass spectrometry and are labelled above (j). Full mass spectrometry 
results can be found in Appendix C.14.  
j 
a b c d e 
f i g h 
   




A Western blot was performed using the samples from Figure 4.25 to detect FimA monomer, FimA 
polymer and Flagellin in the OMV samples (Figure 4.26). For a direct comparison of the SDS-PAGE 



















Two proteins related to fimbriae were detected in OMVs from Clinical isolates 3 and 4. A BLAST 
protein alignment was performed to see if these proteins were similar to FimA and could have been mis-
identified. Clinical isolate 3 OMVs contain F7-2 fimbrial protein. However, this only has 34% amino 
acid identity to FimA. Similarly, Clinical isolate 4 OMVs were found to contain KS71A fimbrillin 
which has 33% amino acid similarity with FimA (see Appendix C.16 for BLAST protein alignments). 
Although both are fimbriae-associated proteins, it appears that they were not a mis-identified FimA 
monomer. Lastly, the Flagellin band in the OMVs of Clinical isolate 3 is higher than that of Clinical 
isolate 6 and ΔfimA. However, it should be noted that Clinical isolate 3 is a UPEC strain where Flagellin 
has a molecular weight of 61 kDa rather than 51 kDa (see Appendix C.17 for further discussion). The 
mutually exclusive packaging of FimA and Flagellin is summarised in Table 4.4. Clinical isolates 1, 2 
and 4 have neither FimA or Flagellin present in the OMVs. Clinical isolate 3 has both FimA and 
Flagellin present and Clinical isolates 5 and 6 have FimA and Flagellin monomers packaged in a 
mutually exclusive way. 
 
 
Table 4.4 Mutual exclusivity of FimA and Flagellin packaging in OMVs from various E. coli clinical 








Figure 4.26 Comparison of FimA/Flagellin packaging in OMVs purified from six E. coli clinical 
isolates, BW25113, ΔfimA and ΔfliC strains 
A Bradford assay was performed and all samples were standardised to be the same protein concentration. 
TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. Purified OMV 
samples were probed using the following antibodies anti-FimA monomer, anti-FimA polymer and anti-
Flagellin. For original Western blot images, see Appendix C.15. 
1 MS207 0 No No Neither present
2 MS10 4 No No Neither present
3 MS1 0 Yes Yes No
4 MS343 0 No No Neither present
5 MS190 5 Yes No Yes











Number of antibiotics 
strain is known to be 
resistant to





Table 4.5 summarises the mutual exclusive packaging of FimA and Flagellin monomer in E. coli OMVs 
from all strains of interest. The results of this Table are discussed in Section 4.3.3.  
 
Table 4.5 Final summary tables to compare mutual exclusivity of FimA and Flagellin packaging 
in OMVs from various E. coli strains (K-12 and B strains). Table a is a summary of the findings 
from all strains tested. Table b summarises the percentage of E. coli strains that give rise to OMVs with 
FimA and Flagellin packaged in a mutually exclusive way. Table gives c the percentage of E. coli 
strains that give rise to OMVs with FimA and Flagellin packaged in a mutually exclusive way 
excluding from the data set any strains do not contain FimA or Flagellin in their OMVs.  









WT parental BW25113 Yes No Yes
ΔfliC Yes No Yes
ΔfimA No Yes Yes
ΔfimC No Yes Yes
ΔfimB No Yes Yes
ΔfimE Yes Yes No
 ΔfimF No Yes Yes
ΔfimG Yes Yes No
ΔfimH Yes Yes No
ΔfimD No No Neither present
ΔfimI Yes Yes No
ΔfimZ Yes No Yes
WT MG1655 Yes No Yes
FimB-LacZ fusion No Yes Yes
Fimbriae locked on Yes Yes No
BL21 No No Neither present
BL21 (DE3) No No Neither present
ΔlrhA Yes Yes No
ΔfliD Yes No Yes
fliS Yes No Yes
flhA Yes No Yes
Clinical isolate 1 No No Neither present
Clinical isolate 2 No No Neither present
Clinical isolate 3 Yes Yes No
Clinical isolate 4 No No Neither present
Clinical isolate 5 Yes No Yes
Clinical isolate 6 No Yes Yes
Criteria
Number of strains 
that meet the criteria 
(27 strains studied)
% of total strain 
number studied that 
meet the criteria
OMVs contain neither FimA or Flagellin 6 22
OMVs have mutually exclusive packaging of FimA 
and Flagellin monomer
14 52













4.2.6. Are Type 1 fimbriae and/or flagella co-purified with the E. coli OMVs? 
It could be argued that the SDS-PAGE gels and Western blots are detecting FimA monomer and 
Flagellin monomer from co-purified fimbriae and flagella respectively and not the OMVs. For example, 
it could be argued that during the SDS-PAGE process, co-purified fimbriae and/or flagella may 
depolymerise to give rise to the FimA and Flagellin monomers. However, this section will outline the 
evidence that suggests that this is not true.  
 
The following questions were addressed:  
1. Is FimA monomer packaged into OMVs independently of fimbriae production? Similarly, is Flagellin 
monomer packaged into OMVs independently of flagella production?  
2. Is the packaging of FimA and Flagellin into OMVs directly linked to fimbriae and flagella expression 
on the parent cells? 
4.2.6.1 Identification of fimbriae and/or flagella co-purified with the OMVs 
Using TEM to identify fimbriae and flagella 
All the strains in Tables 4.5a-c were analysed to determine if fimbriae and/or flagella were co-purified 
with the OMVs from each strain. TEM images alone were used to detect flagella in OMV samples as 
they are very distinctive (discussed in Section 3.2.1.5). Figure 4.27 shows TEM images of OMVs 
known to be co-purified with either flagella or fimbriae. This can be used as a reference point for later 















Number of strains 
that meet the criteria 
(/21 strains)
% of total strain 
number studied that 
meet the criteria
OMVs have mutually exclusive packaging of FimA 
and Flagellin monomer
14 67




Figure 4.27 TEM images 
of OMVs purified from 
six E. coli strains to 
compare co-purification 
of flagella and fimbriae 
TEM analysis of purified 
OMVs from E. coli 
strains: a ΔfimA, b 
Parental BW25113, c 
ΔfliC, d FimB-LacZ 
fusion, e MG1655 and f 
fimbriae production 




Figure 4.27 shows that flagella are thicker and longer than fimbriae and are also curvy/wavy. Type 1 
fimbriae were found to be short, thin and straight appendages compared with the flagella. This agrees 
with the previous findings in Section 3.2.1.5. 
 
Western blotting with anti-polymerised FimA to detect fimbriae 
Additional methods were used to confirm the presence of fimbriae along with EM images. As 
previously described, FimA monomers polymerise to form the main structural subunit of fimbriae. 
These polymers are so stable that they do not depolymerise during SDS-PAGE and are therefore too 
large to migrate through the gel (see Appendix C.18 for further details on the stability of fimbriae). For 
this reason, polymerised FimA was detected in the wells of Western blots when probing with the anti-
FimA polymer antibody. As polymerised FimA is the main structural subunit of fimbriae, detection of 
polymerised FimA can be used to indicate the presence of fimbriae. OMVs purified from ΔfimA were 
always run as a negative control and ΔfliC OMVs were always used as a positive control (Figure 4.28).  
Fimbriae agglutination test with E. coli cells to detect fimbriae 
In order to determine whether E. coli cells (from which the OMVs are purified from) express functional 
and intact fimbriae, a simple yeast agglutination test can be performed. The E. coli cells of interest were 
mixed 1:1 with Saccharomyces cerevisiae cells on a glass microscope slide. If fimbriae are present, 
FimH (the adhesin on the tip of Type 1 fimbriae) adheres to the S. cerevisiae cells. This causes the 













Figure 4.28 Polymerised FimA positive and negative Western 
blot controls 
A Bradford assay was performed and all samples were standardised 
to be the same protein concentration. TCA precipitation was used to 
concentrate samples prior to loading on an SDS-PAGE gel. Purified 
OMV samples were probed using anti-FimA polymer antibody. 
Image was cropped from Figure 4.27 to show positive and negative 





Figure 4.29 Yeast 
agglutination test to 
detect fimbriae 
expression on E. coli 
cells 
Saccharomyces 
cerevisiae were mixed 
1:1 with the following E. 
coli strains:  fimbriae 
locked on (a),  MG1655 
(b), FimB-LacZ fusion 
(c), BL21 (d), BL21 
(DE3) (e), LB only (f). 
Yeast cell agglutination 
was visualised using light 
microscopy at 400x 
magnification. Green 
ticks indicate yeast cell 
agglutination and 












For yeast agglutination test of all other strains, see Appendix C.19. All the evidence for whether E. coli 
strains are producing fimbriae and/or flagella are summarised in Table 4.6. 
 
Table 4.6 Summary table to confirm which strains produce fimbriae and/or flagella using all 
available strain evidence. Purple indicates which strains express fimbriae only, yellow indicates which 
strains produce flagella only and orange represents strains that produce both fimbriae and flagella 
together. 
 
In order to address the two questions outlined at the start of Section 4.26, the packaging of FimA and 
Flagellin into OMVs should be compared to whether the parent cell produces fimbriae and/or flagella. 
Table 4.7 addresses the questions: if fimbriae is produced in the parent cell, is FimA monomer always 
packaged into the OMVs? Similarly, if flagella are produced in the parent cell, is Flagellin monomer 










WT parental BW25113 Yes Yes Yes No Fimbriae only
ΔfliC Yes Yes Yes No Fimbriae only
ΔfimA No No No Yes Flagella only
ΔfimC No No No Yes Flagella only
ΔfimB No No No Yes Flagella only
ΔfimE Yes Yes Yes No Fimbriae only
 ΔfimF No No No Yes Flagella only
ΔfimG No No No Yes Flagella only
ΔfimH No No No Yes Flagella only
ΔfimD No No No No Neither
ΔfimI Yes Yes Yes Yes Both
ΔfimZ Yes Yes No No Fimbriae only
WT MG1655 Yes Yes Yes No Fimbriae only
FimB-LacZ fusion No No No Yes Flagella only
Fimbriae locked on Yes Yes Yes No Fimbriae only
BL21 No No No No Neither
BL21 (DE3) No No No No Neither
ΔlrhA No Yes Yes Yes Both
ΔfliD Yes Yes Yes No Fimbriae only
ΔfliS Yes Yes Yes No Fimbriae only
ΔflhA Yes Yes Yes No Fimbriae only
Clinical isolate 1 No Unclear No No Neither
Clinical isolate 2 No Unclear No Yes Flagella only
Clinical isolate 3 Yes Unclear Yes No Fimbriae only
Clinical isolate 4 Yes Unclear No No Fimbriae only
Clinical isolate 5 Yes Yes Yes No Fimbriae only







for whether T1F 
and/or flagella 
are expressed
Evidence for T1F expression in strain




4.2.6.2 Is the packaging of FimA/Flagellin monomers into OMVs independent of the 
production of fimbriae and/or flagella on the parent E. coli strain? 
 
Table 4.7 Summary table to compare the packaging of FimA and Flagellin monomers into OMVs 
with the production of fimbriae and/or flagella in the parental strain. The criteria for a ‘match’ is 





























There are 7 instances out of 27 strains in total (26%) where packaging of FimA and/or Flagellin 
monomers into OMVs is independent of whether fimbriae or flagella are expressed on the parent 
cell. These examples will be discussed further in Section 4.3.3. 










Is it a 
match?
WT parental BW25113 Yes No Fimbriae only Yes
ΔfliC Yes No Fimbriae only Yes
ΔfimA No Yes Flagella only Yes
ΔfimC No Yes Flagella only Yes
ΔfimB No Yes Flagella only Yes
ΔfimE Yes Yes Fimbriae only No
 ΔfimF No Yes Flagella only Yes
ΔfimG Yes Yes Flagella only No
ΔfimH Yes Yes Flagella only No
ΔfimD No No Neither Yes
ΔfimI Yes Yes Both Yes
ΔfimZ Yes No Fimbriae only Yes
WT MG1655 Yes No Fimbriae only Yes
FimB-LacZ fusion No Yes Flagella only Yes
Fimbriae locked on Yes Yes Fimbriae only No
BL21 No No Neither Yes
BL21 (DE3) No No Neither Yes
ΔlrhA Yes Yes Both Yes
ΔfliD Yes No Fimbriae only Yes
ΔfliS Yes No Fimbriae only Yes
ΔflhA Yes No Fimbriae only Yes
Clinical isolate 1 No No Neither Yes
Clinical isolate 2 No No Flagella only No
Clinical isolate 3 Yes Yes Fimbriae only No
Clinical isolate 4 No No Fimbriae only No
Clinical isolate 5 Yes No Fimbriae only Yes
Clinical isolate 6 No Yes Flagella only Yes
FimA/Flagellin monomer present in OMVs T1F/Flagella present on cell
FimA monomer only T1F expression only
Flagellin monomer only Flagella expression only
FimA and Flagellin monomer T1F and flagella expression 






4.2.7. Can FimA be used to target proteins and other molecules for delivery within 
OMVs?  
A construct of E. coli MG1655 strain with a FimA-GFP fusion protein was available to use from 
Professor Sander Tans from AMOLF in the Netherlands (Adiciptaningrum et al. 2009). In this strain, 
GFP was inserted within the chromosomal fimA DNA sequence, which is the first gene of the fim 
operon (Adiciptaningrum et al. 2009). This results in the production of GFP-FimA protein fusion 
instead of FimA. See Appendix C.20 for full details about the FimA-GFP fusion strain.  
 
4.2.7.1 Visualisation of purified OMVs from the E. coli FimA-GFP fusion strain using TEM  
The OMVs purified from the MG1655 FimA-GFP fusion strain and the WT MG1655 strain were 
visualised by TEM (Figure 4.30). OMVs isolated from E. coli WT MG1655 are co-purified with 
fimbriae which the parent cells express. Interestingly, the FimA-GFP fusion strain produces flagella 







Figure 4.30 TEM images of OMVs purified from E. coli MG1655 strain and FimA-GFP 
fusion strain   






Immunogold labelling of resin-embedded OMVs 
 
Immunogold labelling showed co-localisation of both FimA and GFP in the OMVs, which indicates that 
the GFP-FimA fusion protein was successfully delivered. Flagellin also appeared to be detected within 
the OMVs too (Figure 4.31). Photos g and h show how the immunogold labels are localised to the sites 
containing the embedded OMVs and are not spread evenly over the grid. Additional TEM photos can be 
found in Appendix C.21. 
 
Figure 4.31 Immunogold labelling of embedded E. coli FimA-GFP strain OMVs 
TEM analysis of thin-sectioned OMVs embedded in resin. The sections were immunogold labelled 
and probed with: anti-GFP antibody (a) anti-FimA monomer antibody (b, g and h), anti-FimA 
monomer and anti-GFP antibodies mixed (c), anti-Flagellin antibody (d). As a negative control, the 
embedded OMVs were incubated in TBST only (no primary antibody). The samples were then 
incubated with the following secondary antibodies: 15 nm gold label (e) or 10 nm gold label (f) 
 
 
a c b 





The E. coli FimA-GFP fusion strain cells were embedded in resin and the sections were immunogold 

































4.2.7.2 Co-localisation of both FimA and GFP in the OMVs 
Western blots also confirmed co-localisation of both FimA and GFP in the OMVs, which indicated that 
the GFP-FimA fusion protein was successfully delivered. Proteins were purified from the OM and 
periplasm of the GFP-FimA fusion strain and MG1655 strain (without the protein fusion). This was 










Figure 4.32 Immunogold labelling of embedded E. coli FimA-GFP strain cells 
TEM analysis of thin-sectioned and cells embedded in resin. The sections were immunogold labelled 
and probed with: anti-GFP antibody (a) anti-FimA monomer antibody (b), anti-FimA monomer and 











































The Western blots confirmed that there was a protein present in the OMV sample at approximately 50 
kDa which was detected by both the anti-GFP antibody and anti-FimA monomer antibody. This was 
further evidence that the FimA-GFP protein had successfully been delivered to the OMVs. This protein 
Figure 4.33 Detection of FimA, Flagellin and GFP in MG1655 and the MG1655 GFP-FimA protein 
fusion strain 
Proteins were purified from the OM and periplasm of the cells and compared to the OMVs and whole 
cells. A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. 
The SDS-PAGE gel was silver stained and the two bands labelled were excised from the gel and 
identified by mass spectrometry (a). Western blots were performed on these samples using the following 
antibodies: anti-GFP, anti-FimA monomer and anti-Flagellin (b). Mass spectrometry data and original 








was also detected in the periplasm meaning that the GFP fusion to FimA did not disrupt the export of 
the protein to the periplasm or the signals necessary to package the protein within the OMVs. 
 
In the WT MG1655 strain, FimA monomer (18 kDa) was packaged into the OMVs but not Flagellin (51 
kDa). OMVs from the GFP-FimA fusion strain did not contain the FimA monomer (18 kDa) due to its 
absence in the FimA-GFP protein fusion strain. As seen in OMVs from the ΔfimA strain, the GFP-FimA 
fusion caused packaging of Flagellin (51 kDa) into OMVs and not FimA monomer. The mutually 
exclusive packaging of FimA and Flagellin remained in the OMVs. 
 
4.2.7.3 Is the FimA-GFP fusion protein protected within the OMVs? 
The Proteinase K test was performed using the OMVs purified from the FimA-GFP fusion strain 
(Figure 4.34).  
 
The Proteinase K test was performed on the OMVs from the E. coli FimA-GFP fusion strain. As 
explained previously, the sample containing ‘OMVs + Proteinase K – SDS’ reveals which proteins are 
protected within the OMVs. Flagellin was protected within the OMVs from degradation by Proteinase 
K but the FimA-GFP fusion protein was degraded. This may be because the addition of the GFP to the 
FimA protein disrupted how the FimA monomer protein is usually packaged within the OMVs. For 
example, when GFP is fused to FimA, the protein is more than double its usual molecular weight and 
therefore it could be more exposed to degradation by proteases than usual. Furthermore, applying the 
Proteinase K test to FimA has previously been unsuccessful (Section 4.2.2). The FimA monomer may 
be packaged into a different part of the OMVs where it is less protected from Proteinase K (for 
example, it could be OM-associated). Therefore, the degradation of the FimA-GFP protein in this 
Proteinase K test should not be used as evidence either way for whether the FimA-GFP fusion protein is 
OMV-associated. 
Figure 4.34 Proteinase K test on OMVs from E. coli FimA-GFP fusion strain 
OMVs were incubated in the presence and absence of 10 µg/mL Proteinase K and various concentrations 
of SDS for 30 mins at 37ºC. 5 mM was added to inhibit Proteinase K and samples were incubated for 
another 30 mins at 37ºC. TCA precipitation was used to concentrate samples prior to loading on an SDS-
PAGE gel. The samples were used for Western blotting and probing with the following antibodies: anti-






4.2.8. Can FimA be used to target proteins and other molecules for delivery within OMVs 
using an alternative method (ie. expression of the fusion protein on a plasmid)? 
4.2.8.1 Targeting a FimA-mNeon green fusion protein to E. coli OMVs 
After the success of the FimA-GFP fusion protein targeting to the OMVs, expression of a FimA fusion 
protein using a plasmid was trialled. If successful, this could be very useful therapeutically for targeting 
proteins of interest to E. coli OMVs. A pJB005 plasmid (details in Section 2.12.1) was produced which 
resulted in the synthesis of a FimA-mNeon green fusion protein when induced in a competent E. coli K-
12 strain. The plasmid was selectable by using the antibiotic chloramphenicol. The plasmid was used to 
transform competent E. coli ΔfimA cells and E. coli WT parental BW25113 cells which were induced to 
produce the FimA-mNeon green fusion protein. The OMVs were purified and the protein profile was 
compared from both E. coli strains. The first aim was to see if the FimA-mNeon green fusion protein 
had been packaged into the OMVs successfully. The second aim was to see if the re-introduction of 
FimA changed the proteins packaged within the OMVs. A pJB005 plasmid containing a FimC-mNeon 
green fusion protein was also produced. However, this plasmid was never used due to time constraints.  
 
Expression of a plasmid containing FimA-Neon green protein fusion in E. coli BW25113 parental 
and ΔfimA strains 
The plasmid was transformed into competent E. coli ΔfimA and E. coli WT parental BW25113 cells. 
One colony from each successful transformation was used to produce an overnight strain, which was 
then used to inoculate 2 identical flasks containing LB with chloramphenicol. When the OD600 of the 
cells was 0.25-0.3 (early stationary phase), IPTG was added to one of the flasks. The other was not 
induced as a negative control. When the induced cells had reached an OD600 of approximately 1.0, 
OMVs were purified using the standard protocol (see Section 2.6.1). The OMVs were visualised using 
TEM (Figure 4.35). It appears that induction with IPTG causes hypervesiculation (comparing a and b to 














Figure 4.35 TEM images of 
OMVs purified from E. coli 
strains expressing pJB005 
plasmid 
The plasmid was transformed 
into competent E. coli ΔfimA and 
E. coli WT parental BW25113 
cells. When the OD600 of the 
cells was 0.25-0.3 (early 
stationary phase), IPTG was 
added to one of two identical 
flasks containing either E. coli 
WT Parental BW25113 or ΔfimA 
competent cells (c and d). The 
other was not induced as a 
negative control (a and b). When 
the induced cells had reached an 
OD600 of approximately 1.0, 
OMVs were purified using the 









A Western blot was performed on the purified OMVs and compared to the whole cell protein profile. 
This was to detect the FimA-mNeon green fusion protein using an anti-mNeon green antibody (Figure 















Although, the FimA-mNeon green protein was expressed when the cells were induced with IPTG, there 
was no indication that the fusion protein was packaged in the OMVs. 
 
Is the FimA-mNeon green fusion protein transported to the periplasm? 
To investigate further, transformed E. coli ΔfimA and E. coli WT parental BW25113 cells were grown 
and induced with IPTG as done previously. However, this time periplasmic proteins and OM proteins 
were also isolated from the cells as well for comparison, The OMVs were visualised by TEM as done 
previously (Figure 4.37).  
  
Figure 4.36 Detection of FimA-mNeon green fusion protein in OMVs purified from E. coli strains 
expressing pJB005 plasmid 
The plasmid was used to transform competent E. coli ΔfimA and E. coli WT parental BW25113 cells. 
When the OD600 of the cells was 0.25-0.3 (early stationary phase), IPTG was added to one of two 
identical flasks containing either E. coli WT parental BW25113 or ΔfimA competent cells. The other was 
not induced as a negative control. When the induced cells had reached an OD600 of approximately 1.0, 
OMVs were purified using the standard protocol. A Bradford assay was performed and all samples were 
standardised to be the same protein concentration. TCA precipitation was used to concentrate samples 
prior to loading on an SDS-PAGE gel. A Western blot was performed on these samples using anti-mNeon 
green antibody.  
 
Figure 4.37 TEM images of OMVs 
purified from E. coli strains expressing 
pJB005 plasmid 
The plasmid was transformed into 
competent E. coli ΔfimA and E. coli WT 
parental BW25113 cells. When the OD600 
of the cells was 0.25-0.3 (early stationary 
phase), IPTG was added to one of two 
identical flasks containing either E. coli WT 
Parental BW25113 or ΔfimA competent 
cells (c and d). The other was not induced 
as a negative control (a and b). When the 
induced cells had reached an OD600 of 
approximately 1.0, OMVs were purified 







A Western blot was performed to detect whether the FimA-mNeon green fusion protein had been 








































Figure 4.38 (a) shows that the FimA-mNeon green protein was expressed as the band was present in the 
whole cell samples after induction with IPTG (Lane 1). However, the protein was not transported to the 
periplasm in either strain and was therefore not found in the OM or OMVs either (Lanes 2-4). The E. 
coli WT Parental BW25113 strain OMVs always contain FimA. An anti-FimA monomer antibody was 
used to check that the FimA monomer was still packaged into E. coli WT parental BW25112 OMVs 
successfully in the conditions trialled. If the conditions were not correct for FimA monomer to be 
packaged, this may be the reason that the FimA-mNeon green fusion protein was not packaged into the 
OMVs. However, Lane 4 of Figure 4.38 (b) does have a band representing FimA monomer in the 
Figure 4.38 Detection of FimA-mNeon green fusion proteins from E. coli strains expressing pJB005 
plasmid 
Proteins were purified from the OM and periplasm of the cells and compared to the OMVs and whole 
cells, A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. 
Western blots were performed on these samples using the following antibodies: anti-Neon green (a), anti-
FimA monomer (b) and anti-Flagellin (c). 
b 
c E. coli Parental BW25113 strain 
containing plasmid with FimA-Neon green 
fusion protein 
E. coli ΔfimA strain containing plasmid 





OMVs. The usual 18 kDa FimA was successfully delivered to the OMVs in these conditions but the 
FimA-mNeon green protein was not. E. coli ΔfimA OMVs normally contain Flagellin so an anti-
Flagellin antibody was used to see if the Flagellin had successfully been packaged within the OMVs. 
Lane 4 of Figure 4.38 (c) shows that Flagellin was packaged as normal. Although FimA and Flagellin 
monomers were packaged as usual into the OMVs, the FimA-mNeon green protein was not transported 
to the periplasm and was not packaged within the OMVs. This is discussed further in Section 4.3.5. 
4.2.8.2 mNeon green fused with FimA signal peptide  
SDS-PAGE gels and Western blots have shown FimA at a molecular weight of 18 kDa and not 15 kDa. 
FimA is synthesised in vivo in a precursor form with an N terminal signal peptide sequence that allows 
it to be exported across the IM using the Sec translocase in the Sec pathway (Natale, et al. 2008). After 
this has occurred, the FimA signal peptide sequence is cleaved off to make a 15 kDa protein. 
Interestingly, the FimA monomer in OMVs has always been found at 18 kDa and never 15 kDa. This 
makes it possible that the signal peptide sequence remains on the FimA protein if it is destined to be 
packaged into OMVs (rather than into fimbriae). To test this hypothesis, a FimA signal peptide 
sequence was added to the N terminus of a mNeon green protein through cloning into a pJB005 plasmid 
(see Section 2.12) to see if the protein was packaged into the E. coli OMVs.  
 
The plasmid was transformed into competent E. coli ΔfimA and E. coli WT parental BW25113 cells. 
Two identical flasks containing LB with chloramphenicol were inoculated with a transformed colony. 
When the OD600 of the cells was 0.25-0.3 (early stationary phase), IPTG was added to one of the 
flasks. The other was not induced as a negative control. When the induced cells had reached an OD600 
of approximately 1.0, OMVs were purified using the standard protocol. The OMVs were visualised 





Figure 4.39 TEM images of 
OMVs purified from E. coli 
strains expressing pJB005 
plasmid 
The plasmid was transformed into 
competent E. coli ΔfimA and E. coli 
WT parental BW25113 cells. When 
the OD600 of the cells was 0.25-0.3 
(early stationary phase), IPTG was 
added to one of two identical flasks 
containing either E. coli WT 
parental BW25113 or ΔfimA 
competent cells (c and d). The other 
was not induced as a negative 
control (a and b). When the 
induced cells had reached an 
OD600 of approximately 1.0, 
OMVs were purified using the 







Interestingly, induction by IPTG appeared to cause hypervesiculation of the strain and a reduction in 
production of fimbriae and flagella. This was seen previously with expression of the FimA-mNeon 






























Induction using IPTG appeared to disrupt the regulation of which proteins were packaged to the OMVs. 
After IPTG was added in the E. coli parental WT BW25113 strain, FimA monomer was no longer 
packaged into the OMVs. There were also many more additional proteins packaged with no particular 
enrichment of any protein. Similarly, in the ΔfimA strain, there were many more proteins packaged into 
the OMVs after induction. Interestingly, Flagellin was still enriched in the OMVs from the ΔfimA strain. 
This is further evidence that FimA and Flagellin are packaged into the OMVs using different 
mechanisms as disruption of FimA does not also mean disruption of Flagellin. Due to time contraints, 
this experiment was not optimised further.   
Figure 4.40 Detection of FimA-mNeon green fusion proteins in OMVs from E. coli strains 
expressing pJB005 plasmid 
The plasmid was transformed into competent E. coli ΔfimA and E. coli WT parental BW25113 cells. When 
the OD600 of the cells was 0.25-0.3 (early stationary phase), IPTG was added to one of two identical 
flasks containing either E. coli WT parental BW25113 or ΔfimA competent cells. The other was not 
induced as a negative control. When the induced cells had reached an OD600 of approximately 1.0, OMVs 
were purified using the standard protocol A Bradford assay was performed and all samples were 
standardised to be the same protein concentration. TCA precipitation was used to concentrate samples 





4.3.1 Comparison of OMVs purified from E. coli K-12 vs B strains 
4.3.1.1 E. coli B strains hypervesiculate compared to K-12 strains (Section 4.2.1) 
The number of OMVs released from the engineered and proprietary BL21 strains was higher than E. 
coli WT strains. The possible reasons for this are discussed below. 
 
Gene knockouts that may lead to hypervesiculation of B strains 
Kulp and Kuehn (2015) determined the vesiculation production for the whole CGSC Keio collection 
library of E. coli mutant strains. The study found approximately 150 new genes, which are thought to be 
involved in OMV production (Kulp, Kuehn. 2015). The study indicated that a gene mutation that 
disrupts outer membrane structures such as LPS leads to hypervesiculation. These genes are outlined in 
Supplementary tables S1-S5 (Kulp, Kuehn. 2015). 
 
OmpC and OmpF 
It has previously been found that OMV production increased when there were disruptions in genes 
involved in outer membrane protein expressions, the synthesis of peptidoglycan and the σE envelope 
stress response. In this study, they found that disruption of the outer membrane porin proteins OmpC 
and OmpF genes gave increased vesiculation levels (McBroom et al. 2006). In E. coli BL21 strains, the 
ompC gene contains an insertion element making it non-functional. OmpC is not produced, which could 
contribute to the increased hypervesiculation of this strain (Marisch et al. 2013).  
 
cAMP and ppGpp 
Cyclic adenosine monophosphate (cAMP) is a derivative of ATP and is an indicator of metabolic stress 
in the cell. In an environment with low concentrations of glucose, levels of cAMP increase. cAMP can 
form a complex with a regulatory protein called cAMP receptor protein (CRP). The binding of CRP to 
cAMP causes a conformational change to form an active transcriptional regulator. CRP controls the 
transcription initiation of over 100 promoters (Zhan et al. 2008). These genes which are regulated by 
CRP are mainly involved in the catabolism of non-glucose carbon sources. As E. coli preferentially uses 
glucose as a carbon source, the CRP regulon is activated when glucose is absent in the environment. In 
this way, elevated cAMP levels are an indicator of glucose starvation. A study in 2013 found that levels 
of cAMP in E. coli B strains (BL21) were consistently higher than in K-12 strains despite the presence 
of glucose in the media (Marisch et al. 2013). It is possible that CRP-cAMP play a role in causing 
hypervesiculation in B strains either directly (by activation of specific genes that induce 
hypervesiculation) or indirectly (due to the cell being in a state of stress). 
 
Similarly, the nucleotide (guanosine pentaphosphate) ppGpp is a signalling molecule which causes up-
regulation of many of the genes involved in the stringent stress response. Some of these genes encode 




survive harsh conditions. E. coli B strains were also found to contain high levels of ppGpp compared 
with the K-12 strains, indicating that the cells are in a state of stress (Marisch et al. 2013). The higher 
levels of ppGpp are another indicator that E. coli B strain cells are in states of stress, which could be the 
reason for their hypervesiculation.  
 
4.3.1.2 E. coli K-12 OMVs are enriched with specific proteins unlike OMVs from B strains 
(Section 4.2.1) 
OMVs from E. coli BL21 and BL21 (DE3) strains contain many more proteins than E. coli K-12 WT 
OMVs and there are no dominant bands on the SDS-PAGE gels. In E. coli K-12 WT OMVs, specific 
proteins (identified as FimA and Flagellin) appear to be selectively included and excluded. The 
appearance of the OMVs from E. coli BL21 (DE3) in the TEM photos match those in the literature 
(Figure 2A of Bartolini et al. 2013). The protein profile of BL21 and BL21 (DE3) OMVs is not clear 
from the literature. For example, OMVs have been isolated from E. coli BL21 ΔompA and an SDS-
PAGE gel has been run to show the OMV protein profile. However, the strain contains a deletion of 
OmpA and expression of recombinant proteins of interest, which means that they are not directly 
comparable to the results in this study (Fantappie et al. 2014). After reviewing the available evidence in 
the literature, it appears that E. coli B strain cells are producing and secreting OMVs as part of a stress 
response. The cargo packaged is non-specific whereas E. coli K-12 strain OMVs is a more regulated 
process with careful enrichment and exclusion of certain proteins such as FimA and Flagellin monomers 
(as explained in Section 4.3.1.1 above).  
 
4.3.2 Evidence that FimA and Flagellin are packaged into E. coli K-12 OMVs (Sections 
4.2.1 - 4.2.6) 
4.3.2.1 Methods used as evidence that FimA and Flagellin are packaged within E. coli K-12 
OMVs 
Firstly, the immunogold labelling of E. coli OMVs embedded in resin confirmed the presence of FimA 
and Flagellin (Figures 4.6 and 4.31). Secondly, SDS-PAGE gels, Western blots and mass spectrometry 
identified FimA and Flagellin in the periplasmic fraction of E. coli cells and their respective purified 
OMV samples (Figures 4.7-4.8). Lastly, the Proteinase K showed that Flagellin monomer is OMV-
associated and protected within the OMVs (Figures 4.9 and 4.11). 
4.3.2.2 The Proteinase K test cannot be used to prove that FimA monomer is packaged into 
K-12 OMVs (Section 4.2.1) 
According to ExPASy peptide cutter tool, Proteinase K should cut at 108 cleavage sites within the 
FimA monomer protein (see Appendix C.6). However, it was not possible to optimise the Proteinase K 
test in a way that would allow the degradation of FimA. Only two conditions were found that made 




Firstly, TCA precipitation of the OMV sample prior to the Proteinase K test made the FimA monomer 
susceptible to degradation. It may be that the FimA monomers within OMVs are in a conformation 
where all cleavage sites are sequestered from proteases. As discussed previously, TCA causes a protein 
to denature in a way that it loses its secondary structure (Koontz et al. 2014). This change in protein 
conformation may make the protease cleavage sites now accessible to Proteinase K and allow 
degradation. 
 
Secondly, the creation of the fusion protein FimA-GFP resulted in a protein that was now susceptible to 
degradation by Proteinase K under the usual assay conditions. ExPASy peptide cutter tool indicates that 
GFP (GFP_AEQVI) contains 112 cleavage sites that can be cut by Proteinase K (Appendix C.24). GFP 
has a molecular weight of 27 kDa so adding this within the FimA protein (18 kDa) will drastically 
disrupt the protein conformation as well as adding 112 new cleavage sites for Proteinase K.  
 
4.3.3.3 FimA monomer in OMVs may be in a different conformer to FimA in fimbriae 
It is possible that the FimA monomer found in OMVs is a conformer of the usual FimA monomer found 
in fimbriae. Puorger et al. (2011) produced an incredibly stable variant form of FimA, which was 
generated to mimic the state of the usual FimA monomer in the context of the quaternary structure of 
the pilus rod. It was made by ‘elongation of FimA at the C-terminus by its own donor strand generated a 
self-complemented variant (FimAa) with alternative folding possibilities that spontaneously adopts the 
more stable conformation’ (Puorger et al. 2011). Perhaps the form of FimA monomer found in OMVs is 
in a different conformation to the usual FimA monomer (found in fimbriae), which is more resistant to 
proteolytic degradation (see further discussion in Section 4.3.4). 
 
4.3.3 Discussion of the mutual exclusive packaging of FimA and Flagellin into OMVs 
from a variety of E. coli strains (Sections 4.2.3-4.2.6). 
In the literature, Flagellin has already been reported as present in the lumen of E. coli W3110 OMVs 
which is a K-12 strain (Manabe et al. 2013). Similarly, FimA has also been found in OMVs in the 
literature (Bai, et al. 2014). However, the mutually exclusive packaging of FimA and Flagellin has not 
yet been addressed in the literature. One particular study indicates that pathogenic E. coli cells 
reciprocally regulate the expression of flagella and fimbriae (Cooper et al. 2012). It is possible that the 
regulation of packaging FimA and Flagellin monomers into OMVs could also be reciprocally regulated 
or linked to the expression of flagella and fimbriae. Table 4.8 a-c below summarises whether FimA and 







Table 4.8 Is the packaging of FimA and Flagellin monomers into OMVs mutually exclusive?  
Table a compares OMVs from five commonly used E. coli strains from Chapters 3 and 4. Table b 
compares OMVs purified from a range of E. coli strains with deletions of various fimbriae or flagella 
associated proteins. Table c compares OMVs purified from 6 clinical isolates. In the following tables, 




















Discussion of mutual exclusivity of FimA and 
Flagellin packaging within OMVs
WT MG1655 Yes No Yes
MG1655 is K-12 WT strain. The OMVs contain FimA 
monomer but not Flagellin (same as the Keio collection 
WT parental strain BW25113).
FimB-LacZ fusion No Yes Yes
The FimB-LacZ fusion strain contains a deletion of fimB 
which inhibits the production of T1F and so flagella is 
expressed instead. This leads to the packaging of Flagellin 




When T1F expression is locked on, both FimA and 
Flagellin are packaged into the OMVs. The exclusion of 
Flagellin from the OMVs has been disrupted.
BL21 No No Neither present
BL21 (DE3) No No Neither present
All E.coli  B strains examined do not express T1F or 
flagella and do not package FimA or Flagellin into the 
OMVs. There appears to be a loss of regulation into 




   











Discussion of mutual exclusivity of FimA and 




The Parental strain of the Keio collection (from which the 
other knockout strains are derived) has FimA packaged in 
the OMVs but not Flagellin.
ΔfliC Yes No Yes
Deletion of Flagellin from the E.coli  BW25113 Parental 
strain does not affect the packaging of FimA.
ΔfimA No Yes Yes
Deletion of fimA causes a switch where Flagellin is 
packaged instead of FimA (mutual exclusivity).
ΔfimC No Yes Yes
Deletion of fimC causes a switch where Flagellin is 
packaged instead of FimA. FimC is a chaperone protein 
which could play a role in directing FimA monomers to be 
packaged within OMVs. 
ΔfimB No Yes Yes
FimB is a site-specific recombinase that can bind to fimS 
and switch T1F expression either on-to-off or off-to-on. 
When FimB is absent, all fimbriae production is locked 
off which means that there is no expression of FimA. In 
this case, Flagellin is packaged instead of FimA.
ΔfimE Yes Yes No
FimE is a site-specific recombinase that can bind to fimS 
and switch T1F expression on-to-off. When FimE is 
absent, T1F production is locked on. As with the other 
strain where fimbriae production was locked on, both 
FimA and Flagellin are packaged within the OMVs.
 ΔfimF No Yes Yes
FimF binds to FimA in the formation of T1F. Perhaps 
FimF plays a role in the packaging of FimA to the OMVs 
as FimA is no longer packaged when it is absent. 
ΔfimG Yes Yes No
ΔfimH Yes Yes No
ΔfimD No No Neither present
FimD is an OM protein that is an usher to aid the 
formation of T1F. When FimD is absent, neither flagella 
or T1F appear to be expressed on the cells and no FimA 
or Flagellin is packaged into the OMVs.
ΔfimI Yes Yes No
The role of FimI in T1F formation is unclear from the 
literature. However, deletion of fimI led to the packaging 
of Flagellin as well as FimA into the OMVs.
ΔfimZ Yes No Yes
FimY and FimZ independently activate the promoter 
which controls the expression of fim structural genes. 
Therefore, even though FimZ was absent, FimY could 
promote fimA expression and there was no effect on the 
OMV protein profile. 
ΔlrhA Yes Yes No
LrhA is a key regulator of the transcription of genes 
relating to flagella. Without the regulation of LrhA, flagella 
are expressed and Flagellin is packaged along with FimA.
ΔfliD Yes No Yes
ΔfliS Yes No Yes
ΔflhA Yes No Yes
FimG and FimH are fimbrial tip proteins that have no 
known interaction with FimA monomer. When FimG and 
FimH are absent, FimA is still packaged into OMVs in the 
usual way. However, there are no functional T1F without 
the tip proteins and this leads to the expression of flagella 
on the cells. This also led to the packaging of Flagellin 
into the OMVs from these strains.
Absence of these proteins that interact with Flagellin did 







4.3.4 What is the function of packaging FimA and Flagellin into E. coli OMVs? 
It appears that in the majority of strains, FimA and Flagellin are reciprocally regulated and are packaged 
into OMVs independently (see Section 4.2.6). In 2012, a study proposed that there is a reciprocal 
regulation of adherence (by expressing Type 1 fimbriae) and motility (by expressing flagella) in UPEC 
E. coli (Cooper et al. 2012). The cells are either motile or adhering, which are opposing virulence 
objectives but both essential for colonisation of the urinary tract (Cooper et al. 2012). From this 
evidence, it seems possible that FimA and Flagellin could also be packaged into OMVs in a way that is 
also reciprocally regulated. 
 
4.3.4.1 Discussions of FimA monomer in the literature 
FimA can form a stable monomer conformation  
During the formation of Type 1 fimbriae, FimA monomers polymerise by donor-strand 
complementation (see Section 1.6.3). The FimA monomer has a donor strand which inserts into an 
immunoglobulin-like fold of the preceding FimA monomer to complete it. In this way, chains of FimA 
monomers form stable polymers. More recently, however, FimA has been found to adopt a monomeric 
self-complemented form. To remain stable, the self-donor strand is inserted in the opposite orientation 
to that during polymerisation to prevent any other FimA monomers from forming oligomers (Walczak 
et al. 2014).  
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Discussion of mutual exclusivity of FimA and 
Flagellin packaging within OMVs
Clinical isolate 1 No No Neither present
Clinical isolate 1 did not appear to express flagella or T1F. 
Previous analysis of the virulence genes determined that 
the strain was deficient in fimA. Neither FimA or Flagellin 
was packaged within the OMVs.
Clinical isolate 2 No No Neither present
Genetic analysis of this strain determined that FimB was 
non-functional and that there was no expression of T1F. 
Although, flagella was expressed on the cell, neither FimA 
or Flagellin were found in the OMVs.
Clinical isolate 3 Yes Yes No
This strain appeared to express fimbriae only but both 
FimA and Flagellin were packaged within the OMVs. F7-
2 fimbrial precursor protein was also identified in the 
OMVs by mass spectrometry.
Clinical isolate 4 No No Neither present
Neither FimA or Flagellin were found in OMVs from 
Clinical isolate 4. However, KS71A fimbrillin protein was 
also found which is related to fimbriae and may have a 
similar function to FimA.
Clinical isolate 5 Yes No Yes
Clinical isolate 5 expressed T1F and is evidence of the 
mutually exclusive packaging of FimA (and not Flagellin) 
in a real-life clinical isolate E.coli strain.
Clinical isolate 6 No Yes Yes
Clinical isolate 6 expressed flagella and is evidence of the 
mutually exclusive packaging of Flagellin (and not FimA) 




FimA monomers can inhibit cell apoptosis (innate immune response) 
In 2010, a study found a soluble, monomeric form of FimA that could suppress host cell apoptosis by 
targeting a Mitochondrial complex (Sukumaran et al. 2010). Many bacterial pathogens improve the 
chances of survival by inhibiting the apoptosis of host cells, which is part of the innate immune 
response. A pro-apoptotic protein called Bax is known to play a major role in the mitochondrial 
signalling pathway. When apoptosis is induced, Bax inserts into mitochondrial membranes and causes 
the release of cytochrome c into the cytosol (Heimlich et al. 2004). Cytochrome c then induces 
formation of an apoptosome which triggers a cascade of events resulting in cell apoptosis. In this study, 
FimA (from E. coli K1 supernatants) was shown to be a potent inhibitor of Bax-mediated release of 
cytochrome c from mitochondria (Sukumaran et al. 2010).  
 
This soluble form of FimA was also found in Shigella flexneri and Salmonella enterica supernatants. It 
was also shown to selectively block Bax from integrating into the mitochondrial membrane (Sukumaran 
et al. 2010). Interestingly, FimA was found to later dissociate from the mitochondria, which allowed 
apoptosis to resume. The authors hypothesised that the bacteria may benefit from stalling apoptosis 
temporarily for bacterial survival then allow apoptosis to occur to facilitate dissemination (Sukumaran 
et al. 2010). They also contemplate how a soluble FimA monomer could be found in the supernatant. 
Based on the results of this study, one could argue that these FimA monomers are the same as those 
found in E. coli K-12 OMVs here. Their FimA monomer was also found at approximately 18 kDa in 
their Western blots rather than the usual 15 kDa FimA in fimbriae. 
 
FimA monomer has been detected in OMVs from other bacterial strains 
FimA has also been found in OMVs from other bacterial strains including Porphyromonas gingivalis 
(Mantri et al. 2015). P. gingivalis is a Gram-negative OMV-producing pathogen that plays a role in 
causing chronic periodontitis (gum disease). OMVs were found to contain virulence factors such as 
hemagglutinin and a protease called gingipain, which degrades cytokines and reduces inflammation.  
4.3.4.2 Discussions of Flagellin monomer in the literature 
Flagellin monomer has been detected in the lumen of E. coli K-12 OMVs as well as other bacterial 
strains 
In 2013, a study found that an E. coli K-12 strain (W3110) produced OMVs that were enriched with 
Flagellin monomer (Manabe et al. 2013). In this study, the authors detected Flagellin within the lumen 
of the OMVs which agrees with the findings in the current study. Flagellin type B was detected in P. 
aeruginosa OMVs in this study. This agrees with another study in the literature which found Flagellin 
type B in OMVs from PA01s and S470 strain. S470 is a P. aeruginosa clinical isolate from the sputum 
of a cystic fibrosis patient, which makes this finding clinically relevant (Bauman et al. 2006). Similarly, 
Flagellin has also been found in the supernatant and OMVs from pathogenic enterotoxigenic E. coli 






Flagellin monomer is pro-inflammatory 
Flagellin is a bacterial virulence factor that is recognised by the innate immune system. Flagellin is 
detected by receptors on innate immune cells which leads to the production of cytokines. In 2012, a 
study showed that E. coli K-12 Flagellin induced a pro-inflammatory immune response in mice (Zgair, 
2012). Flagellin is known to bind to Toll-like receptor 5 (TLR-5) which activates NF-κB signalling in 
the cell (Yoon et al. 2017). NF-κB is a transcription factor that induces the expression of cytokines, 
chemokines and expression of pro-inflammatory genes. These pro-inflammatory cytokines activate the 
adaptive immune response which is specific for the bacterial antigen. TLR-5 receptors are found on a 
range of cell types including macrophages, neutrophils, lymphocytes, dendritic cells and epithelial cells 
(Hajam et al. 2017).  
 
In the 2012 study, Flagellin was purified from depolymerising E. coli K-12 flagella into Flagellin 
monomers. To observe the effect on the immune system in the lungs of mice, Flagellin was instilled 
intranasally. The presence of Flagellin induced the expression and production of the pro-inflammatory 
cytokine’s interleukin 1 beta, interleukin 6 and tumour necrosis factor alpha. High numbers of 
neutrophils were also recruited to the lungs after 24 hours (Zgair, 2012) as well as high levels of 
cytokines and chemokines. Flagellin from E. coli has also been reported to be recognised by TLR11 in 
mice (Hatai et al. 2016). Lastly, it appears that Flagellin is also recognised by the NAIP5/NLRC4 
inflammasome, which promotes the secretion of pro-inflammatory cytokines (Hajam et al. 2017). 
 
4.3.4.3 Current hypothesis 
Table 4.9 below outlines how packaging FimA and Flagellin into OMVs may be beneficial to the 
OMV-producing cell. If an E. coli cell is adhering to a surface to colonise and cause infection, releasing 
OMVs that contain an anti-inflammatory molecule to the host system would be beneficial. Similarly, if 
a cell is motile, releasing a trail of OMVs containing a pro-inflammatory molecule such as Flagellin 
may be beneficial to cause the immune response to react to the OMVs rather than the parent cell. 
 
Table 4.9 Hypotheses of how packaging FimA and Flagellin monomers inti OMVs may be 




Current hypothesis: FimA and Flagellin monomers have opposite effects on the hosts’ immune 
response so it makes sense to package them in a mutually exclusive way into OMVs. This is discussed 
further in Chapter 6.1.5. 
Cell Adhering Cell Motile
Fimbriae expressed Flagella expressed
OMVs enriched with 
monomeric FimA
OMVs enriched with 
monomeric Flagellin
FimA monomer is anti-
inflammatory





4.3.5 How can this finding be used for therapeutic purposes? 
GFP was successfully targeted to E. coli K-12 OMVs by protein fusion to FimA. Table 4.10 below 
summarises the differences between the two methods of targeting a protein of interest to the OMVs 
using FimA. 
 
















The experiments showed that to target a protein of interest to E. coli K-12 OMVs, a chromosomal insert 
of the protein within the fimA gene is required. Expression of a FimA fusion protein by plasmid caused 
an unexpected hypervesiculation of the strain. Furthermore, the OMVs produced appeared to contain 
many proteins with no particular protein dominant. Both the appearance of the OMV protein profile and 
hypervesiculation resembled an E. coli B strain rather than a K-12 strain. This could be because plasmid 
expression puts the cell under stress and causes hypervesiculation as in the B strains and loss of specific 
protein inclusion/exclusion from the OMVs. This method would need to be optimised further if plasmid 
expression was to be used to target cargo to OMVs for therapeutic applications. 
Was the FimA fusion protein 
successfully targeted to the OMVs?
Yes No
Was the FimA fusion protein  
transported to the periplasm?
Yes No
Was there hypervesiculation compared 
to OMVs produced in the WT strain?
No Yes
Were plasmids used to express the FimA 
fusion protein of interest?
No Yes
Was IPTG added in the media? No Yes
Was antibiotic added to the media? No Yes
OMVs from E.coli 
MG1655 GFP-FimA 
fusion strain
OMVs from E.coli 







Chapter 5  
Streptomyces S4 cells secrete Membrane Vesicles 
containing the antifungal compound Candicidin 
5.1 Introduction 
5.1.1 Comparison of OMVs (from Gram-negative bacteria) to MVs (Gram-positive 
bacteria) 
Chapter 3 and 4 focussed on OMVs that are secreted by Gram-negative bacteria. As discussed 
previously, OMVs are formed from the bacterial outer membrane and contain a range of cargo including 
some periplasmic proteins. Gram-positive bacteria do not have an outer membrane (Figure 5.1a) and so 
do not produce outer membrane vesicles. Instead, the vesicles produced are thought to be composed of 
the cytoplasmic membrane and contain cytoplasmic proteins (Figure 5.1b). These will be referred to as 
Membrane Vesicles (MVs) instead of OMVs. For details on the hypotheses for the formation of Gram-
























Figure 5.1 Comparison of membrane vesicles from Gram-positive and Gram-negative bacteria 
Gram-positive and Gram-negative bacteria have different membrane compositions (a). Gram-negative 
bacteria produce OMVs which are formed from the Outer Membrane and contain some periplasmic proteins. 
MVs from Gram-positive bacteria are thought to be composed of the cytoplasmic membrane and contain 
cytoplasmic proteins (b). Image (a) was sourced from: http://simbac.gatech.edu/outer-membrane-proteins/. 




5.1.2 Streptomyces S4 strains 
As summarised in Chapter 1, membrane vesicles (MVs) have previously been purified from the Gram-
positive strain Streptomyces lividans (Schrempf, Merling. 2015). The Streptomyces S4 strain produces 
the antifungal compounds candicidin and eight antimycins (Seipke et al. 2011). Due to the known 
success of the delivery of amphotericin B within a liposome to fungal cells (Section 1.9.3), it led us to 
hypothesise if a similar process occurs in nature. This was tested by purifying membrane vesicles from 
Streptomyces S4 and we hypothesised that candicidin and/or antimycin is packaged and released in 
Streptomyces S4 MVs for enhanced uptake in the target cells. Professor Hutchings (UEA) kindly 
donated the following strains for study into MV production in Streptomyces S4 (Table 5.1 and 
Appendix D.1).  
 
Table 5.1 Brief introduction to the Streptomyces S4 strains used in Chapter 5.  
 
 
Membrane vesicles produced by Gram-positive bacteria (such as Streptomyces) is a new and emerging 
field with many unanswered questions. The standard OMV purification protocol was applied to 
Streptomyces S4 and the three mutant strains to see if MVs could be isolated.  
5.1.3 Main chapter aims: 
1. To compare and contrast MV composition, cargo and function from both Gram-negative and Gram-
positive bacterial strains  
2. To gain a deeper understanding into cross-species signalling using MVs 
3. To gain insight into the function of any cargo discovered (i.e. why would this be beneficial in vivo?)  
4. To develop and optimise new protocols for MV purification, characterisation and manipulation 
5. To gain a fundamental understanding of vesiculation in Gram-positive bacteria.  
Strain name Strain information References
Streptomyces S4 
wild type
The Streptomyces S4 strain was isolated from the attine ant 
species A. octospinosus  in Panama. Attine ants cultivate fungus 
for food and have developed a symbiotic relationship with 
Actinobacteria to protect their cultured fungus from other 
microorganisms. Streptomyces S4 produces the antifungal 
compounds candicidin and eight antimycins which likely offer 
their food source protection against microfungal weeds.
Streptomyces S4 
ΔantC
AntC encodes a nonribosomal peptide synthetase which is 
thought to play a role in the biosynthesis of antimycins. Deletion 
of the gene antC  inhibits the synthesis of all eight antimycin 
compounds usually produced by Streptomyces S4. The 
antifungal compound candicidin, however, is still produced by 
this strain.
Streptomyces  S4 
ΔfscC 
In the ΔfscC strain, the polyketide synthase gene (fscC ) is 
deleted. This encodes the candicidin biosynthetic module and 
disruption of this gene causes inhibition of candicidin production. 
In this strain, antimycin is still produced.
Streptomyces S4 
ΔantCΔ fscC 
This double mutant strain does not produce candicidin or 
antimycins and has no antifungal activity against C. albicans.
Barke et al.  2010     
Haeder et al. 2009    
Seipke et al.  2011  
Hopwood et al. 2012    




Figure 5.2. Visualisation of purified MVs from Streptomyces S4 strains using TEM 
TEM analysis of purified MVs from the following Streptomyces S4 strains: Streptomyces S4 WT (a-c),     
Streptomyces ΔantC (d-f), Streptomyces ΔfscC (g-i), Streptomyces ΔantC ΔfscC (j-l). White asterisks in 




6. To identify drug targets to prevent infection by MV-producing pathogens or use MVs in therapeutic 
applications such as drug delivery or vaccines. 
5.2 Results 
5.2.1 Visualisation of Membrane Vesicles (MVs) from Streptomyces S4 by TEM 
The OMV purification protocol was applied to Streptomyces S4 WT and the three mutant strains to see 
if any MVs could be isolated (see Section 2.6.3 for further details). The resulting samples were 
concentrated then visualised using TEM and photos were taken at various magnifications (Figure 5.2). 
The TEM images indicated that MVs had been purified from all four Streptomyces S4 strains. The 
purified MVs were very similar in appearance to OMVs purified from E. coli and P. aeruginosa 
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5.2.2 Visualisation of Streptomyces S4 cells and MVs using WGA-FITC  
Streptomyces S4 cells and MVs were visualised using WGA-FITC based on a protocol found in the 
literature (Celler et al. 2016). WGA refers to wheat germ agglutinin, a lectin from Triticum vulgaris 
(wheat) conjugated to the fluorescent conjugate fluorescein isothiocyanate (FITC). This product was 
developed for the fluorescent detection of glycoproteins containing β(1→4)-N-acetyl-D-glucosamine 
(Sigma-Aldrich L4895). This is found in the peptidoglycan layer of Gram-positive cell walls. In the 
literature, evidence suggests that Gram–positive MVs are formed from the cytoplasmic membrane 
without the peptidoglycan layer (see Figure 5.1). If this theory is correct, the WGA-FITC will bind 
successfully to the peptidoglycan on whole Streptomyces S4 cells but will not bind and fluoresce when 
applied to purified MVs. Figure 5.3 shows whole Streptomyces S4 cells treated with WGA-FITC. 
Before incubation with WGA-FITC, half of the cells were washed 3x in PBS to remove any MVs from 
around the cells (a). The other half of the cells remained unwashed in PBS and may still have MVs in 

























































WGA-FITC successfully bound to the Gram-positive Streptomyces S4 cells so that they could be 
visualised. Furthermore, areas of intense fluorescence were found on the membranes of the cells which 
may be the sites of vesiculation (white arrows on Figure 5.3b). This appeared to be more present in the 
cells which had not been washed 3x with PBS (discussed further in Section 5.3.1).  
Next, purified MVs from all four Streptomyces S4 stains were incubated with WGA-FITC (Figure 5.4). 
Any areas of fluorescence were very dispersed and difficult to find (Figure 5.4 a-d). This suggests that 
the MVs are composed of the cytoplasmic membrane only and do not contain peptidoglycan on their 
surface (Figure 5.4 e).   
 
Figure 5.3. Visualisation of Streptomyces S4 cells and MVs using WGA-FITC.  
Streptomyces S4 cells were grown for 48 hrs then concentrated by centrifugation at 13200 RPM. Half 
of the cells were washed 3x in PBS in an attempt to remove all MVs around the cells (a). The other 
half remained unwashed with PBS and may contain MVs (b). Cells were fixed in 2% (w/v) 
paraformaldehyde then incubated in 100 µg/mL WGA-FITC (Sigma L4895) in the dark for 1 hour. 15 
μL cells were added onto a coverslip before being inverted onto a drop of ProLong Gold antifade 
mountant on a glass slide. Samples were visualised the next day by confocal microscopy (Zeiss lsm 
880 with airscan) under the supervision of Matt Lee. Scale bar was added to images using Fiji (Image 







Figure 5.4. Visualisation of Streptomyces S4 MVs using WGA-FITC.  
MVs were purified from the following strains: Streptomyces S4 WT (a), ΔantC (b), ΔfscC (c) and ΔantC 
ΔfscC (d). MVs were concentrated by centrifugation at 13200 RPM.  MVs were fixed in 2% (w/v) 
paraformaldehyde then incubated in 100 µg/mL WGA-FITC (Sigma L4895) in the dark for 1 hour. 15 μL 
cells were added onto a coverslip before being inverted into a drop of ProLong Gold antifade mountant on 
a glass slide. Samples were visualised the next day by confocal microscopy (Zeiss lsm 880 with airscan) 
under the supervision of Matt Lee. Scale bar was added to images using Fiji (Image J). Lastly, the same 
Streptomyces S4 MV WT sample was concentrated by centrifugation 50x and the images of the sample 
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Figure 5.5 Comparison of MV protein profile from Streptomyces S4 and the 3 mutant strains 
MVs were purified from four different Streptomyces S4 strains: WT, ∆antC, ∆fscC and ∆antC ∆fscC. 
A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. The SDS-PAGE gel was run then silver stained to visualise the MV protein profile.  
 
5.2.3 Characterisation of Streptomyces S4 MV proteome 
5.2.3.1 Comparison of the Streptomyces S4 MV protein profiles  
The protein profile of MVs purified from the four Streptomyces S4 strains was compared (Figure 5.5). 
The protein profile of MVs from Streptomyces S4 WT (lane 3), ∆antC (lane 5) and ∆fscC (lane 7) 


























5.2.3.2 Densitometry comparison 
Protein densitometry plots were generated using Fiji (Image J) to compare the protein profile of the 
MVs from each strain (Figure 5.6). The densitometry plots indicated that the MVs purified from the 
double mutant did have extra proteins compared with MVs from the other 3 strains. Perhaps the 
regulation of which proteins enter the MVs was disrupted when the cell no longer produces the 






















Figure 5.6 Densitometry comparison of MV protein profile from Streptomyces S4 and the 3 
mutant strains 
MVs were purified from four different Streptomyces S4 strains: WT, ∆antC, ∆fscC and ∆antC ∆fscC. A 
Bradford assay was performed and all samples were standardised to be the same protein concentration. 
TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE gel. The SDS-
PAGE gel was run then silver stained to visualise the MV protein profile (a). Protein densitometry plots 
were generated from the SDS-PAGE gel photos using Fiji (Image J) (b). 
 
b Lane 3 Lane 3 
Lane 5 Lane 5 
Lane 7 Lane 7 





5.2.3.3 Protein profile of Streptomyces S4 MVs compared with the whole cell 
The Streptomyces S4 MV protein profile was compared to the whole cell to see which proteins are 
enriched and excluded from Streptomyces S4 MVs (Figure 5.7). One band in particular appears to be 
enriched in Streptomyces S4 MVs compared to the levels in the cell (labelled with a blue arrow). This 







Figure 5.7 Comparison of MV protein profile from Streptomyces S4 and the 3 mutant strains 
MVs were purified from four different Streptomyces S4 strains: WT, ∆antC, ∆fscC and ∆antC ∆fscC and 
were compared to the whole cell samples. A Bradford assay was performed and all samples were 
standardised to be the same protein concentration. TCA precipitation was used to concentrate samples 
prior to loading on an SDS-PAGE gel. The SDS-PAGE gel was run then silver stained to visualise the MV 
protein profile (a). Protein densitometry plots were generated from the SDS-PAGE gel photos using Fiji 


















5.2.4 Do Streptomyces S4 MVs contain proteases?  
Two bands of interest in Streptomyces S4 MVs were extracted and identified by mass spectrometry 
(Figure 5.8). The mass spectrometry results indicate that all Streptomyces S4 MV samples contain a 
serine protease and that the ∆antC ∆fscC strain MVs contain a fumarate reductase/succinate 
dehydrogenase flavoprotein subunit. 
  
Figure 5.8 Comparison of MV protein profile from Streptomyces S4 and the 3 mutant strains 
MVs were purified from four different Streptomyces S4 strains: WT, ∆antC, ∆fscC and ∆antC 
∆fscC. A Bradford assay was performed and all samples were standardised to be the same protein 
concentration. TCA precipitation was used to concentrate samples prior to loading on an SDS-PAGE 
gel. The SDS-PAGE gel was run then silver stained to visualise the MV protein profile (a). The two 
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5.2.4.1 Release of proteases from Streptomyces S4 MVs when SDS is added 
In Section 3.2.5, E. coli OMVs were incubated with SDS, which appeared to cause disruption to the 
membrane of the OMVs and release of active proteases from within. These proteases degraded some of 
the OMV-associated proteins (and flagella) and changed the OMV protein profile. This method was 
applied to purified Streptomyces S4 WT MVs to see if they contain active proteases (Figure 5.9). 
Streptomyces S4 WT MVs were purified and resuspended in 10 mM HEPES buffer. Half of the purified 
MVs were resuspended in 10 mM HEPES buffer only (Lanes 3-6). The other half were resuspended in 
10 mM HEPES buffer then filtered through a 0.22 µm filter (Lanes 7-10). Many of the bands 
disappeared when various concentrations of SDS were added (Lanes 4-6 compared to Lane 3 and Lanes 
8-10 compared to Lane 7). This indicates that proteases are present which are released when MVs are 

















Figure 5.9 Do Streptomyces S4 MVs contain proteases? 
Streptomyces S4 WT MVs were incubated with various concentrations of SDS at 37 ºC for 60 mins. 
The samples were run on an SDS-PAGE gel then silver stained to visualise the MV protein profile (a). 











5.2.5 Are any antifungal agents present within the purified Streptomyces S4 MVs? 
5.2.5.1 Positive control: Candicidin 
In order to determine if Streptomyces S4 MVs contained any antifungal compounds, a method to 
observe the effect on the growth of Candida albicans was developed. This was initially trialled with 
various concentrations of candicidin (purchased from Bio-Australis) and antimycin (purchased from 
Sigma-Aldrich). Candicidin was dissolved in absolute ethanol and diluted to give various concentrations 
of candicidin ranging from 200 µg/mL to 1 µg/mL. 10 μL was spotted on to a LB agar plate and left to 
soak in. This was then overlayed with C. albicans mixed in with LB 0.5% (w/v) agar and left to set and 
the diameter of the zones of inhibition (ZOI) were measured the next day (Figure 5.10). The ZOI are 












Figure 5.10 Effect of varying concentrations of candicidin on C. albicans   
Candicidin was resuspended in ethanol then diluted to give various concentrations ranging from 200 
µg/mL-1 µg/mL. 10 μL candicidin was added to LB plates and left to soak/dry for a minimum of 2 hrs at 
room temperature. 10 μL ethanol only was used as a negative control. This was then overlayed with C. 
albicans mixed in with LB 0.5% (w/v) agar and left to set. Plates were incubated at 37 ºC for 18 hrs and the 
diameter of the ZOI was measured (a). All plates were prepared in triplicate and the average ZOI was 









5.2.5.2 Positive control: Antimycin 






Figure 5.11 Effect of varying concentrations of antimycin on C. albicans   
Antimycin was resuspended in ethanol then diluted to give various concentrations ranging from 200 
µg/mL-1 µg/mL. 10 μL antimycin was added to LB plates and left to soak/dry for a minimum of 2 hrs at 
room temperature. 10 μL ethanol only was used as a negative control. This was then overlayed with C. 
albicans mixed in with LB 0.5% (w/v) agar and left to set. Plates were incubated at 37 ºC for 18 hrs and 
the diameter of the ZOI was measured (a). All plates were prepared in triplicate and the average ZOI was 









5.2.5.3 Effect of Streptomyces S4 cells on C. albicans growth 
This method was then trialled by observing the ZOI caused by the four Streptomyces S4 strains 
overlayed with C. albicans. As expected, ZOI were produced from Streptomyces S4 WT strain, ∆antC 
and ∆fscC but not from the ∆antC ∆fscC strain (Figure 5.12).  
 
  
Figure 5.12. Effect of Streptomyces S4 cells on C. albicans growth 
Streptomyces S4 colonies (from MS plates) were inoculated into TSB:YEME (two media mixed 1:1) 
grown up for 72 hrs. 5 μL of this culture was spotted at the centre of a LB agar plate and left to soak/dry 
for 2 hrs. Plates were incubated at 30ºC for 72 hrs to allow growth of Streptomyces. C. albicans mixed 
with LB 0.5% agar was overlayed on to the plates and left to set. Plates were incubated at 37ºC for 18 
hrs and the diameter of the ZOI was measured (a). All plates were prepared in triplicate and the average 











5.2.5.4 Effect of Streptomyces S4 MVs on C. albicans growth 
Purified MVs from the four Streptomyces S4 strains were concentrated and added to a LB agar plate and 
left at room temperature to dry/soak in. This was then overlayed with C. albicans mixed in with LB 
0.5% (w/v) agar and left to set (see Section 2.13.1 for full protocol). Plates were incubated at 37ºC for 
18 hours and the diameter of the ZOI measured using a ruler. The aim of this was to determine if the 
antifungal compounds candicidin or antimycin were present within any of the purified MVs by 
measuring the ZOI produced (Figure 5.13a). Each experiment was done in triplicate and the zones of 






























The results of Figure 5.13 suggest that Streptomyces S4 MVs contain the antifungal compound 
candicidin and not antimycin (see Table 5.2) which is a novel finding. 
Figure 5.13 Do Streptomyces S4 MVs contain antifungals?   
5 μL concentrated MVs (in 10 mM HEPES buffer) were added to LB plates and left to soak/dry 
for at room temperature. C. albicans mixed with LB 0.5% (w/v) agar was overlayed on to the 
plates and left to set. Plates were incubated at 37ºC for 18 hrs and the diameter of the ZOI was 
measured (a). All plates were prepared in triplicate and the average ZOI was calculated and 
























5.2.5.5 Further comparison of MVs from all Streptomyces S4 strains 
To explore this further, Streptomyces S4 MVs were treated in 3 different ways to observe the effect on 
the ZOI. Streptomyces MV pellets were resuspended in 5 mL 10 mM HEPES buffer and filter sterilised 
as part of the OMV purification procedure. 5 μL of this sample was added to LB agar plates labelled as 
the ‘MV 1x concentration’ sample (Figure 5.14 a). The MVs were then concentrated 25x by pelleting 
the MVs and resuspending in a smaller volume of 10 mM HEPES buffer to give an ‘MV 25x 
concentrated’ sample (b). Lastly, the MVs were pelleted and washed 3x in 10 mM HEPES buffer to 













 Figure 5.14 Preparation of MVs for zone of inhibition plates with C. albicans                
Streptomyces S4 MVs were treated in 3 different ways to observe the effect on the ZOI. The 
preparation of the following samples was summarised: ‘MV 1x concentration’ (a), ‘MV 25x 












Explanation for the result
Streptomyces 
S4 wild-type
The Streptomyces S4 strain produces both of the antifungal compounds candicidin and 
antimycin. The MVs must contain at least one of these compounds as there's a zone of 
inhibition against C. albicans.
Streptomyces 
S4 ΔantC
The Streptomyces  ΔantC strain produces candicidin but not antimycin as its 




The Streptomyces ΔfscC strain produces antimycin but not candicidin. The MVs must 





The Streptomyces  ΔantCΔ fscC  strain does not produce candicidin or antimycin so as 
expected, the MVs have no zone of inhibition against C. albicans.












































A B Sample key 
A = MV 1x concentration 
B = MV 25x 
concentrated 
C = MVs 3x washed 
D = 10 mM HEPES 
buffer only 
C D 
Figure 5.15 Do Streptomyces S4 MVs contain antifungals?   
Streptomyces S4 MVs were treated in 3 different ways to observe the effect on the ZOI. 5 μL of the 
following MV samples were added to the LB plates: ‘MV 1x concentration’, ‘MV 25x concentrated’ 
and ‘MVs 3x washed’. C. albicans mixed with LB 0.5% (w/v) agar was overlayed on to the plates 
and left to set. Plates were incubated at 37ºC for 18 hrs and the diameter of the ZOI was measured 
(a). All plates were prepared in triplicate and the average ZOI was calculated and presented as a 
graph (b). 
 
Streptomyces S4 Streptomyces ΔantC 















The results from Figure 5.15 still indicate that the Streptomyces S4 WT MVs contain candicidin. 
Although the MVs are concentrated 25x, the ZOI produced is only slightly larger for the ‘MV 25x 
concentrated’ sample compared to the ‘MV 1x concentration’ sample and is not proportional (discussed 
in Section 5.3.3). Lastly, the MV pellets were also washed 3x with 10 mM HEPES buffer to remove any 
non-OMV associated contaminants and the ZOI remained. This is evidence that the candicidin is MV-
associated and this was explored further. 
5.2.5.6 Is Candicidin MV-associated? 
In order to find further evidence that candicidin is MV-associated, Streptomyces S4 MVs were washed 
1x, 2x and 3x with 10 mM HEPES buffer. This was to remove any extracellular material from around 
the MVs so that any antifungal activity observed was from MVs only. Figure 5.16 summarises how the 
























Figure 5.16 Preparation of MVs with 
various numbers of wash steps for zone of 
inhibition plates with C. albicans. The 





































































‘MV washed 2x 
supernatant’ 
































Streptomyces S4 WT MVs still appear to contain candicidin. As in Figure 5.17, ZOI produced for the 
‘MV concentrated’ sample compared to the ‘MV dilute’ sample is not proportional. The Streptomyces 
S4 MVs were washed in 10 mM HEPES buffer either 1x, 2x or 3x. The supernatant was also taken each 
time and added to the LB plates to see if there was a ZOI with C. albicans. The supernatants from the 
concentrated MV sample and the supernatant after 1 wash in 10 mM HEPES buffer contained 
candicidin and/or antimycin as there was a ZOI. However, after two or three washes in 10 mM HEPES 
buffer, the MV supernatants do not contain candicidin or antimycin as there is no ZOI produced. This 
indicates that anything extracellular to the MVs (e.g. antifungals or lysed cells in the supernatant) has 
now been washed away with the 10 mM HEPES buffer. Therefore, this provides further evidence that 





Figure 5.17 Do Streptomyces S4 MVs contain antifungals? Various numbers of washes of the MV 
pellet with 10 mM HEPES buffer  
Streptomyces S4 MVs were washed up to 3x in 10 mM HEPES buffer to observe the effect on the 
ZOI. 5 μL of the following MV samples were added to the LB plates: ‘MV Dilute’, ‘MV 
Concentrated’, ‘MV washed 1x’, ‘MV washed 2x’ and ‘MV washed 3x’ as well as 5 μL of their 
corresponding supernatants (as explained in Figure 5.15). C. albicans mixed with LB 0.5% (w/v) 
agar was overlayed on to the plates and left to set. Plates were incubated at 37ºC for 18 hrs and the 
diameter of the ZOI was measured (a). All plates were prepared in triplicate and the average ZOI 









5.2.6 Detection of candicidin in Streptomyces S4 MVs by Ultraviolet–visible spectroscopy 
(UV-Vis) 
Candicidin and antimycin can both be identified by their distinct UV-Vis spectra (see Appendix D.3 for 
examples in the literature). Candicidin and antimycin were purchased and dissolved in absolute ethanol 
which was then diluted to give various concentrations. These samples were run on the 
spectrophotometer (Agilent Technologies Cary 60 UV-Vis) to give the UV-Vis spectra characteristic to 
candicidin and antimycin (Figure 5.18). These spectra were used as positive controls to detect 
































Figure 5.18 UV-Vis spectra of candicidin and antimycin  
500 μL samples were loaded on to the spectrophotometer (Agilent Technologies Cary 60 UV-Vis) in 
quartz cuvettes to give the UV-Vis spectra. Candicidin dissolved at 1 mg/mL which gave the clearest 
spectra and there was a proportional decrease in Absorbance when 100 µg/mL was run (a). 
Antimycin dissolved at 1 mg/mL gave the clearest spectra and there was a proportional decrease in 
Absorbance when 100 µg/mL was run (b). The peaks that are ‘characteristic’ of each antifungal 







5.2.6.1 Extraction of candicidin from Streptomyces S4 MVs was trialled using 3 different 
methods 
Detection of candicidin and/or antimycin was then investigated in Streptomyces S4 MV samples. 
Initially, Streptomyces S4 MVs resuspended in 10 mM HEPES buffer were trialled on the UV/Vis 
spectrophotometer with no success (see Appendix D.4). Three methods were trialled to extract the 
antifungal compounds from the other contaminating MV components using butanol (Figure 5.19). 
Methods to extract candicidin using butanol were based on a method in the literature which was used to 
















Butanol and 10 mM HEPES buffer only were run on the spectrophotometer to visualise the UV-Vis 
spectra as negative controls (Figure 5.20).    
  
Figure 5.19 Different methods of butanol extraction trialled on Streptomyces S4 MVs to identify 
candicidin 
In Method 1, MVs were resuspended directly into butanol then the butanol was extracted for analysis. In 
Method 2, MVs were resuspended into 10 mM HEPES buffer first then extracted using butanol. In Method 
3, MVs were washed 3x in 10 mM HEPES buffer then extracted using butanol 
 
Figure 5.20 UV-Vis 
spectra of butanol 
and 10 mM HEPES 
buffer 
500 μL butanol or 10 
mM HEPES buffer 
were loaded on to the 
spectrophotometer 
(Agilent Technologies 
Cary 60 UV-Vis) in 
quartz cuvettes to give 





5.2.6.2 Candicidin extraction Method 1 (MV pellet resuspended directly into butanol) 
At the last step of the MV purification protocol, MV pellets were resuspended directly into butanol 
(rather than into 10 mM HEPES buffer) and ran on the spectrophotometer to generate the UV-Vis 






























MVs from Streptomyces S4 and ΔantC gave peaks characteristic of candicidin. There was no indication 
of candicidin in MVs from the ΔfscC or from the ΔantC ΔfscC strain and there was no indication of 
antimycin in MVs from any of the strains. The ZOI plates in Section 5.2.5 showed that MVs from 
Streptomyces S4 and ΔantC gave a ZOI against C. albicans. This indicated that candicidin was present 
in the MVs which agree with the findings here. Another method to detect candicidin in the MVs 
involved resuspending the MVs in 10 mM HEPES buffer first then extracting using butanol. The results 
of using Methods 2 and 3 to identify candicidin can be found in Appendix D.5-D.6. 
a 
b 
Figure 5.21 UV-Vis spectra of Streptomyces S4 MVs resuspended directly into butanol 
Streptomyces S4 MVs were purified using the standard protocol but the MV pellets were resuspended 
directly into butanol. 500 μL MVs (extracted in butanol) were loaded on to the spectrophotometer (Agilent 
Technologies Cary 60 UV-Vis) in quartz cuvettes to give the UV-Vis spectra. The Absorbance range used 
was 200-450 nm (a) and the area of interest was enlarged to see the characteristic  






5.3.1 Streptomyces S4 secretes MVs which were purified and characterised (Sections 
5.2.1-5.2.6) 
5.3.1.1 Presence of Streptomyces S4 MVs were confirmed by TEM 
The OMV purification protocol was applied to the Streptomyces S4 WT strain and the three mutant 
strains (ΔantC, ΔfscC and ΔantC ΔfscC). The resulting samples were visualised by TEM. There 
appeared to be vesicles which were the same shape, size and appearance as OMVs purified from E. coli 
and P. aeruginosa in Chapters 3-4. The purified MVs were also very similar to those purified from 
Streptomyces lividans in the literature (Schrempf, Merling. 2015). 
5.3.1.2 Streptomyces S4 MVs are composed of the cytoplasmic membrane  
WGA-FITC bound successfully to the peptidoglycan on Streptomyces S4 WT cells and the cells could 
clearly be seen. WGA-FITC did not bind and fluoresce when added to purified MVs. The most likely 
explanation for this is that the MVs are composed of the cytoplasmic membrane of the cells with no 
peptidoglycan layer as suggested in the literature (Figure 5.1). This could be resolved further by using a 
specialised EM grid with coordinates so that the same area can be used for confocal microscopy. MVs 
can be tagged with WGA-FITC then the same grid can be negatively stained and used for TEM. The 
images can be overlayed and this would determine the percentage of the MV population that is stained 
with WGA-FITC.  
 
Figure 5.3 shows whole Streptomyces S4 cells treated with WGA-FITC. Before incubation with WGA-
FITC, half of the cells were washed 3x in PBS to remove any MVs from around the cells (a). The other 
half of the cells remained unwashed in PBS and may still have MVs in the sample (b). Areas of intense 
fluorescence were found on the membranes of the cells, which may be points of MV biogenesis. These 
were seen on the cells that were unwashed in PBS but not on the washed cells. It is currently unclear 
why these areas fluoresce more intensely than the membranes alone. Perhaps the peptidoglycan layer in 
these areas is being broken down (in order for the MVs to bulge from the cytoplasmic membrane) and 
the WGA-FITC binds more giving greater fluorescence.  
5.3.1.3 MV protein profile 
SDS-PAGE gels were run to show the protein profile of the purified Streptomyces S4 MVs. The 
densitometry plots indicated that the MVs purified from the double mutant (ΔantC ΔfscC) did have 
extra proteins compared with MVs from the other 3 strains. It appears that there is less regulation of 
which proteins enter the MVs when the cell no longer produces antimycin or candicidin. However, the 




5.3.2 Streptomyces S4 MVs contain proteases (Section 5.2.4) 
The protein profile of the MVs from Streptomyces S4 and the three mutants were compared to that of 
the MV-producing cells. One protein in particular appeared to be enriched in the Streptomyces S4 MVs 
compared with the cells. This was identified by mass spectrometry to be a serine protease. Serine 
proteases have been found within OMVs in the literature although not yet in Streptomyces MVs. The 
serine protease VesC has been found within OMVs from Vibrio cholerae (Mondal et al. 2016). VesC 
was found in an active form within the OMVs and was suspected of play a role in the intestinal 
colonisation of V. cholerae in adult mice. VesC also induced a ‘proinflammatory response in human 
cultured intestinal epithelial cells’ (Mondal et al. 2016). The serine protease detected in the MVs should 
be characterised further to determine its function in vivo.  
 
Lastly, Figure 5.9 provided evidence of active proteases within the Streptomyces S4 MVs. When SDS 
was added to the MVs, the protein profile changed. SDS is a detergent and is known to disrupt the 
membrane of OMVs. It is likely that the MVs are disrupted after SDS addition and any active proteases 
(including the serine protease) were released. These proteases may have caused degradation of other 
proteins and altered the protein profile.  
5.3.3 Streptomyces S4 MVs contain Candicidin (Section 5.2.5-5.2.6) 
5.3.3.1 Positive controls 
Candicidin and antimycin were used as positive controls to optimise the development of the C. albicans 
ZOI plates. The Minimum Inhibitory Concentration (MIC) of candicidin was determined to be 10 
µg/mL and the MIC of antimycin was found to be 5 µg/mL using this method. In the literature, the 
MICs were reported as antimycin (0.125 μg/mL) and candicidin (2 μg/mL) against C. albicans (McLean 
et al. 2016). MICs in this paper were determined by growing C. albicans in 96 well plates with various 
concentrations of candicidin and antimycin. In Chapter 5, zones of inhibition were only measured when 
the growth of C. albicans was fully inhibited and the agar was clear and transparent. At some of the 
lower concentrations of candicidin and antimycin, zones of inhibition were starting to develop but were 
not measured due to the criteria chosen. This made this method of determining the MIC less accurate 
than the 96 well plate method in the literature. 
5.3.3.2 Effect of Streptomyces S4 MVs on C. albicans growth 
MVs were added to a LB agar plate which was then overlayed with C. albicans (in LB 0.5% agar). This 
was to determine if the antifungals candicidin or antimycin were present within the MVs purified from 
each Streptomyces strain. Each strain of Streptomyces was also grown on a LB agar plate and tested in 
the same way as the MVs. Zones of inhibition were produced when an antifungal was present that was 
active against C. albicans. Table 5.3 summarises the main findings from the plates which indicate that 



















In order to find further evidence that candicidin is MV-associated, Streptomyces S4 MVs were washed 
up to 3x with 10 mM HEPES buffer. This was to remove any extracellular material (for example lysed 
cells) from around the MVs so that any antifungal activity observed was from MVs only. Even after 
three washes with 10 mM HEPES buffer, the ZOI was still present which could be evidence that the 
candicidin is genuinely MV-associated. 
5.3.3.3 Detection of Candicidin in Streptomyces S4 MVs by UV-Vis 
Candicidin and antimycin were purchased and run on the spectrophotometer (Agilent Technologies 
Cary 60 UV-Vis) to give their characteristic UV-Vis spectra. These spectra were used as positive 
controls to detect candicidin (and/or antimycin) in Streptomyces S4 MVs as they were almost identical 
to those found in the literature (Seipke et al. 2011). 
 
Streptomyces S4 MVs resuspended in 10 mM HEPES buffer were added to the spectrophotometer but 
no peaks were found in the UV-Vis spectra. Three different methods to extract candicidin using butanol 
were developed. These were based on a method used to extract candicidin from the supernatant of 
Streptomyces S4 strains for LC-MS (Seipke et al. 2011). The optimum method to identify candicidin 
was to resuspend the MVs into butanol instead of 10 mM HEPES buffer. This gave a clear UV-Vis 
spectra characteristic of candicidin found in MVs from Streptomyces S4 WT and ΔantC. These results 
are in agreement with the results of the ZOI plates with C. albicans. 
5.3.3.4 Identification of candicidin by mass spectrometry 
MALDI-TOF and LC-MS have both been trialled to detect candicidin in the Streptomyces S4 MV 
samples. Unfortunately, this has been unsuccessful so far including with the candicidin purchased from 
Bio-Australis. The reason for this is unclear as the purchased candicidin is active against C. albicans 
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and produces a UV-Vis spectrum characteristic of candicidin so appears to be correct. Optimisation of 
LC-MS to detect candicidin is currently ongoing. 
5.3.3.5 Limitations of the ZOI with C. albicans 
Measuring the zones of inhibition using C. albicans is a good method to confirm if an antifungal is 
present within the MV samples or not. The diameter of the ZOI, however, is not necessarily 
representative of the concentration of candicidin in the MVs as it is too variable. The ZOI can vary if 
the 5 μL sample has not dried fully before addition of C. albicans as the sample can smudge and distort 
the ZOI shape. Also, ZOI are not always an exact circle and the diameter measured can vary depending 
on which part is measured. Lastly, the ZOI was only measured when the LB agar was fully clear and 
transparent. Sometimes the start of a ZOI was visible but was not measured due to the criteria as it was 
not fully transparent. 
5.3.4 Wider Implications  
Streptomyces S4 cells appear to secrete MVs containing the antifungal candicidin which is a novel 
discovery. Within the MVs, candicidin is in a concentrated and protected form for release into the 
environment. Streptomyces S4 has a symbiotic relationship with attine ants which use the antifungals 
produced by the bacteria to keep their cultivated food free from fungal contamination. Packaging 
candicidin within a vesicle may increase the uptake of candicidin by the target cells and enhance the 
killing. This is a similar method to the AmBisome where ampthotericin B is packaged in a liposome for 
enhanced uptake (see Section 1.9.3). Although the proteome analysis of the MVs was more limited than 
for the OMVs in Chapters 3 and 4, a serine protease was detected in Streptomyces S4 MVs. This could 
potentially be used as a fusion protein to target cargo to MVs. Lastly, study of MV biogenesis in 
Streptomyces S4 may lead to enhancing the delivery of anti-fungal drugs within vesicles. This will be 














6.1 Main conclusions 
6.1.1 What are the best methods to purify and characterise OMVs? 
6.1.1.1 A protocol was developed that successfully purifies OMVs from bacterial cultures 
The OMV protocol was used successfully to purify OMVs from a wide range of E. coli and P. 
aeruginosa strains. The protocol was also applied to the Gram-positive organism Streptomyces S4 and 
allowed purification of MVs with minimal modifications. It was confirmed that live bacterial cells were 
not co-purified with OMVs using this protocol and that the choice of PES or SFCA membrane type for 
filtration of the supernatant did not affect the OMV purity, yield or proteome. Purified P. aeruginosa 
OMVs were separated from flagella by buoyant density ultracentrifugation but this was not successful 
for E. coli K-12 OMVs. However, separation of OMVs from co-purified fimbriae and/or flagella has 
also been an unresolved issue for others in the literature (Figure 3.34). 
6.1.1.2 E. coli and P. aeruginosa OMV characterisation (Gram-negative bacteria) 
Purified OMVs were visualised by TEM and were very similar in size and appearance to those in the 
literature (Figure 3.17). The proteins found within the purified OMVs were identified by SDS-PAGE 
gels and mass spectrometry and Western blotting was used to confirm the presence of FimA monomer, 
Flagellin monomer and OmpA in E. coli OMV samples. Purified OMVs were confirmed as being whole 
and intact by using a Proteinase K test. The Proteinase K test was optimised during this study and also 
identified which proteins were protected within the OMVs from extracellular proteases. Purified E. coli 
K-12 OMVs were found to contain active proteases capable of degrading flagella. Methods of OMV 
quantification trialled were using a Bradford assay, a NanoPhotometer 50 and DLS. It became apparent 
that the presence of fimbriae or flagella co-purified with OMVs causes errors in DLS readings (Figure 
3.32) and that the protein concentration was below the detection limit for NanoPhotometer 50 (Section 
3.2.6.1). For this reason, a Bradford assay was used for OMV quantification in this study. 
6.1.1.3 Streptomyces S4 MV characterisation (Gram-positive bacteria) 
MVs were purified from Streptomyces S4 and the three mutant strains: ΔantC, ΔfscC and ΔantC ΔfscC. 
The purified MVs were visualised using TEM and were found to be similar in diameter and appearance 
to purified Streptomyces lividans MVs in the literature (Schrempf, Merling. 2015). Confocal 
microscopy using WGA-FITC indicated that the MVs are composed of the cytoplasmic membrane with 
no peptidoglycan layer present (Section 5.2.2). Furthermore, a serine protease was found within all of 
the purified S4 MVs which was identified by SDS-PAGE gels and mass spectrometry. Lastly, a 
reproducible bioassay was developed to measure the antifungal effect of Streptomyces S4 MVs against 




6.1.2 What are the differences in (O)MV composition, cargo and function from both 
Gram-negative and Gram-positive bacterial strains? 
6.1.2.1 E. coli OMV cargo 
OMVs from E. coli wild type and recombinant strains have different protein profiles 
The number of OMVs released from the engineered E. coli B strains was higher than the E. coli K-12 
WT strains. Moreover, E. coli K-12 OMVs are enriched with specific proteins unlike OMVs from B 
strains which appear to contain many proteins with no particular proteins enriched. 
 
FimA and Flagellin monomers are packaged into E. coli K-12 OMVs 
One of the most convincing pieces of evidence to support the packaging of FimA and Flagellin 
monomers into OMVs is the immunogold labelling of OMVs embedded in resin (probed with anti-
FimA monomer and anti-Flagellin antibody). Secondly, SDS-PAGE gels and Western blots repeatedly 
showed FimA and/or Flagellin monomers in the periplasmic fraction of E. coli cells and their respective 
purified OMV samples. Lastly, the Proteinase K tests repeatedly gave evidence that the Flagellin 
monomer is protected (most likely structurally) within the OMVs. Unfortunately, the Proteinase K test 
could not be used as evidence that FimA monomer is packaged into K-12 OMVs. This is because FimA 
monomer was not degraded by Proteinase K under the usual assay conditions. 
FimA and Flagellin monomers are packaged into E. coli K-12 OMVs in a mutually exclusive 
way unless there are mutations in the OMV-producing cell 
E. coli K-12 strains MG1655 and the Keio collection parental strain BW25113 produce Type 1 fimbriae 
and package FimA monomer into their OMVs. Deletions in certain fimbriae or flagella-associated genes 
caused alterations to the FimA/Flagellin packaging into OMVs as follows: 
• If Type 1 fimbriae production is disrupted in an E. coli MG1655 or BW25113 strain, the cell 
switches to production of flagella. This results in the packaging of Flagellin into OMVs instead 
of FimA.  
Examples: FimB-LacZ fusion strain, ΔfimA, ΔfimB, ΔfimF strains. 
• Certain mutations in the E. coli cell lead to a dysregulation in the packaging of Flagellin and 
FimA monomers in a way that both are packaged together. 
Examples: Fimbriae locked on strain, ΔfimE, ΔfimG, ΔfimH, ΔfimI, ΔlrhA strains 
• Mutations in proteins relating to flagella biosynthesis did not affect the cells production of 
Type 1 fimbriae or the packaging of FimA into the OMVs. 
Examples: ΔfliD, ΔfliS, ΔflhA strains 
• If neither flagella or fimbriae are expressed on a cell, neither FimA or Flagellin were packaged 
into the OMVs. 





It was noted that deletion of either FimC or FimF caused the cell to produce flagella rather than Type 1 
fimbriae. This resulted in the packaging of Flagellin into OMVs and not FimA. Both FimC and FimF 
interact with FimA monomers during the formation of Type 1 fimbriae. This could suggest that FimC 
and FimF play a role in preparing FimA monomers for incorporation into OMVs. It is also possible that 
the chaperone protein FimC delivers the FimA monomers to the site needed for incorporation into 
OMVs. 
 
Current theory on the reason for the mutually exclusive packaging of FimA and Flagellin 
It appears that in the majority of E. coli K-12 strains, FimA and Flagellin are reciprocally regulated and 
are packaged in OMVs independently of each other. FimA and Flagellin monomers have opposite 
effects on the hosts’ immune response so it makes sense to package them in a mutually exclusive way 
into OMVs. Table 6.1 outlines other studies in the literature that have found FimA and Flagellin 
monomers in OMVs. 
 












Clinical E. coli K-12 isolate study 
Finally, six E. coli clinical isolates were examined to see if the purified OMVs contained FimA and/or 
Flagellin monomers. Three of the six clinical isolate strain OMVs contained neither FimA or Flagellin. 
One of the clinical isolates contained both FimA and Flagellin packaged together. One clinical isolate 
expressed Type 1 fimbriae and packaged FimA monomer into the OMVs (but not Flagellin). Another 
clinical isolate expressed flagella and produced OMVs containing Flagellin (but not FimA). This makes 
these findings clinically relevant and will be discussed further in Section 6.3.1. However, it does 
highlight that the mutually exclusive packaging of FimA and Flagellin into OMVs is not a clear-cut 
story and that there is further research needed to understand the cargo selection and exclusion process.  
Characteristics Cell Adhering Cell Motile
Extracellular appendages Type 1 fimbriae Flagella 
Protein OMVs are most 
enriched with
Monomeric FimA Monomeric Flagellin
Effect of protein on the 
immune system
FimA monomer is anti-
inflammatory
Flagellin monomer is pro-
inflammatory
Evidence of effect of 
FimA/Flagellin monomer 
on host immune response 
from the literature
Sukumaran et al . 2010
Heimlich et al. 2004
Zgair, 2012
Yoon et al.  2017
Hatai et al. 2016




6.1.2.2 Streptomyces S4 MV cargo 
All evidence found suggests that Streptomyces S4 MVs contain candicidin. There were zones of 
inhibition formed against C. albicans when purified MVs from both Streptomyces S4 wild type and 
ΔantC strains were added to the plates. However, there were no zones of inhibition formed from MVs 
isolated from ΔfscC and ΔantC ΔfscC strains. As the ΔantC strain cannot produce antimycin, candicidin 
must be the antifungal compound present within the MVs (see Section 5.3.3 for full explanation). Three 
different methods were developed to extract candicidin from the Streptomyces S4 MVs using butanol. 
This gave a clear UV-Vis spectra characteristic of candicidin found in MVs from Streptomyces S4 WT 
and ΔantC. These results are also in agreement with the results of the zone of inhibition plates with C. 
albicans. 
6.1.3 Can we target a protein of interest to be incorporated into bacterial MVs? 
6.1.3.1 FimA (E. coli OMVs) 
GFP was successfully targeted to E. coli K-12 OMVs by fusion to FimA monomer. However, 
expression of a FimA fusion protein using a plasmid caused an unexpected hypervesiculation of the 
strain. Furthermore, the OMVs produced appeared to contain many proteins with no particular proteins 
enriched in the OMVs. The experiments showed that to target a protein of interest to E. coli K-12 
OMVs, a chromosomal insert of the protein within the fimA gene was required. 
6.1.3.2 Flagellin (E. coli and P. aeruginosa OMVs) 
It is possible that Flagellin could be used in the same way as FimA to target cargo to E. coli K-12 
OMVs. Additionally, B-type Flagellin was detected as one of the most heavily enriched proteins found 
in P. aeruginosa OMVs so, in theory, could be used in the same way. 
6.1.3.3 Serine protease (Streptomyces S4 MVs) 
One protein in particular appeared to be enriched in the Streptomyces S4 MVs compared with the 
protein profile of the whole cells. This protein was identified by mass spectrometry and it was found to 
be a serine protease. Perhaps this could be used as a target to fuse proteins of interest to or as a 
biomarker of Streptomyces S4 MVs. 
6.2 Unanswered questions and further work 
6.2.1 Possible improvements to the methods used to characterise purified MVs 
6.2.1.1 Is there a better method for purifying OMVs than the protocol developed? 
The OMV purification protocol successfully isolated OMVs from all bacterial strains tested. However, 
fimbriae and flagella are consistently co-purified with E. coli OMVs which was not resolved. One 
solution for this could be to purchase a specialised OMV purification kit which claims to purify OMVs 




market is the System Biosciences ExoBacteria™ OMV Isolation Kit (EXOBAC100A-1). However, 
unfortunately it was not cost effective to purify OMVs using this kit for this project.  
6.2.1.2 What is the best method to quantify MVs? 
In this study, MVs were quantified using a Bradford assay which measures the concentration of protein 
present in each MV sample. Dynamic light scattering (DLS) was also trialled to quantify OMVs. 
However, the DLS appeared to detect the fimbriae and flagella in the samples rather than the OMVs. 
This led to inaccurate quantification of the OMVs. The NanoPhotometer 50 (Implen) also was trialled to 
quantify MVs, however, this technique was found to not accurately detect protein concentrations under 
50 µg/mL. Alternative options for MV quantification are by flow cytometry (Wieser et al. 2014) or 
Nanoparticle tracking analysis (Gerritzen et al. 2017).  
6.2.2.3 Further characterisation of MV proteases 
Further attempts to characterise proteases within P. aeruginosa, E. coli and Streptomyces S4 MVs could 
be beneficial. Characterisation of proteases was trialled in an attempt to couple cargo function to MV 
production. If MV protease activity directly correlates to MV production, a colorimetric assay could 
potentially be developed to quantify MVs and learn more about factors that affect vesiculation. In this 
study, MVs from E. coli, P. aeruginosa and Streptomyces S4 were incubated for 1 hour with the 
chromogenic esterase substrate 4-nitrophenyl acetate. Unfortunately, it was discovered that the substrate 
was unexpectedly reacting with both LB and ammonium sulphate. For this reason, the colour change 
could not clearly be correlated with MV protease activity. In order to characterise MV proteases further, 
kits such as the Sigma Protease Fluorescent Detection Kit (PF0100) or Zymogram gels (Novex) could 
be used. 
6.2.2.4 Characterisation of the lipid and DNA components of purified MVs 
The main focus of this study was to characterise the protein profile of the MVs. Unfortunately, time did 
not allow for characterisation of the lipid content of the MVs. Initially, purified membrane vesicles 
could be visualised using Nile red or FM4-64 dyes, which would provide further evidence that the 
OMVs purified are genuine. During the Proteinase K test in Chapter 3, the presence of 0.02% (w/v) 
SDS caused disruption of E. coli and Streptomyces S4 MVs. This allowed Proteinase K access to the 
proteins, which are usually protected within the MVs and allowed their degradation. However, this did 
not seem to be the case for OMVs purified from P. aeruginosa strains PA01 and PA14, which did not 
appear to be disrupted after addition of 5% (w/v) SDS. This could be investigated further using a range 
of detergents and comparing the lipid composition of E. coli and P. aeruginosa OMVs. A study into 
differences in lipid composition may provide insight into the differences in OMV stability in the 
presence of detergents. Lastly, time did not allow characterisation of any DNA found within the OMVs. 




6.2.2 Main unanswered questions about OMV cargo 
6.2.2.1 How are FimA or Flagellin monomers delivered to the OMVs? 
FimA and Flagellin are likely to be packaged into OMVs via different mechanisms due to their 
locations within the cell. Flagellin monomers usually reside in the cytoplasm whereas FimA monomers 
are found in the periplasm. During flagella biosynthesis, Flagellin monomers are transported directly 
from the cytoplasm into a central channel (which bypasses the periplasm) to be added to the growing 
filament (see Section 1.6.4). However, Western blotting in this study indicated that Flagellin destined 
for the OMVs was transported to the periplasm first (Figure 4.8). In order to elucidate the mechanisms 
of targeting proteins such as Flagellin to the periplasm, the Sec or Tat pathways could be disrupted to 
see the effect on the proteins packaged within the OMVs. An example of this would be inhibition of the 
Type I signal peptidase enzyme, which cleaves the signal peptide of proteins during translocation.   
6.2.2.2 How does the cell prevent premature polymerisation of FimA or Flagellin monomers 
destined for OMVs? 
Both FimA and Flagellin monomers have strong oligomerisation potential and bind to chaperone 
proteins to prevent premature polymerisation (FimC and FliS). It is also known that FimA monomers 
can adopt an alternative conformation which prevents polymerisation (Zyla et al. 2019). It is possible 
that the FimA and Flagellin monomers have an additional signal sequence that targets them to sites 
where vesiculation occurs. To identify any differences in signal sequence, FimA purified from Type 1 
fimbriae can be compared to those found in OMVs by N-terminal sequencing. Similarly, Flagellin 
purified from flagella and OMVs can also be compared. 
6.2.2.3 Is the mutually exclusive packaging of FimA and Flagellin monomers beneficial in 
vivo? 
The effect of FimA monomers and Flagellin monomers on the human immune system from OMVs 
could be studied either in vitro and in vivo. This may give further insight into why these proteins are 
enriched in E. coli OMVs.  
 
6.2.3 Discussion of findings about Streptomyces S4 MVs 
Further characterisation of Streptomyces S4 MVs 
Further MV characterisation is needed to reach the same standard of OMV characterisation from Gram-
negative bacteria. Characterisation work could include application of the Proteinase K test to confirm 
that the MVs are intact and also confirm which proteins are protected within the MVs. Streptomyces S4 
MVs could also be run on the DLS machine to estimate MV size and quantity. MV biogenesis could 
also be studied using TEM and further confocal microscopy using the WGA-FITC tag. In the literature, 
MV biogenesis from Streptomyces lividans was observed using lipid-specific dyes. They discovered 




particles” (Schrempf, Merling. 2015). TEM images could also be improved by embedding the cells and 
MVs in resin for EM to see a cross-section inside the cells/MVs. 
6.3 Wider Implications of study  
6.3.1 Blocking FimA and/or Flagellin incorporation into OMVs could be a drug target for 
preventing or treating E. coli infection 
In this study, six clinical E. coli isolates were examined to see if the OMVs produced contained FimA 
and/or Flagellin. One of the clinical isolates expressed Type 1 fimbriae and the OMVs produced 
contained FimA monomers. Another clinical isolate expressed flagella and produced OMVs containing 
Flagellin. The selective enrichment of these two proteins indicates that the packaging is deliberate and 
most likely beneficial to the pathogenicity of the E. coli cell. For this reason, preventing OMV 
production or disrupting the OMVs produced could be a potential drug target for preventing or treating 
E. coli infection. In this study, B type Flagellin monomer was also detected in OMVs from both PA01 
and PA14 which express flagella. This indicates that this finding could be relevant to a range of other 
bacterial species including P. aeruginosa. 
6.3.2 Using targeted expression of recombinant proteins and other molecules for drug 
delivery using OMVs 
As demonstrated in Chapter 4, GFP was successfully targeted to E. coli K-12 OMVs by protein fusion 
to FimA. Other proteins of interest could be targeted to OMVs using this method which could be used 
for drug delivery. Other enriched proteins in OMVs such as Flagellin could also be used for protein 
fusions. For this application, further research on the effect of these OMVs on the host immune system is 
needed as well as modification of the OMV to reduce its immunogenicity.  
6.3.3 Using Gram-positive MVs for targeted drug delivery 
Packaging antifungal compounds (such as candicidin) within a vesicle may enhance its uptake by the 
target cells and enhance the killing. This is a similar method to the AmBisome where Amphotericin B is 
packaged in a liposome for enhanced uptake (see Section 1.9.3). Studying the natural packaging of 
antifungals in MVs by Streptomyces S4 could be useful in enhancing the delivery of anti-fungal drugs 
within vesicles for therapeutic purposes. The study of MVs from Gram-positive bacteria is a relatively 
new area of research which could have potential for use in vaccines and drug delivery in the same way 
as OMVs. Although the proteome analysis of the Streptomyces S4 MVs was limited, a serine protease 
was detected. Fusion of a protein of interest to the serine protease could be a potential method to target 
cargo to S4 MVs.  
6.3.4 Vaccines and immunogenic properties 
The membrane vesicles secreted by bacteria are naturally immunogenic and so have the potential to be 
used as vaccines against a range of diseases. One advantage of using MVs for vaccines are that they can 




surface. An example of this was the targeting of GFP to E. coli K-12 OMVs by fusion to FimA. Purified 
E. coli OMVs are also being sold as inducers of the immune response for research purposes. For 
example, purified E. coli BL21 OMVs are currently sold as potent inducers of Caspase 11-4/5 
inflammasome and activators of TLR2 and TLR4 which recognise bacterial cell walls (InvivoGen, 
catalogue code: tlrl-omv).  
6.3.5 Packaging of recombinant proteins into OMVs impacts biotechnology 
Information about E. coli OMV biogenesis and cargo is useful as B strains are commonly used for 
recombinant protein production. It is possible that some of the recombinant proteins of interest are being 
packaged and secreted in OMVs, decreasing the final yield of purified protein. It is also still unclear 
how the expression of plasmids influence OMV production and cargo. Further research is needed to 
quantify the yield of recombinant proteins lost through packaging into E. coli OMVs.  
 
6.4 Contributions to the field and final thoughts 
Throughout this project, membrane vesicles have been isolated and characterised from a wide range of 
bacterial strains. During the project, it became possible to separate the membrane vesicles into three 
distinct categories based on their different characteristics. Table 6.2 is a final summary of the findings 
for each membrane vesicle type. Some of the findings in this study are novel and will contribute to the 
current MV knowledge already in the literature. This information may be used in the development of 









Wild type OMVs Recombinant OMVs 
Proposed function of 
vesicles
Signalling function in vivo : 
secreting OMVs that contain 
specific cargo to benefit the 
OMV-producing cell
(e.g. virulence factors)
Secreted as part of a stress 
response. For example, to remove 
any accumulations of unwanted 
products in the cell
Produced to secrete the insoluble 
antifungal compound candicidin 
into the environment
Examples of bacterial 
strains studied
PA01 , PA14 , E. coli  K-12, E. 
coli clinical isolates
E. coli B strains Streptomyces  S4 strains
Membrane vesicle 
composition
Formed from the outer membrane 
and contains cargo from the 
periplasm
Formed from the outer membrane 
and contains cargo from the 
periplasm
Formed from the cytoplasmic 
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Protein cargo detected 
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PA01/PA14 : B type flagellin,
phage tail protein, elastase, 
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